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Abstract 
Title: Characterising Peritumoural Progression of Glioblastoma using 
Multimodal MRI 
Jiun-Lin Yan 
 
Glioblastoma is a highly malignant tumor which mostly recurs locally around the 
resected contrast enhancement. However, it is difficult to identify tumor invasiveness 
pre-surgically, especially in non-enhancing areas. Thus, the aim of this thesis was to 
utilize multimodal MR technique to identify and characterize the peritumoral 
progression zone that eventually leads to tumor progression. 
Patients with newly diagnosed cerebral glioblastoma were included consecutively from 
our cohort between 2010 and2014. The presurgical MRI sequences included 
volumetric T1-weighted with contrast, FLAIR, T2-weighted, diffusion-weighted imaging, 
diffusion tensor and perfusion MR imaging. Postsurgical and follow-up MRI included 
structural and ADC images. 
Image deformation, caused by disease nature and surgical procedure, renders routine 
coregistration methods inadequate for  MRIs comparison between different time 
points. Therefore,  a two-staged non-linear semi-automatic coregistration method 
was developed from the modification of the linear FLIRT and non-linear FNIRT 
functions in FMRIB’s Software Library (FSL).  
Utilising the above mentioned coregistration method, a volumetric study was 
conducted to analyse the extent of resection based on different MR techniques, 
including T1 weighted with contrast, FLAIR and DTI measures of isotropy (DTI-p) and 
anisotropy (DTI-q). The results showed that patients can have a better clinical outcome 
with a larger resection of the abnormal DTI q areas.  
Further study of the imaging characteristics of abnormal peritumoural DTI-q areas, 
using MRS and DCS-MRI, showed a higher Choline/NAA ratio (p = 0.035), especially 
higher Choline (p = 0.022), in these areas when compared to normal DTI-q areas. This 
was indicative of tumour activity in the peritumoural abnormal DTI-q areas.  
The peritumoural progression areas were found to have distinct imaging 
characteristics. In these progression areas, compared to non-progression areas within 
a 10 mm border around the contrast enhancing lesion, there was higher signal 
intensity in FLAIR (p = 0.02), and T1C (p < 0.001), and there were lower intensity in 
ADC (p = 0.029) and DTI-p (p < 0.001). Further applying radiomics features showed 
that 35 first order features and 77 second order features were significantly different 
between progression and non-progression areas. By using supervised convolutional 
neural network, there was an overall accuracy of 92.4% in the training set (n = 37) and 
78.5% in the validation set (n=14). 
In summary, multimodal MR imaging, particularly diffusion tensor imaging, can 
demonstrate distinct characteristics in areas of potential progression on preoperative 
MRI, which can be considered potential targets for treatment. Further application of 
radiomics and machine learning can be potentially useful when identifying the tumor 
invasive margin before the surgery. 
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CHAPTER 1 
 
Introduction 
 
1.1 Background and Epidemiology 
Epidemiology 
Glioblastoma (GBM) is the most aggressive and the most common malignant primary 
brain tumour. The overall age adjusted incidence in England is 4.64 per 100,000 
population,14 and 3.19/100,000 in United States and further causes up to 256,213 
deaths annually worldwide.94 Although the overall incidence is lower than other 
common cancers of the body, its mortality rate is higher than most of the other cancers, 
and is the number one cause of death in cancer patients under 40 years old. 
Furthermore, the prognosis of GBM is poor, the median overall survival (OS) including 
patients without any treatment regime is only 6.1 month.14 With the extensive standard 
multimodal treatment schemes including maximal, safe surgical resection followed by 
radiotherapy with concomitant and adjuvant temozolomide chemotherapy, the median 
OS can only increase to about 14.8 month, and one, 2 and 5 years overall survival are 
only 64.3%, 28.7% and 6.6% respectively.14 
Risk factors 
The exact cause of GBM is unknown. A systemic review focusing on occupational and 
environmental risk factors showed that exposure to ionizing radiation, high voltage 
power lines and agriculture pesticides were the possible risk factors for malignant brain 
tumour.38 However, most GBM cases were sporadic, and only about 5% of the GBM 
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patients had family history of glioma, and some of these familial type were reported to 
be associated with rare genetic syndrome such as Li-Fraumeni syndrome, Lynch 
syndrome, Turcot’s syndrome and neurofibromatosis type1 and 2.93,160 
Symptoms of GBM 
Headache is the most common symptom of GBM, however, it is usually non-specific. 
Associated headache characteristics includes, recent onset with progressive increase 
in severity and frequency, morning headache, accompanied with focal neurologic sign, 
seizure, age more than 50 years old may be red flags of GBM. Other symptoms such 
as nausea, vomiting, gait disturbance, cognitive changes or urinary incontinence can 
also be seen in GBM patients.92 As these are common features to present to primary 
care, much interest at present focuses on the combination of symptoms for the early 
detection of brain tumours. 
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1.2 Pathology and the Biologic Basis of GBM 
1.2.1 The Emerging of Pathology Diagnosis 
Glioblastoma is a highly diverse and complex malignant brain tumour. Traditionally, 
the diagnosis of GBM was largely based on histopathology findings, including 
hypercellularity, nuclear atypia, cellular pleomorphism, mitotic activity, microvascular 
proliferation and necrosis160. However, these microscopic findings were unable to 
explain the variation of patients’ prognosis in the same category. The entity of GBM is 
now clearer due to the advance in genomic technology. In 2008, the TCGA research 
network identified and validated several commonly mutated genes in GBM, such as 
tumour protein 53 (TP53), phosphatase and tensin homolog (PTEN), neurofibromosis 
type 1 (NF1), epidermal growth factor receptor (EGFR), human epidermal receptor 
growth factor 2 (Her2/ ErbB2), retinoblastoma protein (RB1), PIK3R1, and PIK3CA by 
using large scale multidimentional analysis15. In 2010, Verhaak proposed a robust 
gene expression-based molecular classification of GBM into classical, mesenchymal, 
proneural and neural type according to the aberration and expression of EGFR, NF1, 
and platelet derived growth factor receptor alpha (PDGFA)/ Isocitrate dehydrogenase-
1 (IDH1).153 Although not statistically significant, a slightly better clinical prognosis was 
observed in the proneural type. In 2016, an update of WHO GBM classification firstly 
incorporate molecular markers, such as IDH mutation status, into classification for 
GBM.74 The 1p/19q co-deletion, together with IDH mutation as suggested an essential 
criterion to diagnose oligodengroglioma, and K27 mutation in the histone H3 gene 
H3F3A is for the diagnosis of diffuse midline glioma that are commonly seen in 
children/young adults. The emergence of molecular biomarkers can provide us a 
better way for subdividing GBM to hopefully help with diagnosis and treatment. 
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1.2.2 Origin of GBM and molecular biomarkers 
The cell origin of the glioma remains a complicated topic. Many genetic alterations 
have been identified155 as being responsible for transforming a normal neural stem 
cell, stem cell derived astrocyte, or oligodendrocyte progenitor cell to a cancer cell.160 
Two major pathways of the transformation of GBM from precursor cell, primary and 
secondary, were identified (Figure 1.1)155.  
 
 
Figure 1.1 
This figure shows primary and secondary malignant transformation pathway from progenitor 
cells into GBM. 
(The British Journal of Radiology, 84 (2011), S90–S106) 
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IDH-wild type GBM 
Primary GBM, or IDH-wild type GBM, which arises de novo and is associated with 
EGFR proto-oncogene amplification, PTEN, tumour suppressor gene mutation and 
telomerase reverse transcriptase (TERT) promoter mutation.2 The IDH-wild type GBM 
accounts for 90% of the GBM and occurs more in the older population (~ 62 years old) 
with a worse prognosis.  
One of the most important mutation is the amplification of EGFR which occurs in 35% 
of all IDH-wild type primary GBM and only exceptional case in IDH-mutant.74 However, 
the Radiation Therapy Oncology Group (RTOG) 0211 phase I/II trial with gefitinib (an 
EGFR tyrosine kinase inhibitor) for concurrent chemo- radiotherapy showed that the 
median survival is no better than historical control cohort treated with radiation alone18. 
This is due to about half of the tumours with EGFR amplification expressed EGFRvIII 
which is the active form of EGFR that promote tumour growth. Further immunotherapy 
targeted on EGFRvIII-positive GBM by using Rindopepimut™ (a EGFRvIII peptide 
vaccine) showed a promising result on phase II clinical trial123. However, a recent 
phase III study showed no benefit on OS53.  
PTEN, is another gene mutation involve in about 24% of the primary GBM. It is a 
tumour suppressor gene that down regulates the phosphatidylinositol 3-kinase 
pathway that involves the cellular apoptosis and proliferation.160 
Human telomerase reverse transcriptase (TERT) promoter mutation is also a common 
mutation in primary GBM, which occurs in about 72% of the cases but less frequent in 
secondary GBM and pediatric GBM. The telomerase normally regulates the length of 
DNA which further affect the life cycle of the cell. Studies had shown that TERT 
mutation is an independent poor prognostic risk factor in all primary GBM, and the 
authors suggest a more aggressive treatment for these patients.127  
6 
 
IDH-mutation GBM 
The secondary GBM, diagnosed with IDH-mutation, have more frequent mutation in 
TP53, and ATP-dependent helicase (ATRX).2 It arises from the malignant 
transformation of anaplastic astrocytoma or diffuse astrocytoma. The secondary GBM 
accounts for 10% of all GBM, it occurs more in young patients (~44 years old), and 
locates more in frontal lobe. It has a better prognosis, compared to primary GBM. The 
most common is the point mutation in codon 132 of IDH-1 or less commonly in codon 
172 of IDH-2) is the most distinctive markers of secondary GBM99 and the diagnostic 
criteria for oligodendroglioma. There are different types of the R132 mutation in IDH-
1, including the most prevalent R132H (CGT arginnine CAT histine), followed by 
R132C, R132L, R132S and R132G. The main functions of IDH-1 are the lipid synthesis 
and the cellular glucose sensing. The detection of the IDH-1 mutation can be done by 
using immunochemistry staining or DNA sequencing and the concordance between 
this two methods was 99-99%171. IDH-1 is the catalytic enzyme oxidase carboxylation 
of isocitrate to α-ketoglutarate and resulting in the increase of nicotinamide adenine 
dinucleotide phosphate (NADPH) from NADP+ which further prevent cell damage from 
oxidative stress and irradiation injury.42 Therefore, a mutation in IDH-1 can cause the 
decrease production of NADPH and α-ketoglutarate which further increase the 
sensitivity to chemo- radiotherapy. In addition, tts neoformic activity leads to the 
transformation of α-ketoglutarate to 2-hydroxyglutatrate (2-HG) which further interfere 
with normal epigenetic regulation of cells42, for example, induce the hydroxylation of 
the hypoxia-inducible factor-1α subunit resulting tumourogensis in hypoxic 
environment168. 
A less common gene abnormality is the PDFRA gene. There is approximately 30% of 
all glioma have the amplification of PDGFRA. It is the most important characteristics 
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in the proneural type GBM.95 This gene plays an important role in organ development, 
wound healing and tumour progression. Amplification of PDGFRA and PDGF can 
result in the stimulation of glial tumour cell via autocrine and paracrine loop.87  
Neurofibromatosis type 1 gene (NF1) loss or mutated in about 15% of all GBM, and 
mostly in the mesenchymal type of GBM. It is a tumour suppression gene that 
produces neruofibromin 1 which further negatively regulates Ras and mTOR pathway. 
Therefore, loss of NF1 can result in the development of mesenchymal GBM. 
Except for the IDH mutation status, one of the most clinical important marker is the 
methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter. 
MGMT is a DNA repairing gene that modulates the effect of alkylating agent. It can 
restore guanine from O-6-methyguanine which is induced by the chemotherapy. 
Therefore, the GBM become more vulnerable to DNA damage from radiotherapy or 
chemotherapy after the methylation of MGMT promoter. Studies have shown that 
MGMT methylation is an independent favorable outcome predictor for GBM patients 
treated with temozolomide concomitant chemoradiotherapy (median survival 21.7 
months versus 15.3 months).46 In further 5 years follow up of the EORTC-NCIC phase 
III trial also showed this benefit can last for up to 5 years.138 In addition, MGMT 
methylation status also correlates with the pattern of GBM progression after treatment. 
In a study of 79 recurrent GBM, 51 out of 63 MGMT promoter unmethylated patients 
had local recurrent GBM, whist 11 out of 33 MGMT promoter methylated patients were 
locally recurred.13 
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1.2.3 Mechanism of GBM invasion 
Most of the GBMs will recur within 1-2 cm of the primary site after surgical 
resection101,125. It rarely metastasizes outside of the central nervous system due to 
short survival time, blood-brain-barrier, and local immune system. In 1938, Dr. Scherer 
published a systemic study in the invasion of high grade glioma based on the 
pathology observation.121 He proposed that glioma invades through secondary 
structures, (1) perineural and neuronophagic growth (brain parenchymal invasion), (2) 
surface growth (subarachnoid invasion), (3) perivascular growth, and (4) perifascicular 
growth (white mater invasion).  
These findings may tell us where the GBM goes, however, the progression of the GBM 
has two key factors: proliferation and migration165. In this “going and growing” theory8 
suggests that, GBM cells migrate less when in the highly proliferation status (“growing” 
phenotype), and the highly proliferative GBM cells are less invasive. The changing 
between this two phenotypes are largely determined by the environmental factors 
through various pathways. For example, with radiotherapy, chemotherapy or hypoxia, 
the GBM cells may adapt from the proliferation phenotype to a migration phenotype 
which further complicated the treatment by promoting invasion. 
The primary source of GBM invasiveness can be explained by the cancer stem cell 
hypothesis21. The main idea is that GBM, in some circumstances, is transformed from 
the neuroprogenitor cells or stem cells that has the ability to migrate through the whole 
brain. After this transformation, these cancer cells can still migrate as the 
neuroprogenitor cells,21 and actively seek out vessels and migrate alone with them. In 
addition, it will secrete glutamate as a growth factor to support itself, a process similar 
to neuron development in the cerebellum. The invading glioma cell can undergo 
substantial volume and shape change in order to disrupt the normal astrocyte-vascular 
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interface (end feet), to have a better position for nutrition and interfere with the normal 
neurophysiological function. Moreover, these cancer cells can produce proteases and 
metalloproteases to breakdown extracellular matrix which cause damage to normal 
brain tissue.  
Hypoxic induced angiogenesis also plays an important role in GBM proliferation and 
invasion165. When tumours rapidly proliferate it results in high oxygen demand, and 
inadequate nutrient supply which can cause hypoxia at the tumour core. This can 
induce some of the cancer cells migrate from core to the margin, and also produce 
pro-angiogenic factors to induce angiogenesis. The new vasculature is rebuilt to 
restore the blood supply that facilitate cancer cells to migrate and further expand the 
tumour margin. With the very rapid growth seen in GBM the tumour can outstrip its 
blood supply leading to tumour necrosis – a common histological feature. 
In summary, the nature of GBM cells and its invasion involve numerous complex 
regulations from the genetics, epigenetics mutation to extracellular matrix interference. 
In the early stage of the GBM invasion, although some cellular changes can be 
observed, only little can be seen in tissue level which is difficult to detect by using the 
MRI.  
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1.3 Treatment of the GBM 
Standard treatment of the GBM includes maximal safe resection, followed by 
radiotherapy with concomitant and adjuvant temozolomide chemotherapy140. After the 
initial imaging diagnosis, surgical resection is the first choice for treatment and to 
obtain specimen for definite pathology diagnosis. Many studies had shown benefit of 
the extent of tumour resection on the outcome and further tried to maximize 
it3,45,48,68,119. In a large cohort study of 1229 GBM patients, they found that, the median 
survival time was significant longer in the patients with gross total resection than 
subtotal resection (15.2 versus 9.1 months, p < 0.0001)73. Furthermore, the resection 
of > 53.21% of the FLAIR abnormal area beyond the contrast enhancing lesion 
showed a significant longer median survival (20.7 versus 15.5 months, p < 0.001)73. 
Other studies also showed that a surgical resection 1- 2 cm beyond contrast 
enhancing lesion can lower the local recurrent rate from 87.5% to 67%.23 
5-aminolevulinic acid (5-ALA) assisted surgery showed a better complete resection of 
the contrast enhanced tumour than using the light microscope only135. 5-ALA is a 
biochemical precursor of heme synthesis in mammalian cells. In normal cell, the 5-
ALA was metabolized to the endogenous fluorescent protoporphyrin IX (PpIX) in the 
mitochondria, and the addition of Fe+2 by the action of ferrochelatase on PpIX generate 
the heme144. In GBM cell, studies found a down regulation of the ferrochelatase145 and 
increase expression of the ATP-binding cassette transporter 6.  Therefore, oral intake 
of high concentration exogenous 5-ALA can result in the accumulation of the PpIX. 
This produces visualization of violet-red fluorescence after excitation by the 405nm 
wavelength blue light. Therefore, this can be applied to differentiate normal cells from 
GBM cells by using a filtered fluorescent microscope during surgery. Although the 
negative predictive value of the 5-ALA fluorescence guided surgery varied from 
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22~91%, it has a fairly good positive predict value43. In a study of 13 GBM resections, 
the 5-ALA guided resection volume is larger than the contrast enhancing lesion (84cm3 
versus 39 cm3) with a mean distance of 6 mm from contrast enhanced margin122. 
Stummer et al also showed a significant improvement of total resection with the aid of 
5-ALA (60% vs. 36% without) and a higher 6-month PFS (41% vs. 21.1%)135. Further 
meta-anlysis showed that the gross total resection rate can be up to 75.4% (95% CI: 
67.4–83.5, p < 0.001)27. 
For the post-surgical patients or those who are not surgical candidate, concomitant 
chemo- radiotherapy is an option. Stupp in 2005, showed that radiation plus 
concomitant temozolomide followed by six cycles of adjuvant temozolomide had a 
better median survival compared to radiation alone (14.6 months versus 12.1 
months)139, especially in patient with MGMT promoter methylation (median survival: 
21.7 months versus 15.3 months)47. A longer follow-up of this European Organization 
for Research and Treatment of Cancer (EORTC)/ National Cancer Institute of Canada 
Clinical Trail Group (NCIC) showed the benefit of adjuvant temozolomide with radiation 
therapy can last throughout 5 years follow-up (5 year survival rate 9.8% versus 
1.9%).138  
The standard fractionated intensity modulated three-dimensional radiotherapy was 
given to patient with a total dose of 60 Gy in 30 daily fractions in every weekday in six 
weeks period. The gross target volume (GTV) was defined by T1-weighted MR with 
contrast. In EORTC, the clinical target volume (CTV) of 60 Gy was defined as 
extension of 2 cm from GTV, and planning target volume (PTV) was defined a further 
0.5 cm extension from CTV. Other modes of radiation therapy have also been studied 
to improve the tumour control rate, for example using different imaging modalities re-
delineate target volume. The RTOG defined GTV by using the post-operative 
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FLAIR/T2 abnormality. A comparison study showed that there was no difference in the 
recurrent pattern between two methods, however, the median volume percent of brain 
irradiated to high doses was significantly smaller in the EORTC method80. DTI defined 
high risk volume for radiotherapy also showed the reduction of 50% of the CTV7 and 
35% of the PTV57. 
Temozolomide is an oral alkylating chemotherapy that alkylates DNA (mostly at the N-
7 or O-6 positions of guanine residues). Therefore, its clinical benefit can be largely 
affected by the methylation status of the MGMT promoter (also see section 1.2.2). The 
standard dosage was adjusted by patient body weight with 75mg per body surface 
area per day (75mg/m2/day). After 28 days’ break, patients received six cycles of 
adjuvant Temozolomide (150–200 mg/m²) treatment for 5 days monthly. 
Other chemotherapy agents have been developed against GBM, however, majority of 
them showed limited clinical benefit. Bevacizumab, a mono-clonal antibody against 
vascular endothelial growth factor (VEGF), failed to improve survival in newly 
diagnosed GBM.35 Carmustine (an alkylating chemotherapy) wafer implantation during 
surgery into surgical resection tumour bed was designed to enhance local control rate 
due to the difficulty in identifying tumour invasive margin. In a phase three clinical trial, 
the use of carmustine wafer showed a modest benefit.162 Patients with carmustine 
wafers implanted had the median survival of 13.9 months, which is longer than the 
control group (11.6 months). However, in another study of using carmustine wafer 
implantation for local chemotherapy control, the local failure rate was still 80% (33 out 
of 41 patients).26 
There is only limited alternative treatment for GBM. Many treatments targeted growth 
factor pathway, angiogenic pathway, intracellular pathway or combination multi-
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targeted kinase inhibitors have been shown limited therapeutic benefit164. And until 
now, although many efforts have been done in the immunotherapy, there is still no 
sustained clinical benefit in GBM. Tumour treatment field (Optune, Novocure) is a new 
FDA approved treatment for GBM. It is a non-invasive portable device using low 
intensity, intermediate frequency electric field to control tumour. In a phase 3 clinical 
trial compared with best physician chemotherapy in recurrent GBM patients, although 
there was no difference in overall survival, the efficacy of this tumour treatment field 
device was comparable with chemotherapy regime and with lower incidence of 
adverse effect and also provided a better quality of life for patients.141 More recently, 
a phase 3 clinical trial (EF-14) testing the efficacy and safety of tumour treatment field 
showed that a longer median PFS (6.7 versus 4.0 months, p = 0.00005) and median 
overall survival (20.9 versus 16.0 months, p = 0.00006) were found in the tumour 
treatment field group114. 
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1.4 MRI in the Diagnosis of Glioblastoma Invasive Margin 
MRI, due to its high contrast between different soft tissues, is currently the standard 
of diagnosis before the pathology examination from the surgical resection or biopsy 
specimen. MRI can not only be used to make diagnosis, but also provides information 
about the location of the lesion for further treatment planning. Standard sequence for 
diagnosis including a T2 fluid-attenuated inversion recovery (FLAIR), pre-gadolinium 
T1, and post-gadolinium T1.77 These sequence can be obtained with high-resolution 
or 3D volumetric sequences. The typical presentation of GBM by the conventional 
structure MRI is a large heterogeneous mass with central necrosis, hemorrhage, 
contrast enhancement and peritumoural oedema. However, there are several 
limitations of structure MRI which facilitate the emergence of numerous advanced MR 
techniques. 
1.4.1 Structure MRI and Its Limitation 
Studies had shown several limitations of the conventional MRI112. In a cohort of 160 
GBM patient, the sensitivity, specificity, positive predict value and negative predict 
value using conventional structure MRI for the diagnosis of GBM are 72.5%, 65.0%, 
86.1%, and 44.1% respectively69. Another study comparing structure MRI diagnosis 
and histopathology diagnosis, only 42.5% sensitivity and 95.6% specificity were noted 
in the high grade astrocytoma.61  
T1 weighted with gadolinium contrast enhancement can show the breakdown of blood 
brain barrier and thought to be related with high grade tumours. Although contrast 
enhancing is the main finding in GBM, however, reports had shown that it is difficult to 
differentiate low grade and high grade glioma only from the enhancement124. In 
addition, it is difficult to differentiate GBM from other high grade tumour by contrast 
ring enhancement, and many lesions, such as abscess, also share this feature.  
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The hyperintensity in T2/FLAIR presents the vasogenic oedema in the peritumoural 
area. It is not only the exclusive feature of GBM, but also fail to represent the tumour 
infiltration. In a biopsy study, normal signal in conventional T1 and T2 MRI showed 
16% and 4% of false negative rates respectively.109 Besides, in the latest modification 
of the Response Assessment in Neuro-Oncology (RANO), T2/FLAIR for the 
assessment of tumour response has been removed due to its complex physiology 
meaning.31 Therefore, the accurate assessment of treatment response in GBM cannot 
be achieved by using only structure MRI due to the lack of the biology information. 
Gruso et. al.in 2005 used methionine positron emission tomography for the radiation 
therapy target planning showed that the uptake of methionine area was different from 
both contrast enhancement and T2 weighted MRI in the postoperative GBM40. And the 
study concluded that the methionine PET can provide a more accurate gross target 
volume for radiation therapy.  
Pseudo- progression and pseudo-response are also another two challenges in the 
assessment of treatment response in GBM. Pseudo-progression is a temporary 
contrast enhancement in about 20-30% of the patients after surgical resection and 
radiation therapy.161 This is due to the disruption of the vascular permeability by 
surgery or radiation effect which cannot be easily differentiate by using T1 post 
contrast MR. The pseudo-progression happens mostly on within 3 months after 
radiation therapy, therefore a true progression within 3 months can be only defined by 
the progression mainly outside of the radiation field161. The pseudo-progression can 
be affected by the temozolomide, and the MGMT promoter methylation status which 
further complicated the treatment decision.12 Pseudo-response on the other hand, 
showed marked decrease of the lesion enhancement after patient been treated with 
bevacizumab or other types of anti-angiogenic agents. Structural MRI is unable to 
16 
 
distinguish pseudo-progression and true progression, and these phenomena address 
the limitation of T1 contrast enhancement MRI in the tumour biology.  
In addition, although we know conventional structure MRI cannot accurately identify 
the full extent of the disease, surgical and RT planning as well as clinical follow-up, 
are mostly base on T1 contrast enhanced MRI. This weakens the efficacy of the 
standard treatment, and inevitably results in the tumour recurrence, which often 
happens within two centimeters beyond the surgical margin32. In order to overcome 
these problems, numerous imaging methods are now being developed154.  
1.4.2 Diffusion MR 
The diffusion weighted imaging is based on the measurement of the Brownian motion 
of the water molecule. When protons been excited by a homogenous magnetic field in 
MRI, protons can spin likes gyroscope with same precession rate and phase. The rate 
of precession is proportional to the magnetic field strength (Larmor equation). When a 
pulse gradient is applied, the protons may have different precession rates depend on 
the magnetic field (dephasing). However, if another gradient added in the same 
direction, same time duration but an opposite magnetic direction, the protons signal 
theoretically rephrase if there is no proton movement (diffusion restriction). Therefore, 
if the protons move during the two gradient pulses, the protons may remain diphased 
at the end of the dephasing- rephrasing and subsequently lead to signal loss. In 
summary, the diffusion imaging, usually gradient-echo planar imaging, image is 
acquired by sensitizing the motion of protons. The difference in diffusivity (figure 1.2)85 
can be used to differentiate the different types of oedema, cellularity, and even the 
degree of malignancy.63  
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The amount of the diffusion signal loss by gradient application follows the equation: 
S
𝑆0
= e
−𝛾2𝐺2𝛿2(∆−
δ
3)D = 𝑒−𝑏𝐷  
S is the signal with the gradient application and S0 is without gradient. D is the diffusion 
constant. Therefore, higher water diffusion rate (Diffusion constant, D) leads to lower 
diffusion weighted imaging (DWI) signal. The b-value represents how much gradient 
is applied and is dependent on the nuclear gyromagnetic ratio (γ), magnetic field 
strength (G), duration (δ) and the time interval between gradient (∆).84 However, the 
DWI signal can be affected by both b-value and T2-weighted effect. Therefore, 
calculation of the diffusion constant (D) in each voxel can create the apparent diffusion 
coefficiency (ADC) which is used to represent the quantitative measurement of the 
speed of diffusion (mm2/sec). It not only reflects the true diffusion, but also depends 
on spatial orientation, bulk tissue motion, and pulse sequence timing. 
ADC = D 
For example, within the ventricle the water molecule diffusion is assumed to be 
unrestricted, due to the Brownian law this is called isotropic diffusion, and this may 
cause a large signal loss in DWI and a high ADC (3200 x 10-6mm2/s). ADC will also 
increase in the situation of vasogenic oedema, where extracellular fluid increase 
results in the increase of water diffusion. On the contrary, if in circumstance of 
extracellular water restricted due to local pathology, there will be high DWI and a 
reduction in ADC. A reduction in ADC had been shown to be related with increase 
cellularity in glioma143, CNS lymphoma or medulloblastoma117. The value of ADC has 
also be shown to be associated with the grading of glioma, a lower ADC can be seen 
in higher grade glioma resulting in a worse prognosis.49 Howver, when using ADC to 
assess the whole GBM lesion, the mean value can be confusing, due to the 
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intraturmoral heterogeneity which combines necrosis, oedema and hypercellularity.  
In addition, ADC can also be used as a prognostic factor in treatment of GBM. Studies 
using pre-treatment ADC histogram analysis showed that patients with mean lower 
Gaussian curve have longer survival (both OS and PFS) when treated recurrent GBM 
with bevacizumab30. The changes of ADC after treatment can be correlate to clinical 
outcome. A study showed that any changes (increase or decrease) after treatment can 
correlate with poor outcome96. Another study showed that a detectable decrease in 
ADC can predict the development of contrast enhancing lesion41.  
In an actual brain, the diffusion is not always isotropic; instead there is a tendency of 
diffusion along the axon, which is anisotropic diffusion (figure 1.2). Therefore, diffusion 
tensor imaging (DTI) is based on calculating the tensor of the diffusion and provide 
more information about direction (eigenvector) and magnitude (eigenvalue, λ) of the 
anisotropic diffusion. Different calculations had been used in the DTI. The mean 
diffusivity (MD) is for the isotropic diffusion, whereas fractional anisotropic (FA) is often 
reported as a relative measurement of the anisotropic diffusion (figure 1.3)106.  
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Figure 1.2 
Illustration of difference diffusivity in unrestricted isotropic diffusion isotropic restricted 
diffusion and anisotropic restricted diffusion. 
(adapted from Diffusion tensor MR imaging and fiber tractography: theoretic underpinnings. AJNR American 
journal of neuroradiology 2008;29:632-41) 
 
Figure 1.3 
Tensor calculation of diffusivity into mean diffusivity and fractional anisotropy. 
(The role of advanced MR imaging in understanding brain  pathology. British journal of neurosurgery 
2007;21:562-75) 
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A biopsy studied had shown that FA in the peritumoural area is negatively correlate 
with the degree of glioma infiltration.24 And a lower FA, compared with normal 
appearing white matter (NAWM), can be seen in the peritumoural area of the glioma 
or metastatic tumour, but the FA value showed no difference between high grade 
glioma and metastatic brain tumour.75,76 A decrease in relative anisotropic index 
(defined as below) can also be used to detect subtle white matter change caused by 
the malignant tumour infiltration.108 
 
Pêna et al have conducted a series of studies of DTI imaging processing. Further 
dissecting of the diffusion tensor into isotropic component (p) and anisotropic 
component (q) gives us more information. 
p = MD x 1.732 
q = √ (ƛ1-D)2 + (ƛ2-D)2 + (ƛ3-D)2 
P is another representative form of the MD, and q can show the absolute directionality 
of tensor. Studies have shown that q, but not FA, is lower in the GBM peritumoural 
area than in the metastatic peritumoural area which may due to tumour infiltration.156 
By calculating the p q map, the DTI can differentiate when the white matter is displaced, 
infiltrated or disrupted by the glioma cell111. In addition to the change in white matter, 
the utility of the p q map can be an indicator of infiltration, even in the area shown to 
be normal by conventional MRI. A biopsy study showed that an 10% increase in p and 
12% decrease in q can detect the possible tumour infiltration margin with a sensitivity 
of 98% and a specificity of 81%.105 Moreover, by classifying the p q map into diffused 
(p > q ), localized (p > q in a certain direction) and minimal (p = q) infiltrated patterns, 
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this can predict site of progression and show substantial differences in patient 
prognosis.83 And among these three groups the diffused type carried the worst 18-
month progress-free survival. In a more recent study showed that in all patients with 
IDH-mutant GBM had the minimal infiltrated DTI phenotype, while only 8% in the IDH-
wild GBM patients.107 
DTI can also be used for radiotherapy planning. Studies had shown that by using DTI 
defined margin, a 50% reduction in the clinical target volume (CTV)7 and a 35% of 
reduction planning-target volume (PTV)57 can be achieved to cover the site of tumour 
recurrence. This may minimize unnecessary radiation. Therefore, the GBM imaging 
shown by the DTI can provide more information than the conventional MRI. 
The DWI and DTI are based on the hypothesis that water molecules diffuse equally in 
all direction and were calculated according to the Gaussian distribution. However, the 
complexity of the microstructure in real brain causes the diffusion of water molecule in 
a more variant distribution pattern. Therefore, diffusion kurtosis imaging (DKI) has 
been development to evaluate a more accurate diffusion of water molecule in a non-
Gaussian way133. The kurtosis describes the deviation of the peak of probability 
distribution from the Gaussian pattern.  Three parameters are widely used. The mean 
kurtosis refers to the average of the diffusion kurtosis along all directions; the axial 
kurtosis which is the diffusion kurtosis along axial direction; and the radial kurtosis. 
The applications of the diffusion kurtosis imaging have been used in various of clinical 
situations including stroke, degenerative disease, traumatic brain injury, fibre tracking 
and brain tumour. Van Cauter et al. showed a better discrimination of low and high 
grade glioma by using the diffusion kurtosis imaging than the conventional DWI150. 
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1.4.3 Dynamic Susceptibility Contrast MRI (DSC-MRI) 
Neovascularization is one of the features of GBM histology, this may cause change of 
regional cerebral perfusion and vascular permeability. Perfusion MR technique, 
including T2* weighted DSC-MRI, T1 weighted dynamic contrast-enhanced (DCE), 
and arterial spin label MR, were used for the GBM.  
DCS-MRI, relies on the T2* signal drop caused by the passage of a gadolinium-
containing contrast agent through the tissues. The drop in signal is proportional to the 
concentration of the contrast agent and the tissue vascularity. Therefore, we can 
further get the volume of blood in the voxel over the mass of tissue within the voxel by 
calculating the area under relaxavity curve, and this ratio is called relative cerebral 
blood volume (rCBV). However, due to the abnormal vascular permeability in GBM 
that cause contrast leakage, further computational correction11, such as perfusion 
post-processing package in NordicICE (Nordic NeuroLabs, Bergan, Germany). By 
using this method, we can know the histologic grading before the operation. Hakyemez 
et al in a study of 33 glioma patients showed that higher rCBV in high grade glioma 
(6.50±4.29 versus1.16±0.38, p < 0.001) with the cut-off value of 1.98. Price, et al also 
showed that the rCBV is proportional to the mitotic rate (MIB-1 index) 110. A higher MIB-
1 index, which means a more malignant, may show higher rCBV. Besides, increase 
rCBV can be seen in the invasive margin, this can be seen in the study of DTI-defined 
invasive peritumoural area.113 In addition, studies also show that the changes in rCBV 
can detect the malignant transformation of the low grade glioma into high grade glioma 
one year earlier than the conventional contrast MRI study. 
Although DCE-MRI and arterial spin label MRI were not used in this thesis study, both 
are important emerging technique in the study of GBM. DCE-MRI can calculate Ktrans 
which reflects the efflux rate of gadolinium contrast from blood plasma into the tissue. 
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It is affected by the microvascular permeability, vascular surface area, and blood flow. 
DCE-MRI can also be used to differentiate low grade and high grade glioma.72 DCE-
MRI can also help to show pseudoprogression of GBM after treatment. A retrospective 
study showed that in regions of pseudoprogression, there are significant lower plasma 
volume and Ktrans.146 Although this is less commonly used than DSC-MRI, DCE-MRI 
can provide a better spatial resolution and lower magnetic susceptibility artifact.17 
Arterial spin label MR is a non-contrast technique, that use endogenous magnetic 
labeled due to the blood flowing into brain. Although it is less frequently studied, arterial 
spin label MR can provide quantitative value of cerebral blood volume and the 
information of tumour angiogenesis which is also comparable to DSC-MRI.158  
 
1.4.4 Magnetic Resonance Spectroscopy 
MRS is a way to understand local metabolism from the information of chemical 
molecule/ metabolites. The detection of the metabolites is based on the chemical shift, 
which refer to the difference in resonance frequencies of two nuclei in different 
molecular environments. Therefore, for example, proton may have different resonance 
frequency in water and fat. In MRS the frequency change cannot be used for spatial 
encoding, it further transforms the signal into the frequency spectrum. Specific 
molecular compounds can be detected and quantified by measuring their resonance 
frequencies in a certain region in the tissue63. There are different types of MRS and 
the most common is proton MRS (1H MRS). Because the proton is abundant in water 
and fat that may overwhelm the signal of other metabolite, therefore water suppression 
technique should be applied and also avoid voxel selection of the fat in bone marrow 
or scalp.  
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In the 1H MRS, the most important indicator is the Choline (Cho)/ N-acetyl aspartate 
(NAA) index. The choline represents the turnover rate of the cell and the NAA is usually 
an indicator of the normal neuron. Therefore, in the region with active cancer cells 
there is always a high Cho/ NAA ratio. And this can be used to delineate tumour margin 
which is different from structure MRI. Pirzkall et. al in 2001 used the Cho/NAA defined 
target volume for radiation therapy and showed that the metabolically active tumour 
can extent outside of T2 hyperintensity up to 28 mm in 88% of cases102.  
The MRS also contributes to the assessment of treatment response in glioblastoma, 
such as the differential diagnosis of the pseudo- progression and true progression. In 
a systemic review compared the diagnostic accuracy for treatment response between 
different MR techniques showed that the MRS has the highest diagnostic accuracy 
(sensitivity: 91%, specificity: 95%)152. Besides, studies have shown that distinct 
differences exist in the peritumoural 1H-MRS characteristics that can differentiate GBM 
from the non-invasive meningioma.163 
Furthermore, MRS can also be used to detect 2-HG, which is a product from alpha-
ketoglutarate in IDH1-mutant GBM20. However, the detection of the 2-HG is difficult by 
using the standard MRS, its spectrum occurs between 2.4-2.6 ppm that overlaps with 
glutamine and glutamate peaks104. Other types of MRS also provide valuable 
information, 13C MRS is a good tool for enzyme kinetic study, and 31P MRS for 
phsophorylated target detection.  
1.4.5 Multimodal MRI and Radiomics 
With the developing of different advanced MR techniques, both structural and the 
physiological information can be studied now (Table 1)10,154. Numerous studies had 
used the combination of different MR techniques to study the intra-tumoural 
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heterogeneity, tumour invasive margin, clinical prognosis, response to treatment, and 
diagnosis of pseudo-progression/ response. 
Two examples of GBM cases were shown here to demonstrate the heterogeneous 
presentations in different MR techniques (Figure 1.4). In these two cases, we 
compared T1 weighted with contrast MR, DTI-q, DTI-q and MRS on the same level. It 
is clear that, by using different MR techniques, the regions of abnormality are different. 
The contrast enhanced lesions are usually smaller than other MR sequences, this 
indicates the inadequate accuracy of T1 post-contrast MR to outline the GBM. Besides, 
on the MRS figures, where the heat map indicated the Cho/NAA ratio, showed that the 
uneven tumoural activity around the peritumoural area, whereas no difference in the 
structural MR.  
 
Figure 1.4 
Two representative GBM cases shown in T1 post contrast MR, DTI-p, DTI-q and MRS. The 
creamed-color defined the abnormal DTI-q areas, the yellow color showed the abnormal 
DTI-q areas. The heat map on MRS showed the level of Cho/NAA ratio. 
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Table 1 Summary of Different MR Techniques 
 Advantage and biomarkers Limitation 
Post contrast 
T1-weighted  
Can provide good spatial 
resolution by using 3D volumetric 
technique. 
The contrast enhancement is non-
specific which represents disruption 
of BBB, rather than the tumour cell.  
T2/ FLAIR Able to detect tissue water 
content/ oedematous changes. 
Lack biology specificity, which 
unable to distinguish tumour 
infiltration oedema and other types 
of oedema. 
DWI (ADC) Can quantify the diffusivity. An 
increase can be seen in cystic 
lesions, oedema, low cellularity, 
and necrosis.  Decrease 
indicates cytotoxic oedema, and 
higher cellularity.  
Unable to differentiate tumour cell 
from other inflammatory cells. 
Mixture of the oedema and increase 
cellularity may complicate the 
interpretation. 
DTI Can detect subtle white mater 
change, cause by tumour 
infiltration, displacement or 
disruption. Can be used as a 
surrogate for the GBM invasive 
margin. 
Lack detail information for the local 
biology microenvironment.  
DSC-MRI Provide regional rCBV, relative 
cerebral blood volume which 
represent vascularity. 
Analysis is operator dependent and 
calculation need to be corrected 
due to the damaged BBB in GBM.  
DCE-MRI Show vascular permeability 
(contrast transfer coefficient, 
Ktrans), rCBV, rCBF 
Good spatial resolution. 
Analysis is model dependent, 
and based on either flow-limited 
or permeability-limited 
conditions.  
ALS Quantify cerebral blood volume 
without contrast. 
Less applicable 
MRS Can provide metabolic changes in 
microenvironment. Ex. Cho 
(membrane turnover), NAA 
(normal neuron marker), lactate 
(anaerobic metabolite) 
The spectra resolution is time 
dependent, thus provide limited 
spatial accuracy. Susceptibility 
artefact due to blood or metallic 
implants 
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Since each MR techniques had its advantages and limitations. Radiomics can provide 
a more detailed quantification multi-modal MR study. The suffix –omic, originally refers 
to detailed characteristics of biology molecule. Radiomics is defined as the conversion 
of images to higher dimensional data and the subsequent mining of these data.37 This 
can be performed in computed tomography (CT), MRI or positron emission 
tomography (PET). The regions of interest (ROIs) can be a whole tumour or a 
subdivision of the tumour (habitat). The main difference the radiomics is the extraction 
of numerous quantitative images features. In the conventional imaging analysis, few 
quantified features (semantics features) can be extracted, such as location, vascularity, 
and size. And most semantics features, such as shape, can only undergoes qualitative 
analysis. By using high-throughput computing, radiomics can quantify more detailed 
agnostic features including first order, second order or higher order. First order 
features are the histogram analysis of the value in each voxel. This include mean, 
median, standard deviation, minimum, maximum, variance, kurtosis, skewness, 
entropy, energy, uniformity and root mean square. Second order features are the 
texture analysis that take the neighbour voxel into consideration. The second order 
texture analysis was firstly introduced by Haralick in 1973 by using the grey-tone 
spatial-dependence probability-distribution matrices to generate 14 different texture 
features44. Such features can provide information about images homogeneity, contrast, 
linear structure, and complexity. Grey-level co-occurrence matrix (GLCM) is a statistics 
based texture analysis, based on how often a pixel of intensity i finds itself within a 
certain relationship to another pixel of intensity j22. The GLCM texture analysis mainly 
provides energy, homogeneity, dissimilarity, and correlation. Another commonly used 
texture analysis is the run-length matrix (RLM) which calculates the run-length of the 
matrix from different directions. In an image with fine texture, more short runs with 
similar gray-level intensity can be found, whereas a course image has more long runs. 
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(more detailed explanations are shown in Chapter 7 section 7.2.3).  
Higher order analysis includes filter grid or wavelet analysis for the images. The 
application of the filters (such as Laplacian of Gaussian bandpass) can extract specific 
imaging strutures depending on the width of the filter. Other higher order texture 
analysis, such as model-based and transform-based methods were also used to 
maximise the imaging features131. 
The methodology of the radiomics is still under development, and there has not been 
a standard protocol for these radiomics process. Still, numerous studies have recently 
been published to investigate different kind of tumours. In 2014, Aerts used 440 
radiomics features of lung cancer from CT scan and showed different tumour 
phenotype with clinical prognosis correlation.1 Gevaert et at, in 2014 published a work 
in GBM.34 They showed the radiomics features can correlate with manual radiologist’s 
Visually Accessible Rembrandt Images features, and patient clinical survival. 
Moreover, 7 of these features can also correlate with gene expression. Another study 
used quantified radiomics data from 121 GBM patients to cluster 3 distinct MR 
phenotypes, the peri-mulifocal, spherical and rim-enhanced.54 They found each cluster 
had its different pathway which possibly explain the distinct prognosis. Radiomics can 
also be used to help clinical decision making. Hu et al, in 2015 used multi-parametric 
MRI and texture analysis to predict tumour density in both enhanced and non-
enhanced part based on a biopsy study and showed 85% accuracy in training set and 
81.8% accuracy in the validation.52 Therefore, by using multimodal MRI with radiomics 
can provide a non-invasive way to understand GBM more and provide further support 
in clinical decision. 
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1.5 The Peritumoural Zone and Its Clinical Manifestation 
The peritumoural zone is an extension area from the primary tumour site which is 
usually identified by T1 post contrast MRI. There is no clear definition of this zone, 
however, it is important. As most surgical resection or biopsy is based on the T1 
contrast enhanced MRI, the peritumoural zone harbors the tumour invasive margin 
that is left after surgery. Although standard post-operation radiotherapy covers an 
additional 2-3 cm of the margin, there is still high local recurrent rate, this may due to 
these peritumoural GBM cells frequently have an invasive phenotype that are not in 
the cell cycle, and can be spared from the DNA damaging treatment. However, there 
is still limited understanding of the nature of GBM infiltration outside of contrast 
enhanced lesion. 
From the biology point of view, it is without doubt that the GBM cancer cell can extend 
beyond contrast enhancing area into these peritumoural zone. In one of the studies, 
researchers showed that cancer cell can be detected in 1/3 of the peritumoural zone 
where are contrast nonenhancing and visually normal under operative microscope.70 
They also showed a difference of the peritumoural zone from both contrast enhancing 
lesion and normal brain tissue in the proteomics and transcriptomics study. Similar 
result from Aubrey et al, showed at least 10% infiltrative cancer cell in 5 out of 10 
peritumoural zone biopsy.5  Another MR-guided biopsy study comparing the contrast 
enhancing and nonenhancing regions of the GBM showed that there are different 
molecular and cell types by using RNA-sequencing and histology analysis.36 In their 
study, the nonenhancing parts showed more neural type, and the contrast enhancing 
part predominant with proneural, mesenchymal and classic type of GBM. However, 
the biology characteristics of this peritumoural zone still not fully understood due to 
GBM spatial and temporal heterogeneity. The other possible reason is the sites of 
biopsy were roughly decided on structure MRI. 
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The common radiology definition of the peritumoural zone is hyper-intensity in FLAIR 
without contrast enhancement. An imaging study focus on this FLAIR defined non-
enhancing regions of GBM showed that, the increase of rCBV in these areas marked 
correlates with worse clinical outcome, both OS and progression free survival (PFS) 
(p = 0.0103, p = 0.0233).56 And they also found that worse prognosis in those patients 
with non-enhancing regions crossing the midline of the brain. However, the abnormal 
FLAIR signal in GBM is largely affected by the vasogenic oedema. Many of the 
emerging advanced MR techniques and imaging processing methods are now 
accessible. Therefore, many studies had used different MR techniques to identify the 
imaging biomarkers in this peritumoural zone. As previous mentioned, DTI can showed 
distinct characteristics in GBM peritumoural zone from metastatic tumours or 
meningioma.76,156 MRS studies also showed a higher Cho/NAA ratio in the 
peritumoural zone of the GBM than metastatic tumours/ meningioma or normal brain 
tissue.163 Still, a concise imaging definition of the invasive margin in the peritumoural 
zone is not identified.  
Furthermore, these peritumoural zones usually left behind surgical resection not only 
be the potential site of tumour progression/ recurrence, but also correlate with patients’ 
prognosis. As previously mentioned in section 1.3, the extent of resection may largely 
affect the clinical outcome. Surgical resection guided with fluorescence 5-ALA, can 
maximize the extent of resection that provides longer time to progression in GBM 
patient.27,135 Besides, studies had shown that the residual contrast enhancing lesion 
can largely affect both OS and PFS.65 Grabowski et al further showed not only residual 
contrast enhanced lesion but also the residual FLAIR were significant predictors of 
survival after controlling for age and performance score39.  
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In summary, the peritumoural zone has cancer activity, although is complexity of its 
biology is not fully understood, the clinical benefit can be achieved after the extended 
resection. However, the imaging biomarkers to identify a more defined invasive area 
in the peritumoural zone need to be further studied. 
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1.6 Summary and Conclusion of Literature Review 
GBM is the most common and malignant primary brain tumour arise from astrocyte/ 
neural progenitor cell. It can be classified into IDH-mutant and IDH-wild type which 
represents different pathogenesis and also different clinical presentation. However, the 
prognosis is still dismal even after multi-disciplinary treatment. 
Current imaging diagnosis and treatment planning rely on the T1 contrast MRI. The 
lack of biology specificity of this conventional structure MRI compromises the 
treatment effect. The peritumoural zone where tumour cells can infiltrate are left in situ 
after surgery due to lack of the contrast enhancement. This results in the high local 
recurrence/ progression rate even after radiotherapy and chemotherapy. Besides, 
oncology researchers may focus on the resected specimen which is thought to be the 
majority of the tumour mass, and study of the tumour activity in the peritumoural zone 
is previously underestimated. Currently, our understanding of the GBM heterogeneity 
is not only intra-tumoural but also peritumoural. Molecular biology study showed 
different genetic expressions in the core, the margin and the peripheral area of the 
tumour. This can be explained by its complex spatial and temporal evolution. 
Although more and more studies had shown the important in this peritumoural zone, 
not all the peritumoural zone (usually defined by FLAIR) is the tumour invasion margin, 
and the identification of this invasive margin remained unsolved. The development of 
different MRI techniques (DWI, DTI, perfusion MRI, MRS…) provide more information 
in cancer physiology behavior rather than simply anatomical location. This attempts 
give us a hint to find the invasive margin outside of contrast enhancement. In addition 
to different MR techniques, data processing including the utilization of radiomics and 
machine learning provide us a new direction to search. 
Therefore, in order to identify the GBM invasive margin and to better understand its 
invasiveness, multimodal MRI with advanced data management is needed. 
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CHAPTER 2 
Hypothesis 
 
The aims of this thesis are to understand the imaging characteristics of the 
peritumoural zone where GBM recurs or progresses after surgical resection by using 
current multimodal MR techniques and further generates a model to identify/ predict 
the tumour invasive margin prior to surgery. 
 
Hypothesis Tested 
1. A more accurate image co-registration in brain tumour MRI between different time 
points can be achieved by using a two stage semi-automatic non-linear co-
registration method to overcome the massive regional distortion caused by surgery 
or tumour progression. The first stage is to calculate the transformation between 
resected lesion and resected cavity, then secondly apply to the brain parenchyma. 
(Chapter 4) 
2. A larger extent of resection, based on the DTI-defined invasive regions, can result 
in a better prognosis. Use the above method to coregister the post-operative MRI 
to the pre-operative MRI can conduct an accurate volumetric study to test the 
clinical effect of the extent of resection based on different MRI sequences. (Chapter 
5) 
3. The peritumoural abnormal DTI-q defined invasive area using MRS and perfusion 
MRI can have imaging characteristics similar to the main tumour bulk, such as 
higher Cho/NAA ratio and increase regional perfusion. (Chapter 6) 
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4. Different phenotypes of the peritumoural DTI-q defined invasive margin can be an 
independent factor correlates with patient prognosis. (Chapter 6) 
5. The two stages non-linear semi-automatic coregistration method to coregister MRI 
at tumour recurrence/ progression to the pre-operative MRI can identify the regions 
where eventually recur/ progress. And these peritumoural area that potentially 
recur/ progress can have distinct imaging characteristics comparing to other 
normal peritumoural area by using multimodal MRI and radiomics approach. 
(Chapter 7) 
6. The imaging characteristics obtained from the abovementioned can be used to 
establish a prediction model to identify the possibility of tumour progression in the 
peritumoural zone of the pre-operative MRI by using the machine learning model 
(convolutional neural network). (Chapter 7) 
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CHAPTER 3 
GENERAL METHODS 
 
3.1 Patient Population 
3.1.1 Inclusion and Exclusion Criteria 
Patients diagnosed with supratentorial GBM since 2010 were collected prospectively 
from a NIHR funded “Magnetic Resonance Imaging to Characterise Invasive 
Phenotypes in Cerebral Gliomas” study (ISRCTN62033854). All patients were 
identified and discussed at the neuro-oncology multidisciplinary team meeting. An 
informed written consent was obtained from every patient and this project was 
approved by the local Institutional Review Board (ethics reference no. 10/H0308/23). 
Eligible patients include those aged over 18 years old, with a Karnofsky performance 
score (KPS) of more than 70, and final pathology reported as GBM with or without 
mixed type. Standard treatment protocol of the GBM patient was described as below 
for all inclusion participants. Besides, all patients included in this study were suitable 
for maximal resection (>90%) which is evaluated by the operating surgeon before 
operation. Exclusion criteria were previous cranial surgery, previous cerebral 
radiotherapy or a known other primary tumour. In addition, patients not able to receive 
MRI examination, such as claustrophobia or non-MRI compatible implants, were also 
excluded from the study. 
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3.1.2 Patient Treatment 
All patients received a standard neurosurgical operation including resection followed 
by focal concomitant chemoradiotherapy (CCRT) and adjuvant chemotherapy 
treatment regimen138. Surgical resection was performed with the principle of maximal 
safe resection with fluorescence 5-ALA guidance under the assistance of 
neuronavigation. Standard CCRT was started as soon as possible after stabilization 
of the patient’s post-surgical condition, usually one month after the operation. 
Concomitant Temozolomide treatment was prescribed during radiotherapy, and was 
adjusted by patient body weight with 75mg per body surface area per day 
(75mg/m2/day). After 28 days’ break, patients received six cycles of adjuvant 
Temozolomide (150–200 mg/m²) treatment for 5 days monthly. 
3.1.3 Patient Characteristics and Outcome Measurement 
Relevant patients’ characteristics were listed in the APPENDIX A. 
Extent of resection (EOR) is categorized into gross total resection (GTR) or complete 
resection of the enhancing lesion and subtotal resection (STR). Pre-operative tumour 
volume was defined by T1-weighted contrast MRI with manually segmentation (please 
refer to section 3.2.8). Tumour location was categorized into non-eloquent, near 
eloquent and eloquent area according to Sawaya classification.120 IDH-1 mutation 
status was conducted through immunochemistry test for the R132H mutation.  
Progression free survival was defined from the operation date to time of progression 
based on the modified RANO criteria31. In brief, a progression disease is defined as a 
≥25% increase in sum of products of perpendicular diameters or ≥40% increase in 
total volume of enhancing lesions in at least two sequential scans separated by at ≥4 
weeks. Overall survival was defined from the operation date to time of death or last 
follow up for non-censored patients. 
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3.2 MRI Acquisition and Image Processing 
3.2.1 MRI Study Time Point 
All patients received a standard diagnostic MRI study including 3 dimensional 
volumetric T1 weight with contrast enhancement (magnetization-prepared rapid 
gradient-echo, MPRAGE), T1 weighted without contrast, T2 weighted, FLAIR, DTI, 
DWI, MRS and DSC-MRI within one week before surgical intervention. All other 
following MRI studies include non-volumetric T1 weight with contrast enhancement, 
T2 weighted, FLAIR and DWI. 
After the surgical resection, an immediate post-surgical MRI was done within 72 hours 
after operation. The time point of series MRI studies were done as in figure 3.1. 
Approximately one month after the operation, for those patients suitable to receive 
CCRT, an additional MRI was done for radiotherapy planning. After the CCRT, a post-
RT MRI was obtained for treatment response evaluation. Follow up MRI studies were 
then planned every three months after treatment, with some modification according to 
patients’ condition or clinical needs. 
 
Figure 3.1 
Scheme of patient treatment and MRI studies time points. Note that the pre-surgical 
and post-surgical MRI studies were obtained strictly within 7 days before operation 
and 72 hours after operation. Time points for pre-Radiotherapy (RT), post-RT, post-
CCRT and follow up MRI studies may be varied according to patients’ condition and 
clinical needs. 
38 
 
3.2.2 MRI Acquisition and Parameters 
All pre-surgical MRI studies were performed with a 3.0 Tesla Siemens Magnetron MRI 
system (Siemens Healthcare, Munich, Germany) with a standard 12-channel head coil. 
Detailed parameters for each MRI sequence are listed in table 2. 
Table 3.1 
 
Post-surgical, pre-RT, post-RT, post CCRT and other follow-up MRI studies were 
acquired on a 1.5 Tesla GE Optima, 1.5 or 3.0 Tesla GE Signa (General Electric 
Company, Little Chalfont, United Kingdom) or 1.5 Tesla Siemens Avanto (Siemens 
Healthcare, Munich, Germany) with standard head coil. Parameters and settings were 
varied in these MRI studies. Sequences include a 2D T1-weighted sequence (TR/TE 
440-771/8-21 ms, flip angle 58-90°, FOV 220-240 x 207-240 mm; 20-85 slices; 0-1 
mm slice gap; voxel size 0.429-0.7188 x 0.429-0.7188 x 3-6 mm), a 2D T1 inversion 
recovery sequence (TR/TE 2508-2600/12-42 ms, inversion time 780-920 ms; flip angle 
SIEMENS 3.0 Tesla MRI 
12-channel standard coil 
 T1C PWI T1 T2 T2F DTI MRS 
Sequence GR\IR EP SE SE SE\IR EP csi_se 
TR(ms) 2300 1500 50 4840 7840 8300 2000 
TE(ms) 2.98 30 8.6 114 95 98 30 
Thickness (mm) 1 5 4 5 4 2 20 
FOV 256x240 192x192 240x192 220x165 250x200 192x192 160x160 
Voxel size (mm) 1 2x2x2 0.75x0.75x4 0.6875x0.6875x5 0.78125x0.78125x4 2x2x2 10x10x20 
Number of Slices 192 19 27 23 27 63  
Flip angle 9 90 90 150 150 90 90 
Contrast GADOVIST*      
FOV= field of view; GR= Gradient echo; IR = Inverse recovery; SE= spin echo; EP= echo planner; 
CSI=chemical shift image; MRS acquired matrix size (mm) = 16 x 16; *GADOVIST 9ml given during the 
DSCI at rate of 5ml/sec via a power injector. 
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90-110°, FOV 220 × 220 mm; 20-22 slices; 1-3.5 mm slice gap; voxel size of 0.4297 x 
0.4297 x 6 mm) or a 3D T1 fat suppressed sequence (TR/TE 7/2.948 ms, inversion 
time 900 ms; flip angle 190°, FOV 256 × 256 mm; 190 slices; no slice gap; voxel size 
1 x 1 x 1 mm). T2, T2F and diffusion weighted images were also performed in most of 
the cases. 
 
3.2.3 Pre-processing and Imaging Management 
General diagnostic MRI data retrieve and general imaging processing pipelines are 
shown in figure 3.2. 
 
Data retrieve (Figure 3.2 blue section) 
After the scanning of the diagnostic MRI, raw images data in the format of Digital 
Imaging and Communications in Medicine (DICOM) were stored in the WBIC server. 
These DICOM files were downloaded anonymous and transformed into Neuroimaging 
Informatics Technology Initiative (nifti) files. The use of nifti file not only compatible in 
most of the imaging processing software, but also facilitate the data transferring, 
sorting and processing. The download and sorting were proceeded by using an in-
house built function created by a senior member of the lab, Dr. Timothy J Larkin.  
 
Pre-Processing (Figure 3.2 grey section) 
Position and orientation of the images 
Because MRI studies setting may be slightly modified from time to time during the 
cohort, it is important to correct all MRI studies into the same orientation and use the 
same anatomy target (anterior commissure) as the central point of image volume. This 
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step is mandatory before not only DTI processing but all other imaging processing. 
Therefore, all images were put into radiologic space with a Wolfson Brain Imaging 
Center (WBIC) inbuilt function “nii_to_radio”. And the setting of anterior commissure as 
central point (0 0 0 in x y z coordinates) of all images volume by using the Statistical 
Parametric Mapping (SPM) software package in Matlab (The MathWorks, Inc.). 
Brain Extraction 
Before individual imaging analysis or imaging coregistration, brain extraction by using 
FMRIB Software Library (FSL) function (“bet”) was automatically followed by manual 
correction.128  
 
 
Imaging Processing (Figure 3.2 green section) 
Individual imaging processing will be addressed in the following sections (section 3.2.4, 
3.2.5, and 3.2.6). 
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Figure 3.2 
Pipeline of Diagnostic MRI acquisition and general imaging processing. 
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3.2.4 DTI Imaging Procession 
DTI images were processed using FSL version 5.0.0 (www.fmrib.ox.ac.uk/fsl)59; 
detailed scripts were listed as appendix B. Reposition and reorientation of the images 
were done prior to the processing as described above. 
Eddy current correction 
Eddy current can occurs nearby the conductor whenever magnetic field changes. This 
effect can cause unwilling stretch or shearing of the images due to the changing of the 
magnetic field. The effect of eddy current depends on the rate of changes of the 
magnetic field, therefore in DTI which uses the fast echo-planner imaging can 
commonly have this artifact. Therefore, eddy current correction is needed before 
processing by using “eddy_correct” function in FSL FMRIB’s diffusion toolbox (FDT). 
(Note: a later version of eddy current correction function “eddy” has been recently 
released in FSL) 
Diffusion tensor analysis 
Further DTI parameters were then calculated by using FSL “dtifit” function. Outputs of 
the DTI processing include: 
Table 3.2 Outputs from FDT 
FA Fractional anisotropy 
L1, L2, L3 the tensor eigenvalue (magnitude) 
MD Mean diffusivity 
MO Mode of the anisotropy 
SO raw T2 signal with no diffusion weighting (b0) 
V1, V2, V3 the tensor eigenvector 
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ADC was generated directly from scanner with an inline calculation, utilizing b-values 
0-1000. Further calculation of the p and q were proceeded by using “fslmaths” function 
under FSL terminal100 with the below equation as described previously. 
p = MD x 1.732 
q = √ (ƛ1-D)2 + (ƛ2-D)2 + (ƛ3-D)2 
Examples of the scanner generated ADC, FDT DTI analysis outputs (MD, FA) and p, 
q map were shown in figure 3.3. 
 
Figure 3.3 
Examples from data P100 shown different outputs of DTI analysis. ADC directly from 
scanner (A), outputs of FDT: MD (B), FA (C), S0 (F) and the calculated DTI p (D), DTI 
q (E). 
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3.2.5 Perfusion MRI Processing 
Reoriented, unify central point and brain extracted images were prepared before 
processing perfusion MRI as described above. 
NordicICE (NordicNeuroLab, Bergen, Norway, http://www.nordicneurolab.com) was 
used for the DSC-MRI analysis. Images was then processed with leakage correction 
and pre-bolus range was set approximately 5-10 ms before contrast. The arterial input 
function is generated automatically by software. Gamma variate function was used for 
great vessels and outliers. Relative cerebral blood volume (rCBV), relative cerebral 
blood flow (rCBF), time to peak (TTP) and mean transit time (MTT) were calculated. 
An example was shown in figure 3.4. 
 
Figure 3.4 
An example of DSC-MRI generated from the original PWI (A); rCBV directly from 
scanner (B) in color map (D), and from NordicICE after leakage correction (C) in color 
map (E). 
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3.2.6 MRS Processing 
Spectroscopy data were processed by the LC Model. In order to remove the residual 
water signal, the start of the parts-per-million (ppm) was set at 3.85, and the end of 
the ppm was set at 1.8 to remove the lipid peak. A grid size 8 x 8 (rows and columns) 
was selected visually for analysis by radiologists. Normalized metabolites 
concentration was calculated with absolute concentration divided by Creatine 
concentration in every voxel in order to avoid the dilution effects associated with the 
peritumoural oedema67. Any normalized voxel data with standard deviation greater 
than 20% was excluded. For MRS study, all images and ROIs were coregistered to T2 
space in order to overlay with the voxel grid which was selected in T2 MRI. (Figure 
3.5) 
 
Figure 3.5 
An example of combining coregistered T1 with contrast enhancement and the MRS 
voxel grid. The color map represents the Cho/NAA ratio.  
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3.2.7 Images coregistration (Figure 3.2 orange section) 
All MRI data were coregistered to pre-operative 3D T1 with contrast MRI , except for 
the MRS study, due to the MRS voxel selection were initially done by using T2 
weighted MRI (Figure 3.6). 
Images coregistrations were done in two different ways depends on the purposes. For 
images coregistration within the same scan time point between different sequences, a 
linear coregistration using “FLIRT” function in FSL with the following script.58,60  
flirt -ref <reference image> -in <input images> -out <output of FLIRT> -omat <reference 
transformation> -cost normmi -searchrx -90 90 -searchry -90 90 -searchrz -90 90 -dof 12 -
interp trilinear 
 
Such linear coregistration, transformation, translation, scaling and shearing between 
images can be corrected. However, due to deformation of brain tissue and pathology 
lesion, this requires a greater degree of freedom to fit these changes. The deformation 
before and after surgical operation and further due to the nature disease course, FLIRT 
may fail to achieve optimal co-registration for images between different time points. An 
example comparing linear and non-linear co-registration between pre- and post-
surgical MRI studies by using 3D slicer (http://www.slicer.org/ )33 check border filter 
(figure 3.7) shows significant torsion in the peripheral area. 
Non-linear co-registration, such as FSL FNIRT provides approximately 31,000 
degrees of freedom to fit the requirement. An example of registration between pre- 
and post-surgical T1 weighted with contrast MR is shown in figure 3.8. A grid is added 
to show the transformation of the images before and after registration and this grid is 
transformed in a non-linear pattern. By using FSL FNIRT some deformations images 
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can be well co-registered. A preliminary result to test the torsion of the central area by 
using septum pallucidum, and cerebral aqueduct also shows substantial deviation on 
the x coordinate by using the linear FLIRT (Figure 3.9, p = 0.0038), and only minimal 
difference between reference and the non-linear FNIRT coregistered images (p = 
0.2053). 
Although promising results can be achieved in some cases by FNIRT, this is not always 
the case, particularly in large deformation cases. FNIRT tends to pull two different 
voxel spaces close in order to minimize the difference. In other words, lesion in the co-
registered new image may be significantly torn, due largely to a gap in size between 
reference and input images, especially while coregistration images from different time 
points. Thus, a two stage non-linear semi-automatic coregistration was proposed to 
overcome the problem.151 Further details will be discussed in Chapter 4. 
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Figure 3.6 
Scheme of the coregistration flow. The pre-operative 3D T1 with contrast enhance 
MRI was used as reference images in most of the study except for the MRS (dotted 
square). Images within the same time point were coregistered by using linear FLIRT 
function. The processed DTI (FA, ADC, p, and q) and CBV were coregistered to the 
reference y applying the transformation matrix generated from the coregistration of 
the unprocessed DTI and PWI to the reference.  
 
 
Figure 3.7 
Obvious discrimination (7.02mm) by FLIRT (left) can be seen compared to FNIRT 
(right) by using the check border filter. 
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Figure 3.8 
The non-linear transformation of the grid represents the deformation of the brain 
before and after treatment. 
 
 
 
Figure 3.9 
Significant deviation on x coordinate using FLIRT with reference of septum pallucidum 
and cerebral aqueduct in 6 patients. (paired t-test, p=0.0038) 
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3.2.8 Regions of Interest (ROIs) and Image Analysis 
Regions of Interest (ROIs) (Figure 3.2 yellow section) 
ROIs creation were done by using FSL and 3D slicer (http://www.slicer.org)33. 3D slicer 
is used mainly for manual segmentation. And FSL function “FAST” for automatic 
segmentation of grey mater, white mater, CSF and contrast enhanced component. 
T1 weighted with contrast enhanced ROIs 
T1 weighted with contrast enhanced lesion (CE) of the pre-operative study MRI was 
created semi-automatically. The CE ROIs in this study contains all the volume within 
the abnormal contrast enhanced area. The 3D volumetric T1 with contrast 
enhancement MRI firstly underwent automatic segmentation by using FSL function 
“FAST” (Figure 3.10): 
fast –t 1 –n 4 –o <segmentation output> < corrected BET volume > 
This would give us segmented mask files including gray mater, white mater, CSF and 
CE. However, the output mask files usually not binary, therefore “flsmath” function of 
the FSL is used for binarise.  
fslmaths <mask> -div <mask> <binary mask> 
Furthermore, due to the interference of the true CE lesion and the normal vascular 
enhancement, further manual correction was needed to optimize the CE ROIs. The 
CE ROIs of the post-operative and follow up MRI were drawn manually by using 3D 
slicer with the assistance of the “level tracing effect”. 
The CE ROIs were used for the two stage semi-automatic non-linear coregistration 
method (Chapter 4), extent of GBM resection volumetric study (Chapter 5), the MRS 
study of the peritumoural abnormal DTI (Chapter 6), and the study of characteristics 
of the peritumoural progression zone (Chapter 7). 
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Figure 3.10 
Example of “FAST” segmentation from the brain extracted 3D volumetric T1 weighted 
with contrast MRI to three different mask files, including gray mater, white mater and 
contrast enhancement (CE) / CSF. Note that the resulting mask files are not binary 
and the mixture of CE and CSF need further correction. 
 
FLAIR ROIs 
The abnormal FLAIR signal represents the oedematous area of the lesion. These 
ROIs of abnormal FLAIR were created by using 3D slicer with the assistance of the 
“level tracing effect”. The resulted FLAIR ROIs were used in the extent of GBM 
resection volumetric study (Chapter 5). 
DTI p and q ROIs 
The abnormal increase in p and abnormal decrease in q map of the DTI represent the 
disruption or displacement of the white mater caused by GBM invasion. The ROIs of 
abnormal p and q were created manually by using 3D slicer with the assistance of the 
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“level tracing effect”. Inter-rater validation was done with the senior supervisor of the 
lab, Dr. Stephen J Price. The resulting DICE scores showed an agreement of 0.73 ± 
0.11 in the p ROIs and 0.68 ± 0.08 in the q ROIs. These ROIs were used in the extent 
of GBM resection volumetric study (Chapter 5) and the MRS study of the peritumoural 
abnormal DTI (Chapter 6). 
Normal Appearing White Mater (NAWM) ROIs 
The normal appearing white mater (NAWM) ROI was defined as visually normal on 
MRI study, and was used as control or comparison in studies. This was manually 
selected on the diagonal quadrant to the tumour, and drawn with a 10 mm diameter 
square mask by using 3D slicer. The selection of the NAWM ROIs was also inspected 
by Dr. Anouk van der Hoorn (University Medical Centre Groningen, The Netherlands). 
These were used in the study of characteristics of the peritumoural progression zone 
(Chapter 7).  
The NAWM ROIs in the MRS study of the peritumoural abnormal DTI were selected 
visually from the selected MRS voxel grid which located in the diagonal quadrant of 
the tumour. 
Imaging Analysis (Figure 3.2 red section) 
Images analysis were done by using different platforms depends on the purposes. 
General analysis including extraction of the pixel value, images combination, image 
extraction, and volume calculation were done by using Matlab (The MathWorks, Inc., 
USA) (APPENDIX C). The analysis of nifty file in the Matlab is proceeded by using the 
“Tools for NifTi and ANALYZE image” (Copyright (c) 2014, Jimmy Shen). 
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FSL was used for brain extraction, automatic segmentation, and to binarize images as 
previous mentioned. The dilatation of the ROIs was also proceeded in FSL. 
Specific and detailed imaging analysis procedures would be discussed in individual 
studies (Chapter 5, 6 and 7). 
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CHAPTER 4 
Validation of a Semi-automatic Co-registration of MRI Scans in 
Patients with Brain Tumours during Treatment Follow-up151 
 
4.1 Introduction 
As previously mentioned in Chapter 1, GBM carry a high mortality rate and poor 
prognosis. One of the unmet needs in treatment development research is the ability to 
easily identify differences in tumour characteristics and treatment response with MRI 
imaging biomarkers before, during and after therapy. This would facilitate research on 
treatment response in large sets of patients and discovery of new imaging biomarkers, 
further enabling personalization of therapy. In order to meet this demand, an easily 
applicable coregistration method is needed to coregister postoperative MRI with 
preoperative images during assessment of high grade gliomas. 
The goal of image registration is to find the best transformation to align the structure 
of the moving images to the reference images. Various imaging registration methods 
were developed for multi-modality fusion, longitudinal study and population modelling. 
These methods can be categorised into rigid and non-rigid which includes affine, 
projective, and the different deformation imaging registration (DIR) methods91. In the 
rigid image registration, the pixel-to-pixel relationship is fixed after the transformation 
(translation, rotation, scaling and shearing), on the other hand, the pixel-to-pixel 
relationship changes in the DIR. Before the starting of a typical DIR, a rigid or affine 
coregistration is needed as a baseline initiation. Then the moving image is 
coregistered to the reference image according to different DIR algorithms.  
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The DIR algorithm typically involve three component: an object function, a deformation 
model,  and an optimisation method130. The object function is used to define the 
similarity between image sets and it can be intensity-based, feature-based or both. 
During this process, the deformation vector field (a defined grid of control points to 
determine the involved deformation) is generated according to the transformation 
model, and further applied to the moving image through the Jacobian regularisation to 
obtain the coregistered image90. 
The transformation models can be classified into parametric and non-parametric. A 
typical parametric transformation model consists a group of spline models, for example, 
the B-spline model. Other commonly used parametric model such as statistical 
parametric mapping which is widely used between different functional 
neuroimages.  Diffeomorphic Demons is one of the commonly used non-parametric 
transformation model. In contrast to the parametric model which interpolates the 
deformation vector of many points, it generates the deformation vector field at each 
voxel. Different coregistration methods have been used in clinical practice or research, 
and Klein et al. in a comparison of 14 non-linear registration methods concluded that 
the ART and SyN have the highest accuracy in human brain MRI reistration66. 
As discussed in Section 3.2.7, a nonlinear registration is effective to coregister images 
in the same time point. However, there are significant challenges when comparing 
brain MR images at different time points. These changes do not only occur after the 
initial surgical procedure, but are rather a dynamic continuous process86. In addition 
to the structural changes caused by surgery, tumour response to treatment and 
chronic radiotherapy effects induce further changes. These changes, for example, in 
tumour volume and brain volume126, make the coregistration process even more 
difficult. 
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Though previous research has aimed to address these obstacles, an easily accessible 
and applicable coregistration method is not yet available for preoperative and 
postoperative MRI scans of patients with brain tumours. Most methods focus on 
coregistration of different sequences of the same scan time point with linear and 
nonlinear registration methods in healthy subjects and brain tumour patients. These 
existing methods demonstrate good performances for this intra-subject coregistration 
of data from the same time58,66 or to a standardized brain atlas82,169. Research has 
also demonstrated the value of a nonlinear coregistration for treatment response 
evaluation in patients without surgery28. However, surgery is mandatory to the 
treatment of the high grade gliomas. Therefore, the ability to deal with these 
deformation from time to time should be part of the coregistration method. 
Methods of MRI coregistration taking resection into account are scarce and have 
several limitations making them unsuitable as a widely and easily usable coregistration 
method. The few available clinical studies that have used an intra-subject 
coregistration method after surgery are difficult to replicate and evaluate as they use 
in-house software, and provide only limited details of methodology50,81,148. Technical 
studies suffer from other issues, such as small sample size19. Furthermore, these and 
other technical papers do not provide comprehensible coregistration guideline and 
thereby hinder wide applicability, especially for clinical researchers. 
There are a few methods available that coregister intraoperative images with 
preoperative imaging. However, these are limited by using other modalities, like CT89, 
tracked laser range scanning25 or ultrasound116. CT is inferior to MRI in detecting 
tumour recurrence and thus not routinely used for the treatment evaluation or in 
57 
 
research of brain tumour patients. Ultrasound and laser imaging are only possible 
during surgery when the skull is temporarily removed. The method from Nithiananthan 
and colleagues89 uses an approach that defines resected voxels based on an air 
density. This is not applicable to research with interest in tumour response assessment 
using postoperative MRI imaging as the resection cavity being filled with fluid and/or 
adjacent brain tissue. Other preoperative with intraoperative coregistration methods 
have only tested the complex algorithm on 2D data115. 
Therefore, a need for an easily applicable and usable coregistration method before, 
during and after treatment including surgical resection is clearly required. To address 
this, we developed a semi-automatic coregistration technique using widely used and 
freely available software. This may allow accurate evaluation of treatment response in 
future studies, which is essential for brain tumour imaging research and treatment 
response assessment in large sets of patients. We also provide detailed information 
about the steps and the code used. 
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4.2 Methods 
Patient inclusion and exclusion criteria were described in Section 3.1. All patient 
received standard treatment as previous described. In the beginning of this study, 32 
patients who had complete follow-up images in Cambridge University Hospital were 
included (Appendix A-2, unit: C). MRI data acquisition and processing were as 
described in section 3.2 described.  
4.2.1 Semi-automatic co-registration method 
Coregistration was performed using a two-staged semi-automatic method (Figure 4.1) 
using FSL. Before the coregistration stages commence, all images were realigned with 
the anterior commissure as the center point (coordinate 0, 0, 0) to minimize the 
influence of brain position (as described in section 3.2.3). 
The first stage was the coregistration of the binary masks, which consisted of the outer 
contour of the brain, the ventricles, and contrast enhancing area (presurgical MRI 
images, Figure 4.2, [X]) or resection area (follow up MRI images, Figure 4.2, [Y]). This 
was performed for each subject at the different time points to create a transformation 
matrix (Figure 4.1, step 4, Figure 4.2, A) using the FLIRT, FMRIB's linear image 
registration tool function. The brain contours were created from the inversion of the 
brain masks which were semi-automatically extracted128 followed by manual 
correction (Figure 4.1, step 1 and 2) and further binaries the resulted mask. The 
ventricles were identified with an automatic segmentation using the FSL FAST (Figure 
4.1, step 3, FMRIB's automated segmentation tool) function170. The FAST function also 
allowed a semi-automatic identification of the contrast enhancing area or resection 
cavity. The contrast enhancing area is targeted for resection and is replaced by the 
resection cavity on the direct postoperative and later follow-up MRI scans. Besides, in 
cases without postoperative resection cavity, the algorithm can still work by including 
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also the non-tumour part which is ventricle and outer contour of brain. Therefore, this 
stage of coregistration allowed for optimal correction of variable brain shift and 
surgery-induced changes at different time points. 
The second stage applied the transformation matrix, acquired from the first stage, as 
input for a nonlinear transformation matrix of the brain images (Figure 4.1, step 5 and 
6, using the FNIRT, FMRIB's non-linear image registration tool, functions). The 
nonlinear transformation of the brain images used additional subsampling levels for 
regularization. This also included the binary masks of the brain contour and ventricles 
from both the preoperative reference image and the follow-up image. This resulted in 
a coregistration of the follow-up brain extracted MRI scans with the preoperative brain 
extracted MRI scans. Detailed script of this algorithm is provided in Appendix D. 
Standard linear coregistration (FLIRT function) and standard FNIRT with default 
setting were done separately for comparison using the FLIRT and FNIRT option in 
FSL.  
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Figure 4.1 Coregistration steps  
The steps for the semi-automatic coregistration of the follow-up image with the 
preoperative reference image are illustrated. Number of the steps and filenames 
correspond to the text in the supporting material. The corresponding code can also be 
found in the text of the supporting material. 
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Figure 4.2 Calculating for reference transformation 
First stage of the coregistration aim to calculate the transformation matrix A of the contrast 
enhancing lesion to the post-surgical cavity. [X] = reference mask, including the presurgical 
contrast enhancing lesion, ventricle and external brain area; [Y] = input mask, referred to post-
surgical cavity, ventricle and the external brain area; A = transformation between [X] and [Y] 
 
4.2.2 Validation methods 
Validation was performed using a targeted registration error method for calculating the 
error in different directions. Validation in the x and y directions was performed utilizing 
the cerebral aqueduct and septum pellucidum on the same axial slice (Figure 4.3A). 
Validating in the y and z directions (Figure 4.3B) was performed utilizing the upper 
anterior boundary of the third ventricle, at the level of the foramen of Monro (Figure 
4.3C), on the same coronal slice. The central point of the tumour or cavity was targeted 
automatically for the calculation of the registration error at the location were most 
errors could be expected. Vectors were also calculated for all targets. All targeted 
registration errors were calculated for the semi-automatic non-linear coregistration 
method and compared to the linear coregistered and standard non-linear coregistered 
images. Differences were tested with a Wilcoxon signed rank test or paired t-test 
depending on the normality. Two-sided p-values were used.  
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Figure 4.3 Targeted registration errors 
Targeted registration errors are shown for the septum pellucidum in axial view (A), 
cerebral aqueduct in axial view (B) and the uppermost of the third ventricle (C). Images 
on the left show individual cases to illustrate the locations of the targets and the graphs 
on the right correspond to the whole patient set. Squares indicate coordinates for the 
presurgical MRI. The group mean is indicated by a filled square (■) and individual 
patients by open squares (□). Circles indicate the co-registered image differences after 
semi-automatic non-linear co-registration (SAC) of postoperative and preoperative 
images. The group mean is indicated by a filled circle (●) and individual patients are 
indicated by open circles (○). Triangles indicate the co-registered image difference 
after FNIRT (FMRIB’s Non-Linear Image Registration Tool) non-linear co-registration 
of postoperative and preoperative images. The group mean is indicated by a filled 
triangle (▲) and individual patients are indicated by open triangles (Δ). 
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In addition, a 3D structural similarity map (SSIM) was created157 using Matlab. 
Structural similarity map decomposes image quality into structure, contrast and 
lamination and compares each voxel by other voxels. It is created for each subject 
comparing the preoperative reference scan with the coregistered follow-up scan. The 
function is described as below: 
 
l = lamination; c = contrast; s = structure 
If two images (x, y) are equally similar to each other, SSIM(x, y) = 1 
 
μ= mean; σ= standard deviation; C = constant  
On the other hand, if two images or volume are completely different, SSIM will be -1. 
This was done for scans obtained postoperatively and at tumour recurrence separately. 
To display group results, the preoperative images were coregistered to standard MNI 
(Montreal Neurological Institute) space with a nonlinear transformation of the brain 
images including a lesion mask. This was preceded by a linear transformation of a 
binary mask of the brain exterior and ventricles. A mean structural similarity mask was 
then created by transforming the structural similarity mask of each patient to standard 
MNI space. The resection cavity or contrast enhancing areas were excluded for the 
mean structural similarity image, as these values are inherently different.  
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4.3 Results 
4.3.1 Targeted registration error 
The targeted registration error showed good performance of the co-registration 
method for the direct postoperative and recurrence images with a clear benefit over 
the linear coregistration method and standard FNIRT non-linear co-registration 
method (Table 4.1). In the co-registration of postoperative to preoperative images, in 
comparison with FLIRT, the SAC method showed a smaller vector deviation of the 
cerebral aqueduct (1.1 versus 1.6, p = 0.015). A smaller deviation was also detected 
for the septum pallucidum y coordinate and vector (1.3 versus 2.0, p = 0.029; 1.8 
versus 2.6, p = 0.021), as well as the uppermost of the third ventricle y, z coordinate 
and vector (0.4 versus 2.2, p < 0.001; 1.2 versus 1.9, p = 0.043; 1.3 versus 3.3, p < 
0.001). The SAC method also outperformed the default FNIRT co-registration, where 
there was small deviation between preoperative and postoperative images for most of 
the coordinates and vectors in the central tumour/cavity point, cerebral aqueduct, 
septum pellucidum and the third ventricle at the level of the foramen of Monro. 
 
The benefit of this co-registration method can also be seen in the co-registration of 
recurrence images to preoperative images (Table 4.2). The target error at the cerebral 
aqueduct and the roof of the third ventricle at the level of the foramen of Monro was 
smaller using the SAC method than the linear co-registration and FNIRT co-
registration. When using default FNIRT, there was a larger z coordinate deviation at 
the tumour centroid point. In addition, the linear co-registration failed in three patients, 
and default FNIRT co-registration failed in two patients, for both the postoperative and 
recurrence scan, whereas the semi-automatic method was used without problems. 
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TABLE 4.1 – Targeted coregistration errors between pre- and post-operation 
  Postoperative with preoperative 
  SAC 
mean (range) 
 FLIRT 
mean (range) 
 FNIRT 
mean (range) 
 SAC versus FLIRT 
P-value 
SAC versus FNIRT 
P-value 
Central  x 3.0 (0.3-10.6)  3.3 (0.3-10.6)  7.0 (0.1-46.6)  0.242 0.023* 
tumour/  y 2.5 (0.1-7.4)  2.8 (0.1-8.3)  4.8 (0.2-28.2)  0.256 0.031* 
cavity z 2.6 (0.0-8.1)  2.7 (0.1-10.3)  5.2 (0.4-57.0)  0.758 0.003* 
 vector 5.3 (1.5-11.1)  5.7 (1.3-15.2)  11.6 (0.3-16.9)  0.099 0.002* 
          
Cerebral  x 0.5 (0.0-1.0)  0.7 (0.0-5.0)  0.6 (0.0-4.0)  0.166 0.305 
aqueduct y 0.8 (0.0-3.0)  1.2 (0.0-5.0)  2.7 (0.0-6.0)  0.051 <0.001* 
 vector 1.1 (0.0-3.2)  1.6 (0.0-5.4)  2.9 (0.0-6.1)  0.015* <0.001* 
          
Septum x 0.8 (0.0-4.0)  1.3 (0.0-9.0)  1.2 (0.0-9.0)  0.132 0.280 
pellucidum y 1.3 (0.0-4.0)  2.0 (1.0-8.0)  3.6 (1.0-7.0)  0.029* <0.001* 
 vector 1.8 (0.0-4.5)  2.6 (0.0-9.1)  4.0 (2.7-108.5)  0.021* <0.001* 
          
Third y 0.4 (0.0-1.0)  2.2 (0.0-18.0)  1.7 (0.0-6.0)  <0.001* <0.001* 
ventricle z 1.2 (0.0-4.0)  1.9 (0.0-14.0)  3.9 (0.0-12.0)  0.043* <0.001* 
 vector 1.3 (0.0-4.1)  3.3 (0.0-18.0)  4.5 (1.0-12.4)  <0.001* <0.001* 
Targeted registration errors are provided with the deviations (mm) of the anatomical 
landmark coordinates from the reference images after co-registration of the 
postoperative with the preoperative scan. The semi-automatic non-linear co-
registration (SAC), linear (FLIRT, FSL) and default non-linear (FNIRT, FSL) co-
registration are compared. An asterisk indicates statistical significance. 
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TABLE 4.2 – Targeted coregistration errors between pre-operation and 
recurrence 
Targeted registration errors are provided with the deviations (mm) of the anatomical 
landmark coordinates from the reference images after co-registration of the 
recurrence with the preoperative scan. The semi-automatic non-linear co-registration 
(SAC), linear (FLIRT, FSL) and default non-linear (FNIRT, FSL) co-registration are 
compared. An asterisk indicates statistical significance. 
  Recurrence with preoperative 
  SAC 
mean (range) 
 FLIRT 
mean (range) 
 FNIRT 
mean (range) 
 SAC versus FLIRT 
P-value 
SAC versus FNIRT 
P-value 
Central  x 5.0 (0.2-15.9)  5.6 (0.3-16.3)  9.9 (0.4-73.7)  0.204 0.131 
tumour/  y 4.0 (0.3-16.4)  3.0 (0.3-8.6)  13.6 (0.5-13.1)  0.247 0.226 
cavity z 5.0 (0.5-15.1)  4.2 (0.1-13.2)  11.5 (0.3-29.5)  0.297 0.008* 
 vector 9.1 (0.9-20.2)  10.0 (0.9-24.4)  23.3 (2.7-108.5)  0.875 0.102 
          
Cerebral  x 1.2 (0.0-5.0)  1.3 (0.0-4.0)  0.8 (0.0-6.0)  0.822 0.280 
aqueduct y 1.3 (0.0-3.0)  2.1 (0.0-5.0)  2.3 (0.0-8.0)  0.004* 0.032* 
 vector 2.0 (0.0-5.8)  2.8 (0.0-5.0)  2.7 (0.0-8.2)  0.016* 0.124 
          
Septum x 2.8 (0.0-12.0)  3.3 (0.0-14.0)  2.0 (0.0-19.0)  0.2132 0.188 
pellucidum y 2.8 (0.0-15.0)  2.8 (0.0-16.0)  3.0 (0.0-17.0)  1.0000 0.779 
 vector 4.3 (1.0-19.0)  4.6 (0.0-20.6)  4.1 (0.0-10.2)  0.7280 0.782 
          
Third y 0.6 (0.0-3.0)  3.0 (0.0-16.0)  3.1 (0.0-11.0)  0.0010* 0.001* 
ventricle z 2.6 (0.0-9.0)  2.5 (0.0-13.0)  3.1 (0.0-16.0)  0.8898 0.466 
 vector 2.7 (0.0-9.1)  4.6 (1.0-16.0)  5.1 (0.0-16.5)  0.0112* 0.006* 
68 
 
4.3.2 3D structure similarity 
The mean 3D structural similarity of all 32 patients showed the relative performance 
of the co-registration method (Figure 4.4). The peripheral areas, including the frontal 
and parietal areas, demonstrated the best performance. A good performance was also 
seen at the periventricular regions. A relatively smaller overlap between the co-
registered and reference preoperative scans was seen in the mid-sagittal and central 
areas, the centrum semiovale and central cerebellum. Mean SSIM value between 
semi-automatic co-registration, direct FNIRT and FLIRT is shown in Figure 4.5. 
An example of this co-registration is shown in Figure 4.6. Without appropriate co-
registration, one cannot confidently compare the initial postoperative or tumour 
recurrence images with the pre-operative reference images (Figure 4.6 A). Although 
the standard FNIRT co-registration of postoperative MR and recurrence MR images 
(Figure 4.6 B) realigned the images in the same space as the reference images, 
regional torsions (white arrows) were detected at the resection edges. Using the semi-
automatic co-registration methods, the co-registered postoperative MR (Fig. 4.6 C, left) 
and recurrence MR (Fig. 4.6 C, middle) images were able to show the residual 
contrast-enhanced lesion (yellow contour) and the recurrent area (red contour) in the 
reference MR image (Fig. 4.6 C). 
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Figure 4.4 Mean 3D group structural similarity for co-registration  
The group mean 3D structural similarity of all 32 cases is shown for the direct 
postoperative MRI (A) and later follow-up MRI at the time point of tumour recurrence 
(B), both co-registered to the preoperative MRI. Values indicate the relative structural 
similarity between the co-registered and original preoperative scans for the group 
mean, with higher values indicating a greater similarity between the images being 
compared. The color bar shows the degree of similarity from totally identical (max, red) 
to 0% similar (min, black). 
Figure 4.5 Mean of the SSIM between different coregistration methods 
A significant higher SSIM mean value was noted 
between SAC and FLIRT (p<0.0001). SAC showed 
slightly higher SSIM mean value than direct FNIRT, but 
without significance.  
 
 
 
SAC = semi-automatic co-registration 
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Figure 4.6 Examples of the two-stage semi-automatic non-linear co-
registration  
Without co-registration, the postoperative and recurrence images are difficult to 
compare with the preoperative reference image (A). With standard FNIRT (FMRIB’s 
Non-Linear Image Registration Tool) co-registration (B), although the gross brain 
positions are realigned in both postoperative and recurrence images, regional torsion, 
especially around the lesion (white arrow), may occur. After semi-automatic co-
registration (C), postoperative residual regions (C, left, yellow outline) and recurrence 
regions (C, middle, red outline) can be fitted with the preoperative reference image (C, 
right). 
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4.4 Discussion and Conclusion 
Discussion 
We developed and validated a two staged semi-automatic method for the 
coregistration of preoperative and follow-up MRI scans for both the direct 
postoperative and tumour recurrence time point (Table 4.1, Table 4.2, and Figure 4.5). 
The semi-automatic derived mask of the outer brain contour, ventricles and lesion 
allowed an accurate coregistration despite the changes in brain shift and postoperative 
changes. Therefore, this method is highly applicable to analyze large imaging datasets 
to evaluate treatment response, a growing and clinically important research area. 
Furthermore, it can be easily reproduced, allowing a wide applicability of the method. 
In the standard FNIRT function, an affine transformation is required as a starting guess 
of the coregistration. This affine transformation is typically the result of linear FLIRT 
coregistration between different MR series. However, the deformation in different time 
points happens mainly over the peritumoural regions, resection cavities, and ventricles. 
Our approach was to use the transformation affine of these areas with the greatest 
changes rather than the whole brain images (Figure 4.1 step 4). Furthermore, we 
added an inverted brain mask as an outer frame to our first stage coregistration for the 
gross spatial position (Figure 4.1 step 2 and 3). This resulting affine was further applied 
to the normal brain parenchyma with the mask of ventricle and lesion (Figure 4.1 step 
5) to achieve the optimal coregistration. Previous studies utilizing intraoperative 
coregistration have shown a clear advantage of nonlinear coregistration with high 
diagnostic and stereotactic accuracy28. This supports the results of the postoperative 
coregistrations from our study. 
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To the best of our knowledge, there is a shortage of easily applicable methods that 
allow coregistration of preoperative and postoperative imaging in patients with brain 
tumours. Clinical papers often use in-house software solutions and provide only partial 
description of the methodology. This two-staged semi-automatic coregistration method 
can be replicated by using the FMRIB Software Library which is a freely available and 
widely used software package in the neuroimaging research community. We have 
provided a detailed description of the steps required to recapitulate this approach (see 
Figure 4.1 and Appendix D). This makes this method easily reproducible by others, 
including clinical researchers, which further supported the rationale of using FSL for 
our coregistration method. Given this purpose of this study, we have not tried to 
validate the coregistration of patients with brain tumours using other software 
packages. Interpolation of our semi-automatic method to other software packages 
might be possible, but would require separate validation. 
The MR image acquisition parameters in our dataset varied across subjects and time 
points. In particular, a 3D T1-weighted with contrast enhancement dataset was 
available for the preoperative scan, but the follow-up images were almost always 2D 
and obtained with different MRI parameters and scanners from different manufacturers. 
Another limitation is that this method assumes that the resection cavity is a result of 
surgical resection of contrast-enhancing tumour only, and that the recurrent tumour 
arises from the non-contrast- enhancing surrounding area. However, the resection 
volume may extend beyond the area of contrast enhancement to include the 
‘peritumoural region’, particularly if the resection is conducted under the fluorescence 
guidance of 5-aminoleuvulinic acid122. Despite these differences, our validation 
showed that the method worked in all subjects, making it easily applicable in clinical 
practice. 
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At a time when adequate imaging biomarkers are being sought to evaluate treatment 
response, method applicability is of essence for the development of brain tumour 
research. Overcoming these treatment induced problems in the coregistration makes 
our semi-automatic coregistration a valuable method to facilitate research in the 
expanding area of personalized medicine in brain tumour patients. 
Conclusion 
We developed a semi-automatic coregistration method for MRI images of brain 
tumours to allow the accurate evaluation of treatment response in further research. 
We have demonstrated show good performance of this approach using 3D structural 
similarity and targeted registration error methods. We have also provided a detailed 
description of methodology using freely available software, making it reproducible by 
the neuroimaging community. This is an essential tool for the growing research area 
of brain tumour imaging and treatment response evaluation in large sets of patients. 
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CHAPTER 5 
Extent of Resection of Peritumoural Diffusion 
Tensor Imaging–detected Abnormality as a Predictor 
of Survival in Adult Glioblastoma Patients166 
 
5.1 Introduction 
As described in Chapter 1, GBM is a malignant cancer with high local failure rate. The 
main factors influencing prognosis are age, performance status, tumour molecular 
type, and extent of resection (EOR), of which the former three are fixed and the latter 
can be changed. Therefore, many efforts have made to improve the extent of maximal 
tumour resection while preserving normal brain tissue and function45,48,68. To achieve 
maximal tumour resection, intraoperative neuronavigation, 5-aminolevulinic acid (5-
ALA) and other imaging techniques (e.g., intraoperative MRI or ultrasound) have been 
introduced. Use of 5-ALA increased the EOR to 60-65% of the total contrast-enhanced 
area and prolong the progression-free survival135,137.  
A contrast-enhanced T1-weighted signal has many limitations in accuracy of the 
delineation of tumour margin (Chapter 1.3.1). Consequently, the clinical benefit of 
resection outside the contrast-enhanced area has been investigated73. Recently, it has 
been shown that extending the resection to the peritumoural high T2 signal areas 
beyond the enhanced lesion on postcontrast T1-weighted images can provide longer 
survival than less extensive resections73. This is thought to be due to tumour infiltration 
beyond the contrast-enhanced area118. However, a high signal on T2-weighted imaging 
is not specific for tumour infiltration, because it is also caused by oedema. 
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Application of the DTI, especially by decomposing the diffusion tensor into an isotropic 
component (p) and an anisotropic component (q) can detect tumour extent beyond the 
contrast-enhanced area because of subtle white matter changes. Detailed rationale of 
the DTI and its application has been discussed in Chapter 1.3.2. 
Therefore, this prompted our study analyzing the influences of the EOR of abnormal 
peritumoural DTI areas on patients’ outcome.  
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5.2 Method 
Patient Population and Treatment  
The inclusion, exclusion criteria and the treatment were shown on Chapter 3.2. 
We included 31 glioblastoma patients (mean age 56 years, range 31-68 years; 19 men 
and 12 women) who received complete follow up more than one year in Cambridge 
University Hospital from our consecutive cohort (Appendix A, Lab code: up to 113, Unit: 
C, P). At the time of the study, cases with lab code more than 113 haven’t received 
follow-up more than one year. 
Imaging Processing  
MRI data acquisition and imaging processing were described in Chapter 3.2. The 
coregistration method between post-operative MRI and baseline MRI were done by 
using the two-stage non-linear semi-automatic coregistration methods (Chapter 4). 
General Imaging work scheme was shown in Figure 5.1 by using the contrast 
enhanced T1 weighted MRI as example. After the co-registration of the post-operative 
to the pre-operative MRI, we further apply the generated transformation to the 
resection cavity (Figure 5.2, green mask) to achieve the coregistered resection cavity 
(Figure 5.2 blue mask) which can be further calculated for the extent of resection. 
Detailed description is shown in appendix E. 
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Figure 5.1 Workflow of the Imaging Processing 
The segmentation of the pre-operative images was done separately based on different 
MR techniques. After creation of the individual masks of the lesion, the post-operative 
MRI was coregistered to the pre-operative MRI by using the two stage non-linear semi-
automatic coregistration method. The resulted transformation was further applied to 
the post-operative 3D mask (green) to calculate the coregistered resection mask (blue). 
This can further overlap with the pre-operative lesion mask (red) to calculate the extent 
of resection. 
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Tumour Volume and Extent of Resection Data Analysis 
Extent of resection was determined from the resection cavity in the coregistered, 
postsurgical, postcontrast T1-weighted image (Fig. 5.2, blue outline) by one of the 
authors (Jiun-Lin Yan) blinded to the outcome, with the agreement of a second author 
(Anouk van der Hoorn, radiologist, Department of Radiology, University Medical Centre 
Groningen, University of Groningen, The Netherlands). The 3D, peritumoural, 
abnormal 
FLAIR, p, and q regions of interest were manually selected on the coregistered 
presurgical MR images (Fig. 5.2 B-D). The inter-observer correlation was done by the 
first author (J.L.Y.) and senior author (S.J.P.) with fair agreement (Chapter 3.2.8). The 
coregistered resected region was extracted from the total abnormal presurgical region 
for each sequence, using Matlab (MathWorks Inc.). Detailed function was described 
as below. The resected volumes were calculated for the p, q, and FLAIR regions by 
multiplying all voxels of interests with the slice thickness in Matlab. 
 
Matlab function for the volume calculation 
1. Calculate lesion volume (based on contrast enhancement, p, q and FLAIR) 
mask_lesion=load_untouch_nii('lesion_mask.nii.gz'); %load lesion mask 
roi_lesion=logical(mask_lesion.img); % make it logical 
% volume calculation 
vv=mask_lesion.hdr.dime.pixdim(2)*mask_lesion.hdr.dime.pixdim(3)*mask_le
sion.hdr.dime.pixdim(4); 
vol_lesion=sum(mask_lesion.img(:))*vv/1000; 
2. Calculate resection volume (based on post-operative contrast enhanced T1 MRI) 
mask_resect=load_untouch_nii('resection_mask.nii.gz'); %load resect mask 
roi_resect =logical(mask_resect.img); % make it logical 
% volume calculation 
vv=mask_resect.hdr.dime.pixdim(2)*mask_resect.hdr.dime.pixdim(3)*mask_re
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sect.hdr.dime.pixdim(4); 
vol_resect=sum(mask_resect.img(:))*vv/1000; 
3. Extent of resection (EOR) 
𝐸𝑂𝑅 =
(resection volume) ∩ (preoperative lesion volume)
preoperative lesion volume
 
   Roi_EOR=combineroi(roi_lesion,roi_resect,'intersection'); 
vol_EOR=sum(roi_EOR(:))*vv/1000; 
EOR= vol_EOR/vol_lesion 
 
 
 
Figure 5.1 Regions of interest and EOR 
Presurgical postcontrast T1-weighted image (A), FLAIR (B), and diffusion tensor 
images (C and D) are shown with the resected area contoured in blue in a 
representative patient. The abnormal FLAIR region (B, purple), the isotropic 
abnormality (C, red) and the anisotropic abnormality (C, yellow) are outlined. E: 
Summary of the regions of interest in a postsurgical contrast-enhanced T1-weighted 
image. 
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5.3 Results 
5.3.1 Patients’ Characteristics 
Patients’ clinical characteristics are shown in Table 5.1. Complete resection based on 
postcontrast T1-weighted imaging was achieved in 24 patients (77% of 31 patients). 
Ten patients had the tumour located within an eloquent area, which included the 
primary motor or sensory cortex, speech center, internal capsule, and basal ganglia. 
Ten patients had tumour located in a near-eloquent area, which included the 
supplementary motor area, corpus callosum, and proximity to the calcarine fissure and 
the speech center. The mean midline shift was 3.3 mm (± 3.7 mm; range 0-11.9 mm). 
The mean presurgical, contrast enhanced tumour volume was 46 ml (± 30 ml; range 
8-119 ml). 
The volume of the resection area was 53 ml (± 31 ml; range 10 - 131 ml), which was 
significantly larger than the presurgical tumour (p = 0.001). A total of 57% of the 
abnormal p area, 83% of the abnormal q area, and 59% of the increased FLAIR signal 
area was resected. Residual tumour volume based on p, q, FLAIR, and postcontrast 
T1-weighted images was 38.4 ml (± 30.2 ml; range 4.4-129.4 ml), 8 ml (± 9.7 ml; 
range 0-36 ml), 40.7 ml (± 32.7 ml; range 0.4-127.9 ml), and 2.7 ml (± 6.8 ml; range 
0-26.6 ml), respectively. None of the patients had a major postsurgical neurological 
deficit or Karnofsky Performance Scale score of less than 70, which was our condition 
to undergo temozolomide chemoradiotherapy. 
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TABLE 5.1 Patient characteristics 
 
Data are given as mean ± SD unless otherwise indicated. DTI = diffusion tensor imaging; 
FLAIR = fluid attenuated inversion recovery; GTR = gross total resection; IDH-1 = isocitrate 
dehydrogenase-1; MGMT = O6-methylguanine-DNA-methyltransferase; STR = subtotal 
resection. 
*Based on contrast-enhanced T1-weighted image 
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5.3.2 EOR and Patient Outcome 
Univariate Cox regression models for each variable showed a significant correlation 
of progression-free survival with the EOR of the p area (p = 0.030), complete resection 
of the contrast-enhanced lesion (p = 0.004), and MGMT methylation status (p = 0.041). 
Multivariate analysis was used to test the EOR with other covariates (Table 5.2). The 
results showed that resection of the more abnormal p was a protective predictor of 
tumour progression (HR 0.911; p = 0.009). The EOR of abnormal q areas was also 
significantly correlated with progression-free survival in the multivariate analysis (HR 
0.935; p = 0.006). The EOR based on FLAIR showed no association with progression 
free survival in either univariate or multivariate analysis (p = 0.994 and p = 0.799, 
respectively). The presence of MGMT methylation was found to be a significant 
predictor of progression-free survival in the multivariate models for p (HR 4.626; p = 
0.009), q (HR 6.716; p = 0.006), and FLAIR (HR 95.941; p = 0.001). 
TABLE 2. Extent of resection and patients’ outcome 
EOR Progression-Free Survival  Overall Survival 
by Imaging Type p Value HR 95% CI  p Value HR 95% CI 
p 0.009* 0.911 0.850–0.977  0.795 0.993 0.940–1.049 
q 0.006* 0.935 0.891–0.980  0.041* 0.965 0.934–0.999 
FLAIR 0.799 0.997 0.926–1.061  0.052 1.062 1.999–1.129 
T1C 0.094 6.499 0.727–58.069  0.050* 9.946 1.005–98.464 
Multivariate analysis results showing age, MGMT methylation status, IDH-1 mutation 
status, presurgical tumour volume based on post contrast T1-weighted, midline shift, 
and tumour eloquent location as covariates. EOR = extent of resection; HR = hazard 
ratio; p = isotropic component; q = anisotropic component; T1C = postcontrast T1-
weighted imaging. *Statistically significant. 
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For overall survival, multivariate analysis was performed after controlling for age, 
MGMT methylation status, IDH-1 mutation status, presurgical tumour volume, tumour 
eloquence, and midline shift. Both the EOR based on the q map and the EOR based 
on postcontrast T1-weighted images were identified as predictors for overall survival 
(HR 0.965, p = 0.041; HR 9.946, p = 0.050, respectively). The MGMT methylation 
status was significantly associated with overall survival in the multivariate models for 
p map (HR 3.737; p = 0.043), q map (HR 4.932; p = 0.012), and FLAIR (HR 10.274; p 
= 0.009) images. Presurgical tumour volume based on postcontrast T1-weighted 
images was found to be a covariate associated with increased hazard ratio relative to 
EOR of the q abnormality (HR 1.039; p = 0.024) and on the enhanced area of the 
postcontrast T1-weighted image (HR 1.037; p = 0.040). 
Previous results indicated the importance of the EOR, especially q abnormality, on 
outcome; therefore, we explored this in more detail. Classifying patients into 2 groups 
by using the median of the extent of abnormal q resection resulted in a resection cutoff 
of 89% of the q abnormality. Patients with a resection of greater than 89% of the q 
abnormality had a significantly longer progression-free survival (mean 421 ± 311 
days) than those with a resection of less than 89% of the abnormality (257 ± 214 
days; p = 0.034) and better overall survival (621.9 ± 389.0 days vs 518.13 ± 264.7 
days; p = 0.011) (Fig. 5.3). There was no statistical difference between these 2 
subgroups in age, sex, tumour location, number of patients receiving a gross total 
resection, or MGMT methylation or IDH-1 mutation status (Table 5.3). Similar results 
were seen when subgrouping patients with the median extent of p resection: Longer 
progression-free survival was shown in patients with greater than 60% resection of the 
p abnormal area (421 ± 311 vs 258 ± 176; p = 0.046). 
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Figure 5.3 Patient overall survival according to abnormal q resection ratio 
Cox regression survival analysis showed that patients with a resection of greater than 
89% of the q abnormality had a better overall survival than patients with less than 89% 
resection (p = 0.011). 
 
In our study, 26 patients (83.9%) had tumour recurrence within 2 cm adjacent to the 
resection cavity. Three patients (9.7%) had distal recurrence more than 2 cm from the 
original resection cavity, and 2 had recurrence both locally and distally. All patients with 
solely distal recurrence received complete resection of the enhanced lesion shown on 
the postcontrast T1-weighted image and a greater EOR of the q abnormal area (97.7%) 
than the others (87.4%), and 2 were MGMT methylated. Progression-free survival (721 
± 270 days) and overall survival (954 ± 461 days) were also longer in patients with 
distal recurrence. 
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TABLE 5.3 Patient characteristics for the subgroups of q resection area 
Characteristic q EOR <89% q EOR >89% p Value* 
M 9 10 1 
F 6 6 
 
Age, yrs 53.67 ± 13.16 58.68 ± 8.8 0.4168 
Tumour location, no. 
  
0.1298 
 Eloquent 5 5 
 
 Near eloquent 8 4 
 
 Noneloquent 2 7 
 
Midline shift, mm 3.33 ± 3.90 3.65 ± 3.63 0.8138 
Presurgical tumour size, by imaging type, ml    
 Postcontrast T1-weighted image  35.9 ± 18.4 53.3 ± 30.6 0.0682 
 FLAIR 81.1 ± 37.8 95.8 ± 52.2 0.3888 
 Isotropic (p) DTI 80.1 ± 38.1 90.9 ± 48.2 0.4948 
 Anisotropic (q) DTI 48.8 ± 14.3 54.5 ± 30.8 0.5147 
GTR†, no. of patients 9 15 0.0693 
STR†, no. of patients 6 1 
 
IDH-1 positive, no. of patients 2 1 0.5050 
MGMT methylation positive, no. of patients 5 5 0.9013 
Progression-free survival‡, days 257 ± 214 421 ± 311 0.034* 
Overall survival‡, days 518.13 ± 264.7 621.9± 389.0 0.011* 
Data given as mean ± SD unless otherwise indicated. 
*Statistically significant. 
†Based on contrast 
‡Analyzed by multivariate Cox regression model. 
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5.3.3 Residual Tumour Volume and Patient Outcome 
The correlations of patients’ outcome and residual tumour volume based on different 
MR images are summarized in Table 4. A larger residual volume on DTI was 
associated with a decrease in progression-free survival, which was statistically 
significant for the q abnormality (HR 1.118; p = 0.008), while residual volume of the p 
abnormality was not significant (HR 1.28; p = 0.074). Residual FLAIR volume was not 
correlated with progression-free survival. Overall survival was not influenced by the 
residual abnormal p, q, or contrast-enhanced lesion volumes. Residual FLAIR volume 
decreased the hazard ratio of overall survival (HR 0.942; p = 0.008). 
 
TABLE 5.4 Residual tumour volume and patients’ outcome 
Residual Tumour 
Imaging 
Progression-Free Survival  Overall Survival 
 
p Value HR 95% CI  p Value HR 95% CI 
Postcontrast T1-
weighted image 
0.060 1.393 0.986–1.969  0.401 1.140 0.840–1.549 
p 0.074 1.028 0.997–1.059  0.942 0.999 0.970–1.029 
q 0.008* 1.118 1.029–1.215  0.080 1.053 0.994–1.116 
FLAIR 0.882 1.003 0.968–1.038  0.008* 0.939 0.897–0.983 
Multivariate analysis results showing age, MGMT methylation status, IDH-1 mutation 
status, presurgical tumour volume based on T1 contrast imaging, midline shift, and 
tumour eloquent location as covariates. 
*Statistically significant. 
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5.4 Discussion and Conclusion 
Discussion 
In this study, we retrospectively reviewed the correlation between the EOR based on 
DTI and patients’ outcome. Although the intention of initial resection was based on 5-
ALA rather than on any DTI parameter, this study showed, via multivariate Cox 
regression model, a significant correlation between the EOR, based on both the p map 
and q map, and progression-free survival. Furthermore, a favorable overall survival 
was seen in patients who received greater resection of the q map and the enhanced 
area on postcontrast T1-weighted images. Thus, by resecting more abnormal DTI 
areas, most importantly the q area, the infiltrating tumour burden decreases, leading 
to a better outcome. 
The significance of resecting more of the contrast-enhanced lesion has been shown 
clearly to correlate with patient survival. Sanai and colleagues showed that improved 
overall survival begins at a 78% resection and continues to increase as resection of 
the contrast-enhanced area becomes greater119. A non-volumetric study of high-grade 
glioma has also shown a longer overall survival associated with complete resection 
rather than with incomplete resection (16.7 vs 11.8 months, respectively; p < 0.001)136. 
Others have reported the synergistic clinical benefit of the EOR and concomitant 
chemoradiotherapy134. Moreover, the benefit of reduced tumour burden is related to 
the efficacy of 1,3- bis (2-chloroethyl)-1-nitrosourea (BCNU): In one study, a lower 
concentration was needed to achieve 90% growth inhibition in low-tumour-burden 
groups88. In patients receiving BCNU wafers during surgery, longer median survival 
has been noted in the complete-resection group compared with those in the subtotal-
resection group137. Therefore, reduction of contrast-enhancing tumour burden is an 
important prognostic factor for patient outcome. 
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To date, most studies have defined EOR using the contrast enhanced area only; 
however, a false-negative rate of 16% was found in normal-appearing areas on T1-
weighted images105, and tumour cells often extend beyond the contrast-enhanced area. 
We have shown previously that specific DTI signatures can predict this microscopic 
tumour invasion105,111. In particular, regions with greater than a 10% increase of p 
signified white matter infiltration by tumour, whereas regions with greater than a 12% 
decrease in q showed white matter disruption by cancer. Therefore, using DTI can 
better delineate the actual tumour margin and show the invasive area of tumour. 
Although we did not perform a histological correlation in this study, previous research 
has validated a correlation between DTI and viable tumour cells29. 
A previously conducted tumour-resection treatment-bias study showed that complete 
resection was more often achieved in younger patients and in those with tumours in 
non-eloquent tumour locations136. We tested our result by using a median q-
abnormality EOR of 89% as the cutoff to stratify patients into 2 groups. In these groups, 
a longer progression-free survival was seen in those with a greater than 89% q-
abnormality resection, but other variables, including age, tumour eloquence, MGMT 
methylation status, IDH mutation, midline shift, presurgical tumour size, and complete 
resection of the enhanced lesion on postcontrast T1-weighted images, were all 
comparable (Table 5.3). A bias, therefore, could not be identified, which strengthens 
our results, indicating the importance of the EOR based on DTI. 
Specifically looking at the patients with distal recurrence, a previous study showed a 
correlation between extended resection and recurrence pattern, with a better 
prognosis in those with distal recurrence23. In our study, all 3 patients with distal 
recurrence received a greater EOR of the DTI-detected abnormality (EOR of q 
abnormality > 97%) beyond the contrast-enhanced area. Although the number in our 
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study is small, this finding may indicate that distal recurrence occurs in those with a 
better local control based on DTI and consequently resulted in a better prognosis. 
We also examined the residual tumour volume based on different MR sequences. 
More abnormal q volume left after surgery can significantly increase the risk of 
progression and marginally decrease overall survival. Grabowski and colleagues 
showed that residual contrast-enhanced lesion volume of more than 2 cm3 after 
surgical resection was a strong, unfavorable predictor of overall survival39. 
Furthermore, others also concluded that a residual contrast-enhanced tumour volume 
of less than 10 cm3 can lead to both prolonged time to progression and survival65. In 
our results, only marginal significance in progression-free survival was noted based 
on postcontrast T1-weighted imaging. This may be due to the limited numbers of 
patients in our study. Regardless of the limited numbers, we clearly displayed the 
advantage of the q map, which, according to a previous biopsy studies, represents 
regions of tumour cells105. Thus, a smaller residual abnormality in the q region 
indicated a lower tumour load and a better prognosis. 
Conclusion 
The expanding application of DTI in patients with brain tumours can demonstrate not 
only possible tumour invasion but also can provide a guide for surgeons. Our results 
underscore the importance of abnormal DTI area, especially of abnormal q area, 
showing that patients who received larger EOR and who had less residual abnormal 
DTI had better progression-free survival and overall survival. Further prospective 
studies are needed to clarify the clinical benefit of incorporating DTI into surgical 
planning. 
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CHAPTER 6 
 
Characterizing Tissue Anisotropy of the Peri‐
tumoural Region in Glioblastoma Using Diffusion 
Tensor Imaging 
 
6.1 Introduction 
The malignancy of the GBM has been discussed in Chapter 1.1 and 1.2. Its poor 
prognosis may be due in part to our inability to detect the full extent of the tumour 
margin using standard structural MRI. Therefore, it is important to use advanced MR 
techniques in the detection of GBM (Chapter 1.3), especially DTI. The diffusion tensor 
can be decomposed into isotropic component (p) and anisotropic component (q)100, 
which can be used to identify whether the peritumoural white matter is infiltrated, 
displaced or disrupted by the glioblastoma. A recent study focused on the peritumoural 
p map had shown an increase in tumour metabolic activity and regional perfusion in 
the tumour margin113. On the other hand, an abnormal q can represent GBM gross 
tumour105. The area of the abnormal q is different, sometimes larger than the contrast 
enhancing compartment (Chapter 5, 46 ± 30ml vs 51± 23ml, p = 0.0004). Assessing 
the extent of resection based on DTI has shown that a larger volume of resection of 
the DTI, especially the abnormal q areas, was shown to prolong progression free 
survival and overall survival166 (Chapter 5) due to a better local control. This drives the 
intention to understand more about the peritumoural area with abnormal DTI q. 
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Multi-voxel proton MR spectroscopy (1H-MRS) can detect and quantify specific 
molecule compound by using electron screening and chemical shift in certain regions 
of interest in the brain63 (a more detailed discussion was presented in Chapter 1.3.4.). 
In gliomas, the Choline (Cho)/ N-acetyl aspartate (NAA) index is an important marker 
of cellular proliferation78. Studies have shown that distinct differences exist in the 
peritumoural 1H-MRS characteristics that can differentiate GBM from the non-invasive 
meningioma163. Dynamic susceptibility perfusion MR (DSC-MRI), another valuable 
MR technique, can be used to measure the relative cerebral blood volume (rCBV) a 
measure of tumour vascularity142, angiogenesis4 and tumour cellularity110 (also see 
Chapter 1.3.3).  
Therefore, in this chapter, our aim is to analyze the peritumoural tissue characteristics 
beyond the contrast enhancing compartment by using 1H-MRS and DSC-MRI. Utilizing 
the DTI anisotropic q abnormality map, peritumoural DTI-defined invasive regions of 
interest were compared to other peritumoural areas with normal DTI which can further 
provide a better understanding of the GBM local invasive environment. 
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6.2 Method 
Patient inclusion criteria were discussed in Chapter 3.1. Detailed inclusion patient list 
was shown in Appendix A. Patients with complete pre-operative diagnostic MRI and 
clinical data were included. 
MRI parameter and Imaging processing were as described in Chapter 3.2. All patients 
received standardized preoperative 3D volumetric T1 weight with contrast 
enhancement (MPRAGE), T1 weighted without contrast, T2 weighted, FLAIR, DTI, 
DWI, MRS and DSC-MRI within one week before surgical intervention. 
6.2.1 Regions of Interest and DTI pattern 
The peritumoural abnormal q ROIs were calculated by subtracting the contrast 
enhanced ROIs from the abnormal q areas in Matlab (MathWorks Inc., Natick, MA, 
USA). The abnormal q map were drawn manually by a neurosurgeon (JLY) by using 
3D slicer (http://www.slicer.org/).33 Previous studies have shown fair inter- and intra-
rater agreement (Dice score: 0.68 ± 0.08 in the q ROIs, Chapter 3.2.8). Contrast 
enhancing compartment ROIs were drawn semi-automatically by threshold selection 
and manually correction by using 3D slicer.  
Four regions of interest were compared for characterizing the peritumoural areas 
outside of the contrast enhancing compartments (Figure 6.1).  
1.  The peritumoural abnormal q ROIs;  
2.  The peritumoural ROIs without q abnormality;  
3.  The contrast enhancing ROIs (CE, excluding the central necrotic part);  
4.  The contralateral normal appearing white matter (NAWM).  
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In addition, our previous study had shown that areas of abnormal q are generally larger 
than the contrast enhancing compartment (Chapter 5)166. Therefore, patients were 
classified into two groups according to the pattern of q abnormality: Patients who had 
the q abnormal area larger than contrast enhancing area and those had the q 
abnormal area equal or smaller than the contrast enhancing areas. 
6.2.2 1H-MRS data acquisition 
Tissue characteristics including total N-acetyl-aspartate (NAA), myo-inositol (Ins), total 
choline (Cho) including phosphocholine (PCh) and glycerylphosphorylcholine (GPC), 
glutamate (Glu) and glutamine (Gln), and glutathione (GSH) were all calculated as a 
ratio to the total creatinine for each spectroscopy voxel. Choline/NAA ratio was also 
calculated. Due to a bigger size of MRS voxel (1x 1 x 2 cm) than structure MRI and 
DTI, ROIs data were included only if it occupied more than 50% of the MRS voxel. The 
selection of the corresponding MRS voxel was done in two approaches.  
1. Visually selection of the voxels that were occupied by the ROIs for more than 1/2 
of the voxel size. 
2. A 3 dimensional voxel-wise approach with an in-house program in R (R 
Development Core Team, 2008) (Figure 6.2). By using the 3D voxel wise approach, 
multiple slices of the MRS data could be obtained from different ROIs (Figure 6.2 
blue voxels). This can provide an objective method for the voxel selection. The 
program is developed together by two members of the lab Dr. Timothy J Larkin and 
Dr. Daniel M Fountain (Cambridge Brain Tumour Imaging Laboratory, Cambridge, 
UK) and further modified to fit the study (Figure 6.3). Detailed script for the method 
will be shown in Appendix F.  
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Figure 6.1 Illustration for different ROIs 
Four regions of interests (ROIs) are indicated 
for imaging characteristics comparison. The 
yellow arrows indicates the peritumoural 
abnormal q ROIs; red arrow indicates the 
peritumoural ROIs without q abnormality; 
orange arrow indicates the contrast-
enhancing compartment; white arrow 
indicates the contralateral normal appearing 
white matter. 
 
 
T2-space voxel 
Region of interests 
 
Included MRS voxel 
 
 
Excluded MRS voxel 
 
 
 
 
 
Figure 6.2 3D voxel-wise method for MRS data retrieve 
This figure illustrates the 3D voxel-wise method for MRS data retrieve. White cubes 
represent T2-space voxel (1 x 1 x 1 mm), and the blue cubes represent regions of 
interest. MRS data would be included if regions of interest occupy more than 1/2 of 
the MRS voxel (red outline), else it would be excluded (yellow outline). 
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Figure 6.3 Workflow for the 3D voxel-wise approach for MRS data acquisition 
Matlab functions (orange) were proceeded firstly to extract all MRS information and 
imaging information (for example, voxel position coordinates). Then by using R 
function (blue), can test if the MRS grids have ROIs for more than 50% to obtain the 
needed MRS metabolite data. CSI: chemical shift imaging; ROI: regions of interest  
Statistics 
Data were analyzed by using SPSS version 22 (IBM Inc.). MRS data and rCBV 
between different ROI groups were compared by using one-way ANOVA test. Pair t-
test was used to compares imaging data between the peritumoural abnormal q ROIs 
and the peritumoural ROIs without q abnormality. Comparison of patient’s clinical 
characteristics between different patterns of q abnormality, including age, gender, 
percentage of the total resection of the contrast enhancing tumour, use of gliadel wafer, 
Isocitrate dehydrogenase-1 (IDH-1) mutation status, O6-methylguanine-DNA 
methyltransferase (MGMT) methylation status, were calculated by pair t-test for 
continuous data and by chi-square with Fisher’s exact for small-number categorical 
data. Overall survival and progression free survival between different groups were 
calculated by Kaplan Meier with log-rank test. The statistical significance was defined 
by two-sided p-value < 0.05. 
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6.3 Results 
51 patients (mean age 60.2 years, range 36.7 - 73.8) were included in this study. There 
were 13 female and 38 male. The complete resection based on contrast enhanced T1 
weighted MRI were achieved in 76.3% of the patients. IDH-1 mutation status was 
obtained in 40 patients, and 2 were mutated type. MGMT promoter methylation status 
was available in 41 patients with 21 methylated. The median overall survival was 330 
days ± 288.8 days (median ± SD), and the progression free survival was 194 ± 179.5 
days (median ± SD).  
Number of patients with available MRS spectra data retrieved by different methods in 
different ROIs were shown in Table 6.1. In the contrast enhancing ROIs, different 
substance MRS data were included in 32 to 49 patients. In peritumoural abnormal q 
ROIs, available MRS data were obtained from 22 to 29 patients. And 42 to 49 patients 
were included in the peritumoural ROIs without q abnormality for different substances. 
The unavailable data were mostly due to high standard deviation (>20%) of the 
normalized voxel MRS data, and the size of the ROIs that were smaller than 50% of 
the MRS voxel. 
Volume of the peritumoural abnormal q ROIs in all patients was 48.69 ± 30.34 ml 
(mean ± SD), and the volume of contrast enhancing ROIs was 39.55 ± 28.02 ml (mean 
± SD). 25 out of 51 patients had the q abnormality area greater than the contrast 
enhancing  area for at least ½ of the MRS voxel (60.9 ± 34.8 ml versus 40.0 ± 34.6 
ml), while 26 out of 51 patients had q abnormality area equally or smaller than the 
enhancing area (37.5 ± 21.4 ml versus 39.2 ± 21.8 ml). 
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Table 6.1 Number of patients with available MRS data of different substances 
 Peritumoural abnormal  
q ROIs 
Peritumoural ROIs 
 without q abnormality 
CE NAWM 
 Voxel-wise Visual Voxel-wise Visual Voxel-wise Visual Voxel-wise Visual 
Cho/Cr 25 27 45 27 43 49 43 47 
NAA/Cr 25 25 45 48 43 36 43 46 
Cho/NAA 25 24 45 48 43 38 43 46 
Ins/Cr 23 26 45 49 43 46 43 47 
Glu+Gln /Cr 29 22 45 42 43 32 36 40 
CE: contrast enhanced ROIs 
NAWM: contra-lateral normal appearing white mater 
Voxel-wise: 3D voxel-wise approach for MRS data acquisition 
Visual: visually inspection for the selection of corresponding MRS data 
 
6.3.1 1H-MRS tissue characteristics using 3D voxel-wise method 
Using 3D voxel-wise approach for 1H-MRS data retrieve, Cho/Cr were different in all 
four ROIs (p < 0.0001, Figure 6.4A), highest in the contrast enhancing ROIs, followed 
by peritumoural abnormal q ROIs, peritumoural ROIs without q abnormality and the 
contralateral NAWM. Subgroup analysis showed higher Cho/Cr in the peritumoural 
abnormal q ROIs than ROIs without q abnormality (p = 0.0219). Total NAA/Cr showed 
increase in the contrast enhancing ROIs (p < 0.0001, Figure 6.4B), but no significant 
difference between peritumoural abnormal q ROIs and ROIs without q abnormality (p 
= 0.3532). Significant elevation of Cho/NAA ratio was noted in the contrast enhancing 
ROIs (p < 0.0001, Figure 6.4C). In the peritumoural abnormal q ROIs also showed 
increase in Cho/NAA ratio, compared to the ROIs without q abnormality (p= 0.0346) 
and contralateral NAWM (p = 0.0021). The Glu/Cr was found to be higher over the 
contrast enhancing ROIs and peritumoural abnormal q ROIs than the contralateral 
NAWM (p < 0.0001, p = 0.0158, Figure 6.4D). Glu/Cr of the ROIs without q abnormality 
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had no statistical significant difference to the peritumoural abnormal q ROIs (p = 
0.6981) and contralateral NAWM (p= 0.0682). In addition, there is a significant 
decrease in Ins/Cr in peritumoural abnormal q ROIs, compared to contrast enhancing 
ROIs and contralateral NAWM (p < 0.0001, p = 0.0011, Figure 6.4E). 
Relative CBV were higher in contrast enhancing ROIs and all peritumoural area than 
the contralateral NAWM (p< 0.0001). Subgroup analysis showed marginal increase of 
rCBV in peritumoural abnormal q ROIs than the peritumoural ROIs without q 
abnormality (p = 0.0798, Figure 6.4F). 
 
Figure 6.4 MRS characteristics between different ROIs  
The MRS data of different chemical compounds (A-E) and rCBV (F) between different 
regions of interest (ROIs). Comparison between the ROIs within contrast enhancing 
compartment (CE), the peritumoural q abnormal ROIs, the peritumoural normal q ROIs 
and the contralateral normal appearing white matter (NAWM). Note that in the 
peritumoural q abnormal ROIs have higher Cho/Naa and higher Cho/Cr than the 
peritumoural normal q ROIs.  
Important significant difference are marked the lines and stars. *: p < 0.05; **: p< 0.01; ***: p 
< 0.001 
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6.3.2 MRS data retrieve by using different method 
Comparing visual inspection and 3D voxel-wise method for MRS data retrieve, no 
significant difference of the data value was noted between two methods (Table 6.2). 
In all four ROIs, there were comparable value of the Cho/Cr, NAA+NAAG/Cr, Cho/NAA, 
Glu+Gln/Cr and Ins/Cr in both methods.  
In comparison to the visual inspection method, using 3D voxel wise method had 2 
more missing data in Cho/Cr, 3 more missing data in Ins/Cr, 1 more missing data in 
Glu+Gln/Cr and one less missing data in Cho/NAA. On the other hand, one more 
missing data was found in visual inspection method than the 3D voxel-wise method 
(Table 6.1). 
6.3.3 Clinical Outcome of Different q Abnormality Patterns 
25 patients had peritumoural abnormal q ROIs larger than the contrast enhancing 
ROIs and 26 patients were found with a smaller peritumoural abnormal q ROIs. The 
overall survival was significantly longer in patients with larger peritumoural abnormal 
q ROIs than those with a smaller peritumoural abnormal q ROIs (median: 405 vs 310 
days, p = 0.0103) (Figure 6.5A). And the progression-free survival is also longer in this 
larger abnormal q ROIs group (median: 221 vs 164 days, p = 0.0346). There were no 
statistical difference in age, gender, total resection of the contrast enhancing 
compartment, use of gliadel wafer, MGMT methylation status and IDH-1 mutation 
status between two groups of patients (Table 6.3). 
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Table 6.2 Comparison of different method for MRS data retrieve  
Peritumoural abnormal q 
ROIs 
3D voxel-wise approach  Visual inspection  
value  value  p value 
Cho/Cr 0.486±0.042  0.442±0.021  0.37 
NAA/Cr 0.913±0.059   0.946±0.061  0.70 
Cho/NAA 0.731±0.131   0.639±0.149  0.64 
Ins/Cr 1.373±0.121  1.207±0.064  0.22 
Glu+Gln /Cr 1.842±0.237   1.772±0.138  0.40 
The peritumoural ROIs 
without q abnormality 
3D voxel-wise approach  Visual inspection  
value  value  p value 
Cho/Cr 0.404±0.090  0.390±0.096  0.54 
NAA/Cr 1.001±0.253  1.026±0.297  0.65 
Cho/NAA 0.483±0.307   0.449±0.309  0.55 
Ins/Cr 1.223±0.351  1.305±0.810  0.53 
Glu+Gln /Cr 1.156±0.351  1.748±0.710 0.23 
 
CE 
3D voxel-wise approach  Visual inspection  
value  value  p value 
Cho/Cr 0.657±0.204  0.768±0.408 0.10 
NAA/Cr 0.916±0.279  0.920±0.406 0.52 
Cho/NAA 0.769±0.319  0.879±0.505 0.24 
Ins/Cr 1.579±0.834  1.661±0.865 0.65 
Glu+Gln /Cr 2.654±1.072  3.137±2.184 0.90 
 
NAWM 
3D voxel-wise approach  Visual inspection  
value  value  p value 
Cho/Cr 0.353±0.106  0.355±0.102 0.95 
NAA/Cr 1.356±0.302  1.356±0.356 0.95 
Cho/NAA 0.293±0.149  0.288±0.146 0.90 
Ins/Cr 1.542±0.584  1.520±0.560 0.93 
Glu+Gln /Cr 1.307±0.833  1.341±0.792 0.26 
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Table 6.3 Clinical characteristics in patients with different q abnormality 
pattern 
 
q ≤ T1C q > T1C p value 
Numbers 26 25  
Age (years old) 60.1 ±8.9 60.1 ± 9.0 0.98 
Gender (M/F) 20/6 18/7 0.06 
CRET Rate (%) 77.8 68.4 0.71 
Gliadel Use (%) 52.9 73.7 0.30 
IDH-1  mutation (no.) 0 2 0.22 
MGMT methylation (no.) 10 11 0.76 
Progression free survival (days) 164 221 0.03 
Overall survival (days) 310 405 0.01 
 
q ≤ T1C: patient group with q abnormality areas smaller or equal than contrast 
enhancing areas  
q > T1C: patient group with q abnormality areas larger than contrast enhancing 
areas fore more than 1/2 of MRS voxel size. 
CRET: complete resection of the contrast enhancing compartment  
IDH-1: isocitrate dehydrogenase-1 
MGMT: O6-methylguanine-DNA methyltransferase 
 
 
 
 
 
 
 
 
102 
 
 
Figure 6.5 Survival difference between different q abnormality patterns  
For patients with q abnormal ROIs larger than contrast enhancing area, log-rank test 
showed a longer overall survival than patients with smaller q abnormal ROIs (4A, 
median: 405 vs 310 days, p = 0.0103). Besides, progression free survival was also 
longer in the larger q abnormal ROIs group (4B, median: 221 vs 164 days, p = 
0.0346). 
q<=T1C: patients with the abnormal q ROIs smaller than contrast enhancing compartment 
q > T1C: patients with the abnormal q ROIs larger than contrast enhancing compartment 
 
 
 
Table 6.4 Summary of the Imaging Characteristics 
 Cho/Cr NAA/Cr Cho/NAA Glu+Gln/Cr Ins/Cr rCBV 
CE ↑↑↑ ↓↓↓ ↑↑↑ ↑↑↑ - ↑↑↑ 
Peritumoural q  
abnormal areas 
↑↑↑ ↓↓↓ ↑↑ ↑ - ↑↑↑ 
Peritumoural ROIs 
without q abnormality 
↑ ↓↓ ↑ - ↓↓↓ ↑↑ 
CE: contrast enhanced ROIs 
↑ and ↓ illustrated the increase and decrease of the value. The number of the arrows 
showed the significance of the change. ↑↑↑/ ↓↓↓: p < 0.001, ↑↑/ ↓↓: p < 0.01, ↑/ ↓: p < 
0.05 
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6.4 Discussion and Conclusion 
Discussion 
In our study, we found 25 patients who had the q abnormal ROIs larger than the 
contrast enhancing compartment. And in these peritumoural q abnormal ROIs, 
compared to those peritumoural ROIs without q abnormal, a significant increase in 
Cho/NAA, especially Cho/Cr, can be noticed by using 1H-MRS (summarize in Table 
6.4). Furthermore, patterns of these q abnormal ROIs can have different clinical 
prognostic outcome. 
It is clear that GBM cells can extend beyond contrast enhancing compartment and in 
a previous study where this peri-tumoural region was biopsied had shown evidence of 
cancer cell infiltration in up to one third of patients.70 However, conventional structural 
MRI sequences fail to detect this invasive margin. Many studies have attempted to 
use multimodal MR imaging of the peritumoural areas to differentiate GBM from less 
invasive metastatic brain tumours or benign brain tumours.113 Tsougos et al. had 
shown an increase in Cho/Cr, rCBV and a decrease in NAA/Cr were found in the 
peritumoural areas of GBM compared to metastatic tumour.149 Other studies showed 
an increase in Cho/Cr, Cr/NAA, and Ins/Cr163 in GBM peritumoural areas compared to 
meningioma. Our results not only showed an increase cell turnover rate (increase in 
Cho/Cr) but also a higher Cho/NAA in the peritumoural q abnormal region, compared 
to peritumoural areas without q abnormality. Although NAA/Cr showed no difference 
between peritumoural q abnormal and q normal ROIs, NAA/Cr in all peritumoural ROIs 
were lower than the contralateral normal appearing white mater which is compatible 
with other studies. 
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Some studies showed inconsistent results of DTI in the peritumoural areas, in 
Tsougos’s study there was no difference of apparent diffusion coefficiency (ADC) or 
fractional anisotropy (FA) between the peritumoural area and control149, more studies 
have shown DTI as an imaging biomarker in the invasive tumour margin. Min et al. 
showed a significant higher regression coefficiency of radial diffusivity to axial 
diffusivity and a lower FA79, and Wang et al. also shown a decrease in the q component 
of DTI in the peritumoural area. Furthermore, our previous biopsy studies also shown 
that gross cancer tissue can be shown in abnormal DTI especially in the q area 
(decrease > 12%).105 Sternberg et al. concluded that DTI is the most effective modality 
to delineate the tumour invasion margin beyond the conventional MRI132. 
In our results, an increase of Glu+Gln/Cr in not only contrast enhancing compartment 
but also in the peritumoural q abnormal ROIs compared to the contralateral control. 
Glutamate is known to play an important role in tumour invasion such as the excitatory 
neurotoxicity to peritumoural neuron and also the extracellular matrix which facilitate 
the cancer cell migration.129 Therefore, this finding supports the invasive potential in 
the peritumoural q abnormal ROI.  
The level of the Ins/Cr was lower than control in the peritumoural ROIs especially in 
those area without q abnormality. Myo-inositol is known as a cerebral osmolyte and 
also an astrocyte marker which can be seen in various intracranial pathology.147 The 
change of the Ins/Cr level is variable, Castillo et al showed an increase of Ins/Cr in low 
grade glioma and decrease in glioblastoma.16 The decrease of the Ins/Cr may due to 
reduced reactive astrocyte with in the peritumoural abnormal q ROIs. Other causes of 
the decrease of myo-inositol may be seen in stroke, hepatic encephalopathy, due to 
the balance of osmoregulation. However, this result can be minimize after 
normalization by the Cr. Therefore, the decrease of myo-inositol in the peritumoural 
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area in our series due to marked peritumoural oedema is less likely. Another study had 
shown and decrease of Ins/Cr may be due to an elevation of the Ins/Cr in the 
contralateral normal appearing white matter that Kellenberg et al had described 
possible tumour infiltration in the contralateral cerebral hemisphere of the untreated 
GBM patients with an increase of myo-inositol62. 
Our DSC-MRI showed only marginal higher rCBV in the peritumoural abnormal q ROIs 
than in the peritumoural ROIs without q abnormality (p = 0.0798). However, there is a 
significant elevated in all peritumoural ROIs which is compatible with our previous 
studies113. An increase of rCBV is resulted from the increase tumour density followed 
by hypoxia then angiogenesis which is correlated to cellular proliferation in high-grade 
glioma.110 Other groups have shown that the site of increased rCBV may potentially 
predict sites of tumour progression.9 
Our study has shown that different patterns of abnormal q ROIs impact on clinical 
outcome. We have shown that there is a better overall survival and progression free 
survival in those with larger abnormal q ROIs than contrast enhanced areas. This was 
independent of age, resection type, IDH-1 mutation status and MGMT methylation 
status between two groups. Our previous studies showed DTI abnormality patterns 
can be classified into localised, minimal and diffused types and is associated with 
prognosis83. The classification was based on the relationship of p and q abnormal area 
but not with the contrast-enhancing area. As previously described, a higher Cho/Cr 
level, which represents higher cell turnover rate. And all patients in our study received 
standard temozolomide chemoradiotherapy after surgery. Therefore, our hypothesis 
is that a possible better chemo- radiosensitivity can be seen in this group of patients. 
Studies had shown the use of MRS for assessment of the treatment response.51 Preul 
et al showed that in the chemotherapy responder, there were increase in baseline NAA, 
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Cr and lactate but not the baseline Cho or lipid metabolites, however the ROIs in this 
studies was obtained within the contrast enhancing compartment.103 Another study of 
14 patients showed that a lower baseline NAA/Cr and higher Cho/Cr in the 
peritumoural non-enhancing region were associated with poor outcome.6 Our results 
provides a different aspect to assess the clinical outcome.  
In this study, we used two different method to select ROI in MRS voxel. One of the 
limitation on most MRS studies was to use visual inspection by experienced expert to 
select the MRS voxel from the overlaying ROIs. However, as the MRS voxel is usually 
larger than other MRI sequences, and the shape of the GBM often grows irregularly, 
the 3D voxel-wise approach which the MRS data were retrieved automatically 
according to the different ROIs can minimize the possible error of visually inspection. 
Although, there was no statistical difference of the metabolites value in our results, the 
3D voxel-wise approach tends to have higher standard of voxel selection, we found 
more missing data than visual inspection. This may indicate that the 3D voxel-wise 
approach automatic selection had a higher standard on the MRS voxel quality control. 
 
Conclusion 
In conclusion, a tumour invasive margin can be identify by using DTI. In the 
peritumoural q abnormal ROIs, there was higher Cho/NAA, especially Cho/Cr which 
indicates tumour activity. In addition, different patterns of the peritumoural abnormal q 
may have clinical implication that a larger abnormal q than contrast enhancing 
compartment showed a better progress free survival and overall survival. 
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CHAPTER 7 
MR Imaging Characteristics of the Peritumoural 
Progression Zone 
7.1 Introduction 
The high local progression rate of GBM after treatment is largely due to the difficulty 
in identifying the invasive non-contrast enhancing margin. Studies had shown that the 
GBM cancer cell can extend to the non-contrast enhancing area70,71. Therefore, the 
recurrence is inevitably even in patients with a total resection of the contrast enhancing 
tumour and subsequent chemoradiotherapy. And the recurrence usually happens in or 
directly adjacent to the resection area in up to 90% of the cases101. 
However, the imaging characteristics of this peritumoural non-enhanced invasive area 
is still not clear. The conventional structural MRI failed to identify this area and has 
been addressed in Chapter 1.3.1. Further application of advanced MR techniques and 
radiomics (Chapter 1.3.2~1.3.5) in the diagnosis of GBM provide more understandings 
of the peritumoural area (Chapter 5 and 6). 
Thus, in this chapter we aimed to characterize the preoperative peritumoural non-
enhanced area that demonstrated to have generated tumour progression later on. And 
further applied these features, together with radiomics features to identify areas of 
GBM progression on the preoperative MRI by using the convolutional neural network. 
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7.2 Methods 
7.2.1 Patient inclusion criteria 
We retrospectively included 57 patients with a newly diagnosed cerebral glioblastoma 
in this study. The exclusion and inclusion criteria were described as in Chapter 3.1. All 
57 patients had preoperative MRI in Cambridge University Hospital with same imaging 
protocol. 37 patients received follow-up MRI in Cambridge University Hospital were 
assigned to training group, and another 20 patients who had follow-up MRI in local 
hospital were assigned as external validation group. The MRI scans of the external 
validation group were acquired after the training results of the training group. 5 of thr 
57 patients had pseudoprogression prior to true progression. General characteristics 
were shown in Table 7.1. 
7.2.2 MRI Data Acquisition and Imaging Processing 
MRI data acquisition and imaging processing were described in Chapter 3.2. 
Regions of Interests 
Two main regions of interest (ROIs), progression areas and non-progression areas 
were created in this study (Figure 7.1). 
The site of tumour progression and pseudoprogression were created by coregistration 
of the progression contrast enhanced T1 MRI to the pre-operative diagnostic MRI. The 
psueodoprogression was defined by stable or regression of the contrast enhancing 
lesion in the follow up MRI. This was done by using a previous described two stage 
non-linear semi-automatic coregistration151 (Chapter 4). In short, firstly, we calculated 
the transformation matrix between preoperative tumour and postsurgical resection 
cavity by using the linear FLIRT co-registration. Then we applied this transformation 
matrix to a non-linear FNIRT transformation to coregister the brain. 
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The non-progression area were created from the peritumoural 5, 10, 15, 20 mm 
excluding the progression areas. In addition, a contralateral area of normal appearing 
with matter (NAWM) as control representing normal brain tissue. 
 
 
Figure 7.1 
An example of tumour progression (B) was coregistered to presurgical image (A). The 
coregistered image (C, D blue) can further create progression area (E, red) and 10mm 
non-progression area (F, green).  
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Table 7.1 General Characteristics of the Patients 
  Training 
Group 
Validation Group Pseudo-
progression 
p-value 
Total number of patients 37 20 5   
Males/ females 24/ 13 14/ 6 4/ 1 
 
Age (years) 55 ± 12 60 ± 9 55 ± 9 0.29 
Tumour location   
 
  0.78 
Eloquent 8 4 0   
Near eloquent 14 9 3   
Non eloquent 15 7 2   
Midline shift (mm) 3.8 ± 3.8 3.3 ± 3.1 2.9 ± 3.6 0.84 
Pre-OP tumour size (mL)1  44 ± 25 39 ± 26  40 ±14  0.76 
GTR/ STR1 29/ 8 13/ 7 5/ 0 0.22 
PFS (median, days) 262 181 778 0.01 
OS (median, days) 523 407 864  0.01 
MGMT  un-methylated 16 4 1 0.81 
        methylated 10 9 3   
IDH-1   wild type 34 17 4  0.58 
        mutated 3 1 1   
1 the pre-operative tumour volume and the extent of resection were evaluated based 
on the contrast enhanced T1-weighted MRI 
GTR = gross total resection; STR = subtotal resection; PFS (progression free 
survival); OS = overall survival; MGMT = O6-methylguanine DNA methyltransferase; 
IDH-1 = Isocitrate dehydrogenase. 
 
 
 
 
111 
 
7.2.3 Radiomics Analysis and Machine Learning 
Scheme of the radiomics analysis was shown on Figure 7.2.  
 
Figure 7.2 Scheme of the Radiomics Analysis 
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The preoperative multimodal MRI features were extracted using Matlab (MathWorks 
Inc., Natick, MA, USA), this includes two main components: 
1. Voxel value extracted from different MR techniques, including contrast enhanced T1, 
FLAIR, ADC, FA, p, q and rCBV. 
2. Radiomics features, including first and second order features. 
Voxel value 
Mean if the voxel value extracted from different ROIs (Figure 7.1) were done by using 
the following Matlab function. 
% Load different MRI sequences 
data=load_untouch_nii('FLAIR.nii.gz'); % use FLAIR as an example here 
% Load ROI file 
mask=load_untouch_nii('ROI.nii'); 
data1=data.img; 
mask1=logical(mask.img); 
pixels=data1(mask1); 
FLAIR=mean(pixels); % FLAIR is the mean voxel value extracted from the ROI 
 
First Order Radiomics Features 
First order and second order radiomics features were extracted from 7 different MR 
sequences using Matlab. The MATLAB software code used to compute in the second 
order texture features were shared by the license under the GNU General Public 
License at: https://github.com/mvallieres/radiomics. 
The first order features describe the grey scale level of the voxel without concern of 
the spatial relationship. This includes mean, standard deviation, median, minimum, 
maximum, variance, skewness, kurtosis, energy, entropy, uniformity, root mean square, 
mean gray level. Mathematics details were as following1,98: 
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𝑀𝑒𝑎𝑛 (𝜇) =
1
𝑛𝑥𝑛𝑦𝑛𝑧
∑ (𝑋𝑛𝑥 , 𝑌𝑛𝑦 , 𝑍𝑛𝑧)
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 = √
1
𝑛𝑥𝑛𝑦𝑛𝑧 − 1
∑ (𝑋𝑛𝑥𝑌𝑛𝑦  𝑍𝑛𝑧 − 𝜇)
2
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
 
Median: the value separate the higher half from the lower half in the total volume. 
𝑀𝑖𝑛𝑖𝑚𝑢𝑚 = min (𝑋𝑛𝑥𝑌𝑛𝑦  𝑍𝑛𝑧) 
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 = max (𝑋𝑛𝑥𝑌𝑛𝑦  𝑍𝑛𝑧) 
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 (𝜎2) =
1
𝑛𝑥𝑛𝑦𝑛𝑧 − 1
∑ (𝑋𝑛𝑥𝑌𝑛𝑦  𝑍𝑛𝑧 − 𝜇)
2
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
 
Skewness refer to the asymmetry of the probability distribution to its mean. If the 
distribution is completely symmetric, the mean is equal to the median and gives us 
zero skewness.  
𝑆𝑘𝑤𝑒𝑛𝑒𝑠𝑠 (𝛾1) =  (
𝜇3
𝜎3
) =
(
1
𝑛𝑥𝑛𝑦𝑛𝑧
∑ (𝑋𝑛𝑥 , 𝑌𝑛𝑦 , 𝑍𝑛𝑧)
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
)
3
(
1
𝑛𝑥𝑛𝑦𝑛𝑧 − 1
∑ (𝑋𝑛𝑥𝑌𝑛𝑦  𝑍𝑛𝑧 − 𝜇)
2𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1 )
3 
Kurtosis is another way to measure the tailedness of the distribution of the value. It 
shows the values are more concentrated around the mean or are more concentrated 
to both tails of its distribution. 
𝐾𝑢𝑟𝑡𝑜𝑠𝑖𝑠 (𝛾2) =  (
𝜇4
𝜎4
) =
(
1
𝑛𝑥𝑛𝑦𝑛𝑧
∑ (𝑋𝑛𝑥 , 𝑌𝑛𝑦 , 𝑍𝑛𝑧)
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
)
4
(
1
𝑛𝑥𝑛𝑦𝑛𝑧 − 1
∑ (𝑋𝑛𝑥𝑌𝑛𝑦  𝑍𝑛𝑧 − 𝜇)
2𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1 )
2 − 3 
 
Energy is the summation of the total voxel value in three dimension. 
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𝐸𝑛𝑒𝑟𝑔𝑦 = ∑ (𝑋𝑛𝑥 , 𝑌𝑛𝑦 , 𝑍𝑛𝑧)
2
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
 
Entropy refers to the uncertainty or non-uniformity of the voxel value. A low entropy 
means the voxel value of the images were organized or compacted in a certain value. 
In the contrast, and a higher entropy shows higher disorder. P is the first order 
histogram and 𝑃(𝑖) is the fraction of voxles with gray level 𝑖 . 𝑁𝑔 is the number of 
discrete in gray level. 
𝐸𝑛𝑡𝑟𝑜𝑝ℎ𝑦(𝐻) = − ∑ 𝑃(𝑖) log2 𝑃(𝑖)
𝑁𝑔
𝑛=𝑖
 
𝑈𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 = ∑ 𝑃(𝑖)2
𝑁𝑔
𝑛=𝑖
 
Root mean square (RMS) is the square root of the squared mean in all voxels. 
Therefore it is a natural number which is not affected by the positive or negative value 
in each voxel. 
𝑅𝑀𝑆 = √(
1
𝑛𝑥𝑛𝑦𝑛𝑧
∑ (𝑋𝑛𝑥 , 𝑌𝑛𝑦 , 𝑍𝑛𝑧)
𝑛𝑥𝑛𝑦𝑛𝑧
𝑛=1
)
2
 
Mean gray level is the summation of the gray level 𝑃(𝑥) multiplied by the first order 
histogram fraction of voxles 𝑃(𝑖). 
𝑀𝑒𝑎𝑛 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 = ∑ 𝑃(𝑥)𝑃(𝑖)
𝑁𝑔
𝑛=𝑖
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Second Order Radiomics Features 
The second order features refer to the texture analysis. The texture analysis was 
described firstly by Haralick et al in 197344. This provides information for the 
description of the spatial distribution of the voxel intensities. Two main groups of 
features, gray level co-occurrence matrix (GLCM) and gray level run-length matrix 
(GLRLM), were extracted. In order to generate spatial information represents each 
voxel, a 5 x 5 x 5 voxel of interest (VOI) was created for each voxel (Figure 7.3). 
 
Figure 7.3 
For each voxel in the ROIs (blue cubic), the adjacent 124 voxel were taken to create 
a 5 x 5 x 5 voxel of interest (VOI) to generate the gray level matrix for the extraction of 
the texture features. 
 
 
Gray level co-occurrence matrix (GLCM) 
The GLCM is defined as P(i, j ; δ, α), a matrix with size Ng x Ng. This was created by 
calculating how often a voxel with the signal intensity value (i, grey level) occurs in a 
spatial relationship to a voxel with the value j with distance δ and direction α. Ng  is the 
number of discrete intensity levels in the images. Let: 
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P(i, j): the co-occurrence matrix 
Ng : the number of discrete intensity levels in the images 
μ: the mean of P(i, j) 
μx: the mean of P (i) 
μy : the mean of column P(j) 
σx: the standard deviation of row P (i) 
σy: the standard deviation of column P(j) 
𝑃𝑥
(𝑖)
= ∑ 𝑃(𝑖)
𝑁𝑔
𝑗=1 : marginal row probabilities 
𝑃𝑥
(𝑗)
= ∑ 𝑃(𝑗)
𝑁𝑔
𝑖=1 : marginal column probabilities 
𝑃𝑥+𝑦(𝑘) = ∑ ∑ 𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
, 𝑖 + 𝑗 = 𝑘, 𝑘 = 2,3,4, … ,2𝑁𝑔
𝑁𝑔
𝑖=1
 
𝑃𝑥−𝑦(𝑘) = ∑ ∑ 𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
, 𝑖 + 𝑗 = 𝑘, 𝑘 = 0,1,2, … , 𝑁𝑔
𝑁𝑔
𝑖=1
− 1 
𝐻 = − ∑ ∑ 𝑃(𝑖, 𝑗) log2 𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 : the entropy of P(i, j) 
𝐻𝑥 = − ∑ ∑ 𝑃𝑥(𝑖) log2 𝑃𝑥(𝑖)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 : the entropy of P(i) 
𝐻𝑦 = − ∑ ∑ 𝑃𝑦(𝑗) log2 𝑃𝑦(𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 : the entropy of P(j) 
𝐻𝑋𝑌1 = − ∑ ∑ 𝑃(𝑖, 𝑗) log(𝑃𝑥(𝑖), 𝑃𝑦(𝑗))
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1   
𝐻𝑋𝑌2 = − ∑ ∑ 𝑃𝑥(𝑖)𝑃𝑦(𝑗) log(𝑃𝑥(𝑖), 𝑃𝑦(𝑗))
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1   
 
The GLCM calculated features were listed as following: 
Auto-correlation is the measure of the coarseness of an image and the evaluation of 
the linear spatial relationship between texture primitives. 
𝑎𝑢𝑡𝑜𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 = − ∑ ∑ 𝑖𝑗𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1   
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Contrast represents the local intensity variance 
𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 = − ∑ ∑ |𝑖−𝑗|2𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1   
Correlation shows the linear dependence of the intensity value between each 
neighborhood voxels.  
𝑐𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 = ∑ ∑
𝑃(𝑖, 𝑗)(𝑖 − 𝜇𝑖(𝑖))(𝑗 − 𝜇𝑗(𝑗))
𝜎𝑥(𝑖)𝜎𝑦(𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
Cluster prominence and cluster chad are measures of the asymmetry of the matrix167. 
The images are asymmetric when the cluster prominence and the cluster shad are 
high.  
𝐶𝑙𝑢𝑠𝑡𝑒𝑟 𝑝𝑟𝑜𝑚𝑖𝑛𝑒𝑛𝑐𝑒 = ∑ ∑ [𝑖 + 𝑗 − 𝜇𝑥(𝑖) − 𝜇𝑦(𝑗)]
4
𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝐶𝑙𝑢𝑠𝑡𝑒𝑟 𝑠ℎ𝑎𝑑 = ∑ ∑ [𝑖 + 𝑗 − 𝜇𝑥(𝑖) − 𝜇𝑦(𝑗)]
3
𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝐷𝑖𝑠𝑠𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦 = ∑ ∑ |𝑖−𝑗|𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
Energy is the measurement of the images homogeneity.  
𝐸𝑛𝑒𝑟𝑔𝑦 = ∑ ∑ [𝑃(𝑖, 𝑗)]2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
Entropy represents the randomness of the image texture which can be used as the 
measurement of the inhomogeneity. A homogeneous image can have a low entropy 
value. 
𝐸𝑛𝑡𝑟𝑜𝑝𝑦 (𝐻) = − ∑ ∑ 𝑃(𝑖, 𝑗) log2 𝑃(𝑖, 𝑗)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑜𝑓 𝐸𝑛𝑡𝑟𝑜𝑝𝑦 = ∑ 𝑃𝑥+𝑦(𝑖)
𝑁𝑔−1
𝑖=1
log2[𝑃𝑥+𝑦(𝑖)] 
𝑆𝑢𝑚 𝑜𝑓 𝐸𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥+𝑦(𝑖) log2[𝑃𝑥+𝑦(𝑖)]
2𝑁𝑔
𝑖=2
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𝐼𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 1 =
𝐻 − 𝐻𝑋𝑌1
𝑚𝑎𝑥{𝐻𝑋, 𝐻𝑌}
 
𝐼𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 2 = √1 − 𝑒−2(𝐻𝑋𝑌2−𝐻𝑋𝑌) 
Homogeneity is the uniformity of the voxel intensity in the matrix. 
𝐻𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 − 𝑀 = ∑ ∑
𝑃(𝑖, 𝑗)
1 +  |𝑖 + 𝑗|
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝐻𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦 − 𝑃 = ∑ ∑
𝑃(𝑖, 𝑗)
1 + |𝑖 + 𝑗|2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
Variance (sum of square) refers to the gray level variability of the voxels. A higher 
variance occurs when the gray level value differs from the mean. 
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =
1
𝑁𝑔 × 𝑁𝑔
∑ ∑ [(𝑖 − 𝜇𝑖)
2𝑃(𝑖, 𝑗) + (𝑗 − 𝜇𝑗)
2
𝑃(𝑖, 𝑗)]
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝑆𝑢𝑚 𝑜𝑓 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = ∑ (𝑖 − 𝑆𝐸)2
2𝑁𝑔
𝑖=2
𝑃𝑥+𝑦(𝑖) 
𝑆𝑢𝑚 𝑜𝑓 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ [𝑖𝑃𝑥+𝑦(𝑖)]
2𝑁𝑔
𝑖=2
 
𝑀𝑎𝑥𝑖𝑚𝑎𝑙 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝑚𝑎𝑥{𝑃(𝑖, 𝑗)} 
Inverse difference moment normalized measures the localized homogeneity of an 
image. In contrast to homogeneity- P, it normalizes the square of the difference 
between values by dividing over the square of the total number of discrete values. 
Inversed difference normalized is another way to measure the homogeneity. 
𝐼𝑛𝑣𝑒𝑟𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = ∑ ∑
𝑃(𝑖, 𝑗)
1 + ( 
|𝑖 + 𝑗|2
𝑁2
)
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝐼𝑛𝑣𝑒𝑟𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = ∑ ∑
𝑃(𝑖, 𝑗)
1 + ( 
|𝑖 + 𝑗|
𝑁 )
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
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Gray level run length matrix (GLRLM) 
Gray level run length matrix ( P(i,j)|θ) quantifies the runs of gray level i and the length 
j in the volume ( V(x,y,z)). Ng represents the number of discrete gray levels intensity in V, 
and Lr is the length of the longest run in V. 
Short run emphasis is the measurement of the short run length which is higher in a 
finer texture. 
𝑆ℎ𝑜𝑟𝑡 𝑟𝑢𝑛 𝑙𝑒𝑛𝑔𝑡ℎ = ∑ ∑
𝑃(𝑖, 𝑗)
𝑗2
𝐿𝑟
𝑗=1
𝑁𝑔
𝑖=1
 
Long run length, in contrast to short run lengths represents a more coarse texture in a 
higher value. 
𝐿𝑜𝑛𝑔 𝑟𝑢𝑛 𝑙𝑒𝑛𝑔𝑡ℎ = ∑ ∑ 𝑗2
𝐿𝑟
𝑗=1
𝑁𝑔
𝑖=1
 𝑃(𝑖, 𝑗) 
Gray level non-uniformity measures the similarity of the gray level intensity in the 
image. 
𝐺𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑖𝑟𝑚𝑖𝑡𝑦 = ∑ (∑ 𝑃(𝑖, 𝑗)
𝐿𝑟
𝑗=1
)
2𝑁𝑔
𝑖=1
  
Run length non-uniformity measures the similarity of the run lengths in the image. 
𝑅𝑢𝑛 𝑙𝑒𝑛𝑔𝑡ℎ 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑖𝑟𝑚𝑖𝑡𝑦 = ∑ (∑ 𝑃(𝑖, 𝑗)
𝑁𝑔
𝑖=1
)
2𝐿𝑟
𝑗=1
 
Run percentage measures the homogeneity and distribution of runs of an image. 
𝑅𝑢𝑛 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =
∑ ∑ 𝑃(𝑖, 𝑗)𝐿𝑟𝑗=1
𝑁𝑔
𝑖=1
∑ 𝑗 ∑ 𝑃(𝑖, 𝑗)
𝑁𝑔
𝑖=1
𝐿𝑟
𝑗=1
 
Low gray level emphasis shows the distribution of low gray level intensity. Therefore, 
a lower value represents a greater concentration of low gray level intensity in the image. 
On the other hand, high gray level emphasis shows the distribution of high gray level 
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intensity in the image. 
𝐿𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑛𝑝ℎ𝑎𝑠𝑖𝑠 = ∑ ∑
𝑃(𝑖, 𝑗)
𝑖2
𝐿𝑟
𝑗=1
𝑁𝑔
𝑖=1
  
𝐻𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑛𝑝ℎ𝑎𝑠𝑖𝑠 = ∑ ∑ 𝑖2𝑃(𝑖, 𝑗)
𝐿𝑟
𝑗=1
𝑁𝑔
𝑖=1
 
Putting the above-mentioned features together, a total 13 first order features and 29 
second order texture features generated a total number of 294 features from 7 different 
MR sequences. These features were applied to train supervised machine learning 
voxel-wised. Different machine learning models had been proposed by previous 
study97. Our preliminary results (used only training group with voxel intensity from 
different MR sequences as input features) showed that the convolutional neural 
network (CNN) had the best accuracy (Table 7.2). The CNN was processed by using 
the Neural Network Toolbox in Matlab version 2016b (Figure 7.2).  
After the establishment of the trained model, a heat map of the probability of 
progression was calculated from the preoperative MRI of the validation group (Figure 
7.2, gray box). These results were then compared and validated with their true follow-
up progression MRI in both training group and external validation group. For external 
validation, 3 repeated trainings were done to optimise the validation. 
Table 7.2 Comparison between different machine learning models 
Machine learning model Overall Accuracy 
Tree 60.8-67.6% 
Discriminant 60.8-62.5% 
Supporting vector machine 64.9-73.8% 
K near neighborhood 25-66.9% 
Ensemble boosted tree 69.8% 
Convolutional neural network 85.1% 
The training results were calculated by using gray level intensity of each voxel from different 
MR sequences in 32 training group patients.  
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Statistical analysis 
General patients’ characteristics were tested for group differences with a t-test or 
Mann-Witney U test for continuous variable depending on the normality of the data. A 
chi-square test was used for categorical data. Differences between MRI characteristics 
of the preoperative area later showing tumour progression and non-progression areas 
were done using paired t-test. Two-sided p-values were used. All statistical tests were 
performed using SPSS version 22 (IBM Inc., New York, USA).  
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7.3 Results 
7.3.1 Multimodal MRI Characteristics 
Multimodal MRI characteristics were shown in Figure 7.4. The ADC values in the 
progression area were lower than 5mm and 10 mm peri-tumoural non-progression 
area (Figure 7.4 A, p < 0.001, 0.029). Fractional anisotropy (FA) showed lower in 
progression area than 5 mm non-progression area (Figure 7.4 B, p = 0.041). The 
isotropic p component showed a significant decrease in progression area than 5mm 
and 10mm of non-progression area (Figure 7.4 D, p < 0.001). In areas of progression, 
anisotropic q did not show difference between progression and non-progression area 
(Figure 7.4 E). In areas of later progression, there was significant increase in the 
FLAIR signal (Figure 7.4 C, p = 0.020 ~ < 0.001) and contrast enhanced T1 MRI 
(Figure 7.4 G, p = 0.026 ~ 0.0004) compared to non-progression area. Relative 
cerebral blood volume, was increased in the progression areas than 15-20 mm non-
progression area (Figure 7.4 F, p = 0.038 ~ 0.042). A higher Cho/NAA and lower NAA 
can be seen in the progression areas but without statistical significance (Figure 7.4 H). 
7.3.2 Radiomics Features 
Thirty-five out of the 91 first order radiomics features had significant difference 
between progression area and non-progression area (Figure 7.5). Most distinct 
features were in ADC, p and contrast enhanced T1 MRI (Figure 7.5 A, C, F). In the 
203 second order radiomics features, 77 were found to have significant difference 
between progression and non-progression areas (Figure 7.6). Total 112 radiomics 
features were identified in the progression areas. 
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Figure 7.4 
Figure 7.4 showed the MRI characteristics (A-G) of contrast enhanced, progression, 
non-progression (NP) area in 5-20 mm peritumoural area and contralateral normal 
appearing white matter (NAWM, control). H showed MRS of Cho/NAA, Choline, 
NAA+NAAG and Glu+Gln of progression (P), non-progression (NP) and NAWM. 
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Figure 7.5 First order radiomics features 
Comparison of the first order radiomics features between progression and non-
progression area.  
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Figure 7.6 Secondary radiomics features 
Comparison of the secondary order radiomics features between progression and non-
progression area.  
* p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
 
126 
 
7.3.3 Identification of the progression areas from the pre-operative MRIs 
In the training set (n = 32) of the supervised convolutional neural network, the overall 
accuracy 92.6% (Figure 7.7). The training, testing and validation accuracy were 92.7%, 
92.4% and 92.4% respectively. The overall sensitivity was 80% and the overall 
specificity was 97.7%.  
Further application of the trained model can be used to generate predicted areas of 
progression on the preoperative MRI, and the example case from training group was 
shown in Figure 7.8. 
External validation in the 20 cases were done by overlapping the resulted progression 
map drawn by the convolutional neural network model and the actual progression MRI 
(Figure 7.9). 3 repeated validation results were shown in Table 7.3. The overall 
accuracy in the validation group was 78%. The positive predict value and the negative 
predict value were 17% and 78%. 
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Figure 7.7  
The confusion matrix of the voxel-wise radiomics features in the supervised 
convolutional neural network model. The overall sensitivity, specificity and accuracy 
were 80%, 97.7% and 92.6% respectively. 
 
Table 7.3 External Validation 
 
PPV NPV Overall Accuracy 
Test 1  0.193 0.785 0.780 
Test 2  0.134 0.785 0.780 
Test 3 0.173 0.785 0.780 
 
0.167 0.785 0.780 
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Figure 7.8 
A representative case from the training group showed fair result of the identification of 
the progression area form the preoperative MRI. It showed a high probability of 
progression over the area near right lateral ventricle.  
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Figure 7.9 (part 1) 
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Figure 7.9 (part 2) 
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Figure 7.9 
Progression probability heat maps were drawn on 20 external validation cases. The 
true progression on the follow up MRI were masked as yellow in each pair over the 
left hand side. The right figure in each pair showed the probability heat map. White 
arrow indicates a fair identification, while red arrow showed the suboptimal 
identification. 
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7.4 Discussion and Conclusion 
Discussion 
In this study, we showed distinctive imaging characteristics in the peritumoural areas 
that potentially progress. Lower ADC, p and higher FLAIR, contrast enhanced T1 
signal were noted in these area. Furthermore, the comparison between progression 
and non-progression area by using radiomics features showed up to 112 different 
features. These features support the identification of the peritumoural invasive areas. 
We found a significant lower ADC pixel value in the progression areas this may due to 
the increase cancer cellularity in this invasive peritumoural areas. ADC is usually used 
to quantify the diffusivity of the water. In the circumstances of the normal brain tissue 
or increase extracellular fluid, ADC may increase due to the un-restriction of the water 
diffusion. On the other hand, ADC may decrease due to increase cellularity which 
resulted to the restriction of the extracellular fluid diffusion24. ADC can be seen in 
higher grade glioma143 resulted in a worse prognosis. In addition, an increase in ADC 
after treatment can be a favourable prognostic predictor49. 
DTI p is another representative form of the mean diffusivity. Therefore, similar results 
to the ADC were expected. Previous biopsy had shown an increase of 10% in the p 
can show tumour infiltration105 and further MRS and rCBV study also showed that in 
these p abnormal peritumoural area can have higher Cho/NAA ratio and higher rCBV 
which refers to high cellular turnover rate and angiogenesis113. These cancer cell 
activity findings were compatible with our results that showed a lower DTI p in the 
peritumoural progression area. Our results did not show that DTI q as a feature 
contributed to the identification of the progression area. We have known from previous 
study that the DTI q was found to be largely representative of the  cancer itself. In 
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Chapter 6, we showed this abnormal q map can be larger than the contrast enhancing 
lesion in approximate 50% of the GBM. Moreover, extent of resection study showed 
that a larger resection areas of the abnormal q can result in a better prognosis166. 
Further study in these peritumoural abnormal q areas showed that there were increase 
rCBV and increase Choline which also indicates cancer activity (Chapter 6). However, 
in this study, we found less features by using DTI-q, this may because there was 
another half of the cases that had q abnormal areas smaller or equal to the contrast 
enhancing areas that may potentially masked the difference. FA is the measurement 
of the relative anisotropy in DTI, however, the use of FA to differentiate tumour 
infiltrated oedema was controversial79,156 and there was no significant voxel intensity 
difference between the progression and non-progression area in our results. 
Our data showed that, in the area of progression there was a higher rCBV compare to 
the non-progression areas. The increase of the relative cerebral blood flow can be 
found commonly in GBM due to its neovascularization (Chapter1.3). 
FLAIR and contrast enhanced T1C were the two conventional structural MRI that were 
found as progression features in our study. Although FLAIR represents the vasogenic 
oedema of the brain and is non-specific and can be affected by steroid treatment or 
antiangiogenic therapy such as Avastin. (Chapter 1.3). Many studies used the FLAIR 
to define the non-enhancing peritumoural area and able to detect abnormal cancer 
cell36. Lamee et al, found that about one third of the histology analysis in the FLAIR 
areas had cancer cell infiltration70. Therefore, despite some limitations of the FLAIR, 
a higher signal intensity found in the progression peritumoural zone can be explained 
by the possible tumour infiltration. In our study, we found the signal intensity of the 
contrast enhanced T1 MRI higher in the progression area. Although, the peritumoural 
ROIs were defined as non-enhancing area, this can be due to the subtle blood brain 
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barrier interference by the cancer infiltration that beyond human visual detection 
capability. 
In addition to the difference of voxel value extracted from difference MRI sequences. 
We used quantitative radiomics feature to characterise the peritumoural progression 
area from the preoperative MRIs. We found a total 112 out of 294 features that are 
different between progression and non-progression areas. Most studies focused on 
the features of the contrast enhancing lesion. Gevaert et at, in 2014, showed the 
radiomics features can correlate with manual radiologist’s Visually Accessible 
Rembrandt Images features, patient clinical survival34. Another study used quantified 
radiomics data from 121 GBM patients to cluster 3 distinct MR phenotypes, the peri-
mulifocal, spherical and rim-enhanced55. They found each cluster had its different 
pathway which possibly explain the distinct prognosis.  
The second aim of our study was to identify the progression peritumoural area from 
the preoperative MRI which was calculated by the supervised machine learning, 
convolutional neural network. Two of the main issues on the machine learning are the 
size of number for training and having enough qualitative input features. Our results in 
the radiomics provide a reasonable size of the features to the application of the 
convolutional neural networks. And total 294 features coded in every voxel generated 
a large number of the sample size that can be used to train the model. Although the 
optimal features number and the sample size were not tested in this study. Our attempt 
to use the convolutional neural network to draw the progression probability map from 
the preoperative MRI had shown moderately fair results with the overall accuracy 
around 78%. Although the positive predict value and the sensitivity were lower, 
however, the specificity and negative predict were good. 
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There are several limitations in this study. We are not able to take the MRI scan time 
point into consideration in this study, therefore this may cause potential temporal 
sampling error. GBM progression may change from time to time, our progression area 
was created by coregistration of the first true progression image to the reference image. 
This may underestimate the area of progression in our training group. Another 
limitation is the limited patient sample size. Although we trained the model voxel by 
voxel that increased a large amount of sample size, and most of the radiomics study 
require a large sample size in the machine learning in order to reach a stable training 
model. Besides, patients’ clinical prognosis was different in the training group and the 
validation group (Table 7.1, OS: 523 versus 407 days, p < 0.01). The patients in the 
validation group received follow up in local hospitals and had worse prognosis. The 
cause of the difference was unknown, however this may cause a drop of 92.7% of 
overall accuracy in our initial training to 78% after the external validation. 
 
Conclusion 
Multimodal quantitative MR imaging analysis, including structure MRI, perfusion MR 
and diffusion tensor imaging can demonstrate distinct characteristics in areas of 
potential later progression on preoperative MRI. Moreover, the application of these 
imaging features to our cohort, site of tumour progression can be potentially identified 
via a trained machine learning model. However, due to the limited number of training, 
overfitting of the trained results cannot be rule out, therefore further validation study 
should be studied to achieve a more reliable model. 
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CHAPTER 8 
DISCUSSION and CONCLUSION 
8.1 General Conclusion 
The aim of this thesis was to use multimodal MRI to understand the imaging 
characteristics of the peritumoural invasive area. The main hypothesis explored were: 
1. A more accurate image co-registration in brain tumour MRI between different 
time points can be achieved by using a two stage semi-automatic non-linear 
co-registration method to overcome the massive regional distortion caused 
by surgery or tumour progression. The first stage is to calculate the 
transformation between resected lesion and resected cavity, then secondly 
apply to the brain parenchyma. (Chapter 4) 
In Chapter 4, we proposed a two stage semi-automatic non-linear co-registration 
method to coregister 32 tumour progression and post-operative MRI to the 
preoperative MRI. The target error validation showed that it is more accurate than 
the standard linear (FLIRT) or non-linear (FNIRT) method in most of the landmarks. 
There were less deviation of the centroid of tumour (p = 0.002), y coordinate of 
the cerebral aqueduct (p < 0.0001), y coordinate of the septum pellucidum (p 
<0.0001), and y/ z coordinate of the third ventricle (p < 0.0001). 
2. A larger extent of resection based on the DTI-defined invasive regions, can 
result in a better prognosis. Use the above method to coregister the post-
operative MRI to the pre-operative MRI can conduct an accurate volumetric 
study to test the clinical effect of the extent of resection based on different 
MRI sequences. (Chapter 5) 
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The volumetric study of the extent of resection of different MRI were shown in 
Chapter 5. Complete resection of the enhanced tumour shown on the postcontrast 
T1-weighted images was achieved in 24 of 31 patients (77%). The mean extent of 
resection of the abnormal p, q, and FLAIR areas was 57%, 83%, and 59%, 
respectively. Increased resection of the abnormal p and q areas correlated 
positively with progression-free survival (p = 0.009 and p = 0.006, respectively). 
Additionally, a larger, residual, abnormal q volume predicted significantly shorter 
time to progression (p = 0.008). More extensive resection of the abnormal q and 
contrast-enhanced area improved overall survival (p = 0.041 and 0.050, 
respectively). Therefore, a longer progression-free survival and overall survival 
were seen in glioblastoma patients in whom more DTI-q abnormality was resected. 
3. The peritumoural abnormal DTI-q defined invasive area using MRS and 
perfusion MRI can have imaging characteristics similar to the main tumour 
bulk, such as higher Cho/NAA ratio and increase regional perfusion. (Chapter 
6) 
In Chapter 6, we included 51 patients with primary glioblastoma and showed that 
the peritumoural abnormal DTI-q areas have a higher Cho/NAA (p = 0.0346), 
especially the Cho/Cr (p = 0.0219). The rCBV were not different between the 
peritumoural DTI-q abnormal and normal area (p = 0.0798).  
Different method of the analysis of the MRS voxels were compared in this chapter. 
There were no significant different by using the visually selection and the 3D voxel-
wise approach (p = 0.1046 ~ 0.8993). However, this also highlights the potential 
use of this objective way to obtain MRS voxel data.  
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4. Different phenotypes of the peritumoural DTI-q defined invasive margin can 
be an independent factor correlating with patient prognosis. (Chapter 6) 
The patients with larger abnormal q ROIs than contrast enhancing area had a 
better progression free survival (median: 287 vs 53 days, p = 0.0013) and overall 
survival (median: 464 vs 274 days, p = 0.0055) than those with smaller 
peritumoural abnormal q ROIs. These results were controlled by the age, gender, 
extent of resection based on contrast enhanced lesion, use of Gliadel, IDH-1 
mutation status, and MGMT promoter hypermethylation status. Although these 
peritumoural abnormal DTI-q ROIs are infiltrative tumour cell, the longer survival 
in patients with larger abnormal DTI-q can be hypothesised due to a better local 
control by surgical resection and radiation therapy. The EOR based on the contrast 
enhanced lesion was controlled in two groups, however, the EOR of DTI-q did not 
test in these group. Therefore, the better clinical outcome may due to a larger EOR 
of DTI-q. Besides, in our finding, the peritumoral abnormal q ROIs had higher 
Choline, which represents higher cellular turnover rate. Therefore, under the 
standard postoperative CCRT, the better local control can be due to higher 
radiation sensitive. In summary,  the phenotype of the peritumoural DTI-q 
abnormal area can be an independent factor to patients’ prognosis. 
5. The two stage non-linear semi-automatic coregistration method to coregister 
MRI at tumour recurrence/ progression to the pre-operative MRI can identify 
the regions where eventually recur/ progress. And these peritumoural areas 
that potentially recur/ progress can have distinct imaging characteristics 
comparing to other normal peritumoural area by using multimodal MRI and 
radiomics approach. (Chapter 7) 
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In Chapter 7, we had shown distinct imaging characteristics of the peritumoural 
progression area. There were higher ADC (p < 0.001, 0.029), DTI-p (p < 0.001), 
FLAIR (p = 0.020 ~ < 0.001), and higher rCBV (p = 0.038 ~ 0.042) in the 
peritumoural progression area compared to different extent of the non-progression 
areas. Besides, lower FA (p = 0.041) and contrast enhanced T1 signal (p = 0.026 
~ 0.0004) were found in areas of progression. 
In the radiomics features analysis, there were 112 radiomics features that 
identified in the progression areas. Thirty-five out of the 91 first order radiomics 
features and 77 out of 203 second order features had significant difference 
between progression area and non-progression area. These finding concluded 
that various imaging features can characterise the peritumoural progression area 
pre-operatively.  
6. The imaging characteristics obtained from the abovementioned can be used 
to establish a prediction model to identify the possibility of tumour 
progression in the peritumoural zone of the pre-operative MRI by using the 
machine learning model (convolutional neural network). (Chapter 7) 
We applied totally 294 radiomics features into the convolutional neural network 
machine learning model to generate a model to identify areas of potential 
progression from the preoperative MRI. This can be shown in the probability heat 
map. The overall accuracy was 92.6% with 80% of overall sensitivity and 97.7% 
of the overall specificity. However, the accuracy decreases to 78% after external 
validation. According to the result, we were not able to generate a stable model to 
identify the progression area from the pre-operative MRI. However, this still 
showed the potential of the application of the radiomics, together with machine 
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learning in the understanding of the peritumoural area where progress later on. 
 
 
8.2 Limitation of the study 
The limitations of each studies were discussed in the discussion of Chapter 4, 5, 6 
and 7. Several general limitations were described as following. 
Determination of the optimal Co-registration method 
As Chapter 4 described, it is difficult to co-register MRI with lesion between different 
time points due to its massive regional deformation. Although we proposed a two stage 
semi-automatic non-linear co-registration method that shown to be more accurate than 
standard method. Most of the co-register deviation were < 3mm, however, there were 
still deviation up to 5mm in some of the coordinate (x and z coordinate of the tumour 
centroid between progression and pre-operative MRI). This may be a limitation to the 
volumetric study in Chapter 5 and the determination of the peritumoural progression 
area in Chapter 7. Therefore, a more accurate and robust method to overcome the 
regional deformation between time points in lesional brain MRI is needed in the future 
study. 
Inconsistent sampling time of the follow up MRI 
In Chapter 3, we described the MRI acquisition time point and consistent protocol of 
the preoperative diagnostic MRI and the immediate post-operative MRI. Many studies 
hve addressed the important of the standard of the MRI acquisition159. However, the 
interval of the follow-up MRI were obtained in a more flexible time point. Despite a 
general principle of MRI examination before and after CCRT, and follow-up every three 
months, most follow-up MRI were obtained according to the clinical presentation, and 
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some varied from once a month to twice a year in our cohort. Therefore, this 
inconsistency of the sampling time may be a confounding factor to the study of tumour 
progression. 
The progression MRI in some clinically stable patients may obtained during the routine 
follow-up, whist some were done due to clinical deterioration. This may influence the 
determination of the peritumoural progression area in this study (Chapter 7) which 
were done by co-registration of the first progression MRI to the pre-operative MRI. 
Furthermore, when validation of the generated probability progression heat map, we 
compared the resulted heat map to the first progression MRI of the external validation 
MRI. The sensitivity could be underestimated, because we did not correct the time to 
progression between training group and validation group. 
Lack of image guided biopsy 
One of the main object of this study is to understand about the imaging biomarkers of 
the peritumoural invasive area in GBM. Kentarci in Mayo Clinics suggested that an 
ideal imaging biomarker has four characteristics: 1) detecting a fundamental feature 
of the pathology, 2) being diagnostically sensitive and specific through validation in 
neuropathologically confirmed cases, 3) being precise with good test re-test 
reproducibility for monitoring the therapeutic effects on the pathology, 4) being 
available and accessible for multi-center studies 64. Of these, the most important is the 
validation with its biological characteristics.  
Our limitation is lack of the image guided biopsy to confirm our finding about image 
characteristics in the peritumoural progression area. Therefore, although we found a 
larger extent of resection on the DTI-q defined invasive area can result a better 
prognosis (Chapter 5) and further MRS study showed that these peritumoural DTI-q 
142 
 
abnormal area had a high Cho/NAA ratio (Chapter 6). It is still lack of direct evidence 
to conclude actual tumour activity in the invasive margin. Further image guided biopsy 
study is needed for the peritumoural progressive area. 
8.3 Future direction 
Studies in this thesis can lead to several works in the future: 
An image guided biopsy under multimodal MRI 
As previous mentioned, lack of patho-histology evidence is one of the limitation in our 
study. The image guided biopsy study in the further should take several issues into 
consideration: 
1. Brain shift during and after the resection of GBM 
The brain shift during a brain surgery happens simultaneous after the craniotomy, 
and may shift furthermore after durotomy due to change of the incratranial 
pressure86. In order to overcome this issue, several techniques such as intra-
operative sonography116 or tracked laser scanner25 had been developed. However, 
the brain shift problem can be minimize if the biopsy is taken before the durotomy 
followed by the schedule tumour removal. This can provide the most accurate 
spatial information for the biopsy specimen, although a prolong operation time up 
to 30-45 minutes may be expected.  
2. Peritumoural heterogeneity and balance between adequate tissue sampling and 
patient safety. 
The biopsy targets of the peritumoural area can face the problem of peritumoural 
heterogeneity. Two approaches can be proposed. One is to do biopsy as much as 
possible, however, this may increase the risk of complication. However, the 
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complication can be minimised if the biopsy is done before the craniotomy in the 
same operation. The other is target to the pre-operative defined peritumoural 
invasive area. Although the previous method of identifying the progression area 
(Chapter 7) was based on purely image study, this provide a more targeted 
location to undergo biopsy. 
3. Hypothesis of the microenvironment  
Studies had shown that the GBM cells in the non-enhanced area are different from 
the contrast enhanced part5,36. And the complexity of the molecular pathway in this 
regions remained not fully discovered. Therefore, a thorough plan of testing the 
molecular biology property should be carefully planned. 
Incorporation of the imaging biomarkers into surgical decision 
Our attempts to show the peritumoural invasive margin also showed its clinical benefit 
in the extent of resection study (Chapter 5). However, the study was undertaken 
retrospectively and the surgical plan was not based on the proposed invasive margin. 
Although a prolong PFS and OS can be shown, however, a further prospective study 
should be considered. 
The surgical planning can be in two arms: 1. Aim for the contrast enhanced lesion with 
intraoperative 5-ALA. 2. Aim for the invasive margin with intraoperative 5-ALA. Since 
5-ALA guided surgery can provide most benefit of extent of resection to the patients, 
it should be used in every case. This proposed study can not only compare the clinical 
benefit between surgical planning using different imaging modality, but also provide 
the understanding of the correlation between 5-ALA fluorescence and the proposed 
advanced MRI. 
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Improvement of the use of radiomics and machine learning in the assessment 
of GBM prognosis 
As Chapter 7 discussed, the proposed model to identify progression area pre-
operatively was not completely established. This may require more case numbers and 
an adjustment of time to progression. Besides, two other main topics should also be 
assessed further. One is the determination of input features in the machine learning, 
the other is choosing of the machine learning model. Feature selection is an important 
step prior to the training, also the method we used doesn’t need feature selection, 
however, the training results may still be affected by the size of the features. Therefore, 
further optimization of the training features is needed. The other works can be done in 
the future is the establishment of a stable machine learning model suitable for our MRI 
analysis. Since, this thesis was not aim for the study in the bioinformatics science, we 
created our model by modifying from the established model and further customize to 
our study purpose. Therefore, a future collaboration with bioinformatics engineers is 
needed to provide a better model in our study. 
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APPENDIX A 
 
Patients that used in each study were listed in Appendix Table A-1, and detailed 
characteristics were shown in Appendix Table A-2.  
In Table A-1,  showed the available MRI scans at time point of diagnosis, 
immediate post-operative and tumour progression.  
 indicates the patients used in the Chapter 4 
 indicates the patients used in Chapter 5 
 indicates the patients used in Chapter 6 
 indicates the patients in the training set of Chapter 7  
 patients in the external validation set of Chapter 7. 
LMD: for those patients had their follow up in the local hospital were marked  
Initial NA: the data was not available when the study began 
 
Appendix Table A-1 
Lab 
code 
Diagnostic 
MRI 
Post OP 
MRI 
Progression 
MRI 
Chapter 4 
SAC 
Chapter 5 
EOR 
Chapter 6 
MRS 
Chapter 7 
Progression 
001        
002        
004   LMD Initial NA Initial NA   
006        
008        
009        
010        
012   LMD Initial NA    
013        
018   LMD     
019        
020   LMD  Initial NA   
021        
022   LMD  Initial NA   
024   LMD  Initial NA   
025   LMD  Initial NA   
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026        
027        
028        
029        
030        
032        
033     Initial NA   
036        
037        
038   LMD  Initial NA   
039        
041        
042        
044   LMD  Initial NA   
045        
047     Initial NA   
048        
049     Initial NA   
050   LMD Initial NA Initial NA   
051   LMD Initial NA Initial NA   
052    Initial NA Initial NA   
054        
055     Initial NA   
057    Initial NA Initial NA   
058     Initial NA   
059   LMD Initial NA Initial NA   
060        
061        
062   LMD Initial NA Initial NA   
063     Initial NA   
064    Initial NA Initial NA   
065    Initial NA Initial NA   
066        
067        
068     Initial NA   
069     Initial NA   
070        
071   LMD Initial NA Initial NA   
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073        
074    Initial NA Initial NA   
078        
080        
081    Initial NA Initial NA   
083        
084        
085    Initial NA Initial NA   
086    Initial NA    
087     Initial NA   
088   LMD Initial NA Initial NA   
089        
091        
092    Initial NA Initial NA   
098        
099   LMD Initial NA Initial NA   
100        
103   LMD Initial NA Initial NA   
104        
107        
108   LMD Initial NA Initial NA   
109   LMD Initial NA Initial NA   
110    Initial NA Initial NA   
112        
113        
116    Initial NA Initial NA   
117   LMD Initial NA Initial NA   
118    Initial NA Initial NA   
120    Initial NA Initial NA   
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Appendix table A-2 Patients Characteristics 
Lab 
Code 
sex Age OP date EOR Unit Gliadel Tumour 
volume 
Tumour 
location * 
midline 
shift 
IDH-1 MGMT PFS OS 
      
0=no; 
1=yes ml  cm 
0=no; 
1=yes 
0=no; 
1=yes days days 
001 M 59 2010/8/2 GTR C 1 44.92 2 8.5 0 0 246 548 
002 M 61 2010/8/6 STR C 1 48.77 1 1.66 0 1 244 292 
004 M 61 2010/9/10 GTR I 1 40.22 2 1.83 0 0 389 588 
008 M 66 2010/10/29 GTR C 1 79.88 1 7.69 0 0 14 14 
009 F 61 2010/11/01 GTR C 0 53.30 3 5.4 0 0 367 470 
010 F 51 2010/11/5 STR C 0 50.59 1 4.87 0 0 244 292 
012 M 61 2010/11/26 GTR I 1 53.72 1 6.14  1 153 785 
013 F 66 2010/12/6 STR C 1 24.35 2 11.9 0 0 198 890 
019 F 65 2011/2/14 GTR C 0 30.16 3 0 0 1 189 434 
020 M 62 2011/2/18 STR N 0 112.73 2 6.28 0 0 109 235 
021 M 52 2011/3/11 GTR C 1 20.10 3 0 0 0 929 1025 
022 M 61 2011/3/18 STR I 0 64.89 2 6.2 0 0 109 190 
024 M 63 2011/4/26 STR I 1 33.94 2 3.37  1 164 407 
025 M 67 2011/5/3 GTR N 0 31.66 3 9.44 0 0 265 326 
026 F 38 2011/5/16 GTR C 0 8.94 2 3.84 0 1 758 1077 
027 F 64 2011/6/10 STR C 0 11.9 1 0 0 0 182 287 
032 F 65 2011/7/11 GTR C 1 75.04 3 8.78 0 0 262 351 
036 M 68 2011/8/12 GTR C 1 60.31 3 0 0 1 444 501 
038 M 57.0 2011/9/16 GTR N 1 14.97 2 2.81 0 0 264 348 
039 F 31 2011/9/19 GTR C 0 37.17 2 10 0 1 310 475 
041 M 63 2011/10/7 GTR C 0 31.30 1 4.08 0 1 550 1217 
042 M 68 2011/10/21 GTR C 1 77.32 2 8.53 0 0 424 510 
044 M 72 2011/11/11 GTR N 1 34.29 3 0 0 1 143 248 
045 M 63 2011/12/2 GTR C 1 90.59 3 8.74 0 1 1130 1259 
050 F 63 2012/1/20 STR N 1 25.77 2 1.52 0 0 130 424 
051 F 51 2012/1/20 STR N 1 28.00 3 1.96 0 0 165 709 
052 M 62 2012/2/17 GTR N 1 41.81 1 3.47 0 0 507 782 
054 M 59 2012/3/9 GTR C 1 22.24 2 0 1 1 182 287 
058 M 65 2012/3/30 GTR I 1 29.66 3 3.53 0 1 224 1006 
059 F 62 2012/4/2 GTR N 0 29.66 3 3.2 0 1 406 551 
060 M 49 2012/4/4 GTR C 1 52.24 3 2.25 0 1 607 794 
061 F 50 2012/4/27 GTR C 1 43.58 3 7.03 0 1 648 1173 
062 M 61 2012/6/1 GTR I 0 33.51 1 0 0 0 158 384 
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064 M 39 2012/7/2 GTR N 0 30.34 3 2.99 0 0 193 422 
066 M 36 2012/7/16 GTR C 1 56.08 1 1 0 0 283 588 
067 F 49 2012/7/20 GTR C 1 55.85 2 0 0 0 276 523 
070 M 46 2012/8/6 GTR C 0 30.34 2 3.54 1 1 589 1333 
071 M 69 2012/8/17 STR N 1 20.12 2 2.39 0 0 115 261 
073 M 61 2012/9/24 GTR C 0 118.55 1 2.24 0 0 221 286 
074 M 63 2012/10/15 GTR N 0 67.95 1 6.96 0 0 119 413 
078 M 50 2012/11/30 STR C 1 17.04 1 0 0 0 109 461 
080 M 61 2013/1/4 GTR C 1 8.41 3 0 0  117 384 
081 M 50 2013/1/18 STR C 0 13.00 3 1.7 0  111 455 
085 M 54 2013/3/15 GTR C 0 48.28 3 2.86 0  248 403 
088 F 68 2013/5/13 GTR C 0 24.82 2 0 0  136 261 
091 M 65 2013/6/14 STR C 0 42.22 2 0 0  378 839 
092 M 67 2013/6/25 STR I 0 64.43 3 4.69 0  90 93 
098 F 66 2013/10/18 GTR C 0 9.34 3 0 0  431 462 
099 M 50 2013/10/21 GTR I 0 11.81 3 0 0  521 578 
100 M 63 2013/10/25 STR C 0 77.59 2 0 0  47 104 
103 M 65 2013/11/8 GTR N 1 26.79 3 0 0  441 605 
104 M 67 2013/12/13 GTR C 0 27.04 1 3.19 0  747 901 
107 M 38 2014/1/24 GTR C 0 8.19 1 0 1  108 445 
108 F 34 2014/2/6 GTR I 0 57.60 1 7.43 1  181 303 
109 M 51 2014/2/7 GTR N 0 12.71 3 4.28 0  678 737 
110 F 22 2014/2/17 STR C 0 55.84 2 14.6 1  175 279 
112 M 36 2014/4/11 GTR C 0 36.26 1 3.4 0  105 287 
113 F 68 2014/4/7 STR C 0 55.09 1 2.6 0  25 284 
116 M 70 2014/5/2 GTR C 0 30.25 2 0 0  277 277 
117 F 68 2014/5/19 STR I 0 92.87 2 10.1 0  212 288 
118 F 66 2014/5/23 GTR C 0 54.87 1 3.5 0 0 104 269 
120 F 64 2014/6/21 GTR C 0 19.77 2 0 0 0 572 572 
 
Tumour volume (ml): based on T1 weighted with contrast MRI 
EOR: extent of resection 
GTR: gross total resection (based on T1 weighted with contrast MRI) 
STR: subtotal resection 
Unit: follow-up unit 
C: Cambridge; I: Ipswich; N: Norwich 
Tumour location: refer to the relationship with eloquent area120 
1= eloquent; 2 = near eloquent; 3 = non eloquent 
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APPENDIX B - DTI Analysis Scripts 
 
1. Re-orientation all images  
nii_to_radio <input> radio 
2. Unify central point of brain with anterior commissure  
SPM  
3. Eddy correction DTI data  
eddy_correct DTI.nii data 0 
4. Brain extraction DTI 
bet DTI.nii DTI_brain.nii.gz –f 0.05 –m 
5. Manual correction brain extraction with fslview 
output: DTI_brain_mask_m 
6. Create binary mask for further calculation 
fslmaths DTI_brain_mask_m.nii.gz –div DTI_brain_mask_m.nii.gz 
DTI_brain_mask_m_bin.nii.gz 
7. Create extracted brain with manual corrected mask 
fslmaths DTI.nii –mul DTI_brain _mask_m_bin.nii.gz DTI_brain_m.nii.gz 
8. DTI analysis 
dtifit -k data -m DTI_brain_m -r DTI.bvecs -b DTI.bvals -o dti 
9. Create different maps 
fslmaths dti_MD -mul 1.732 DTI_p 
fslmaths dti_L1 -sub dti_MD -sqr DTI_L1diff 
fslmaths dti_L2 -sub dti_MD -sqr DTI_L2diff 
fslmaths dti_L3 -sub dti_MD -sqr DTI_L3diff 
fslmaths dti_L1diff -add dti_L2diff -add dti_L3diff -sqrt DTI_q 
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APPENDIX C – General Matlab Imaging Analysis Function 
Pixel value extraction 
Pixel value extraction from the base images of the specific ROIs was done by the 
following function. 
% Load image 
data=load_untouch_nii('base_images.nii.gz'); 
% Load mask file 
mask=load_untouch_nii('ROIs.nii'); 
data=data.img; 
mask=logical(mask.img); 
% pixel extraction 
pixels=data(mask); 
M1=mean(pixels1); 
 
Images combination and image extraction 
Creation new mask files by combining, intersecting and extracting of different ROIs 
were done by the following functions: 
% Load mask 1 file 
mask1=load_untouch_nii('roi1.nii'); 
% make it logical 
roi1=logical(mask1.img); 
% Load mask 2 file 
mask2=load_untouch_nii('roi2.nii'); 
% make it logical 
roi2=logical(mask2.img); 
% combine two ROIs 
roi3=combineroi(roi1,roi2,'union'); 
% extract overlying areas of two ROIs 
roi3=combineroi(roi1,roi2,'intersect'); 
% extract area of roi1 without roi 2 = roi1 – roi2  
roi3=combineroi(roi1,roi2,'unique'); 
% save new ROI 
temp4=mask1; temp4.img=roi1; 
save_untouch_nii(temp4, 'new_ROIs.nii.gz') 
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Volume calculation 
Volume (vol) calculation of different ROIs for the extent of resection volumetric study 
was done by the following function: 
% load ROIs 
mask=load_untouch_nii('roi.nii'); 
% Voxel volume 
vv=mask.hdr.dime.pixdim(2)*mask.hdr.dime.pixdim(3)*mask.hdr.dime.pixdim(4); 
% aware of the max value in hdr 
vol=sum(mask.img(:))*vv/1000; 
 
 
Note: 
The analysis of nifty file in the Matlab is proceeded by using the “Tools for NifTi and 
ANALYZE image” (https://uk.mathworks.com/matlabcentral/fileexchange/8797-tools-
for-nifti-and-analyze-image?requestedDomain=www.mathworks.com Copyright (c) 
2014, Jimmy Shen) 
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APPENDIX D – Script of the two stage non-linear semi-automatic 
coregistration 
Steps and code of a semi-automatic method to coregister a preoperative MRI image of a 
patient with a brain tumour to follow-up images, for example direct or later postoperative. 
The steps are illustrated in Figure 1 with corresponding step numbers. 
 
1. Brain extraction of the preoperative and follow-up T1-weighted scans with gadolinium 
Code: bet T1C T1C_brain -f 0.5 -B  
Explanation: (bet <in> <out> <options>). Input is an original T1-weighted image <T1C>. A 
brain extracted image <T1C_brain> and binary brain mask <brain_mask> will be created. 
The brain mask can be manually corrected using fslview. 
2. The brain_mask is inverted creating the brain contour images 
Code: fslmaths brain_mask -mul -1 -add 1 T1C_brain_mask_inv 
Explanation: (fslmaths <input> <options> <output>). The image is multiplied by -1 and 1 
is added. 
3A.  Segmentation to identify ventricles and enhancing tumour area or resection cavity for 
 preoperative and follow-up scans 
Code: fast -t 1 -n 4 -o T1C_brain T1C_brain  
Explanation: (fast <options> <output> <input>). Input is the previously created brain 
extracted T1-weighted image <T1C_brain>. Segmentation creates a map of the ventricles 
and contrast enhancing tumour region <pve_0>. It is recommended to check this step 
and correct manually if needed.  
3B. Create binary mask of brain contour, ventricles and lesion for preoperative and follow-up 
scans 
 Code: fslmaths brain_mask_inv -add pve_0 (ref/in)_mask  
Explanation: (fslmaths <in> <option> <in> <output>). The brain contour is added to the 
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ventricles and lesion. 
4. Create linear transformation matrix  
 Code: flirt -ref pre/ref_mask -in followup/in_mask -out FL_followupT1C_2_preT1C -
omat FL_followupT1C_2_preT1C.mat -cost normmi -searchrx -90 90 -searchry -90 90 
-searchrz -90 90 -dof 12 -interp trilinear 
 Explanation: Reference image <-ref> is the preoperative binary mask of the brain 
contour, ventricles and contrast enhancing lesion. Input image <-in> is the follow-up 
binary mask of the brain contour, ventricles and resection cavity. Output <-omat> is 
the matrix used in the next step. 
5. Create nonlinear transformation matrix which includes binary mask as input 
 Code: fnirt --ref=pre/T1C_brain --refmask=pre/ref_mask --in=followup/T1C_brain  
--inmask=followup/in_mask --aff=FL_followupT1C_2_preT1C.mat --cout=transform  
--config=config.cnf 
 Explanation: The reference image <--ref> is the preoperative T1-weighted image. The 
reference mask <--refmask> is the binary mask of the brain contour, ventricles and 
contrast enhancing lesion. The input images are the follow-up T1-weighted scan <--
in> and binary mask of the follow-up brain contour, ventricles and resection cavity 
<--inmask>. Output <--cout> is a transformation matrix. 
6. Coregister brain from the follow-up scan with the preoperative scan 
Code: applywarp --ref=pre/T1C_brain --in=followup/T1C_brain --warp=transform  
--out=T1C_brain_coreg 
Explanation: The reference <--ref> is the preoperative brain extracted scan. Input <--in> is 
the brain extracted follow-up scan. The transformation matrix <--warp> was formed in the 
previous step.   
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APPENDIX E- Script of the Extent of Resection Based on DTI Study 
Steps cavity/lesion 
1. Use cavity from post data, save as lesion_mask.nii.gz 
2. Create binairy mask cavity 
fslmaths lesion_mask.nii.gz –div lesion_mask.nii.gz lesion_mask_bin.nii.gz 
3. Coregister cavity to T1C pre 
applywarp --ref=pre/Anatomical/T1C_brain_B_m.nii.gz --
in=post/Anatomical/lesion_mask_bin.nii.gz 
--warp=FL_ postT1C_2_preT1C.nii.gz --
out=post/Anatomical/lesion_mask_coreg2preT1C 
4. Manually check for scattering ROIs outside of main lesion 
Steps FLAIR data 
5. Apply nii_to_radio to align all images 
6. Add 0 0 0 point on anterior commissure  
SPM reorient 
7. Brain extraction FLAIR 
bet T2F.nii T2F_brain.nii.gz –f 0.5 -m 
8. Manual correction brain extraction 
fslview to edit mask, save as T2F_brain_mask_m 
9. Create binary mask 
fslmaths T2F_brain_mask_m.nii.gz –div T2F_brain_mask_m.nii.gz 
T2F_brain_mask_m_bin.nii.gz 
10. Create extracted brain with manual corrected mask 
fslmaths T2F.nii –mul T2F_brain_mask_m_bin.nii.gz T2F _brain_m.nii.gz 
11. Coregister T2F pre data with T1C pre data  
# run in folder P--- 
flirt -ref pre/Anatomical/T1C_brain_B_m.nii.gz -in pre/Anatomical/ T2F_brain_m.nii.gz -
out FL_post 2F_coreg2preT1C -omat FL_preT2F_2_preT1C.mat -cost normmi -searchrx -
90 90 -searchry -90 90 -searchrz -90 90 -dof 12 -interp trilinear 
flirt -ref pre/DTI/DTI_brain_m.nii.gz -in pre/Anatomical/ T2F_coreg2preT1C.nii.gz out 
pre/Anatomical/T2F_coreg2preDTI -applyxfm -init FL_ preT1C_2_preDTI.nii.gz -interp 
trilinear 
12. Draw T2F mask (threshold painting) and save as pre/Anatomical/preT2F_mask.nii.gz 
13. Add pre_lesion_mask_bin.nii.gz to preT2F_mask.nii.gz and save as 
preT2F_lesion_mask.nii.gz 
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fslmaths pre/Anatomical/lesion_mask_bin.nii.gz -add 
pre/Anatomical/preT2F_mask.nii.gz pre/Anatomical/preT2F_lesion_mask.nii.gz 
Steps DTI data 
14. Draw ROI p (threshold painting + manual correction) and save as 
pre/DTI/prep_mask.nii.gz 
15. Draw ROI q (manually) and save as pre/DTI/preq_mask.nii.gz 
16. Add pre_lesion_mask_bin.nii.gz to prep_mask.nii.gz,  preq_mask.nii.gz, and save as 
prep_lesion_mask.nii.gz, preq_lesion_mask.nii.gz 
fslmaths pre/Anatomical/lesion_mask_bin.nii.gz -add pre/DTI/prep_mask.nii.gz 
pre/DTI/prep_lesion_mask.nii.gz 
fslmaths pre/Anatomical/lesion_mask_bin.nii.gz -add pre/DTI/preq_mask.nii.gz 
pre/DTI/preq_lesion_mask.nii.gz 
Steps ROI determination 
17. Resection T1C In GTR patients 
Combine post/Anatomical/lesion_mask_coreg2preT1C.nii.gz with 
pre/Anatomical/lesion_mask_bin.nii.gz 
fslmaths pre/Anatomical/lesion_mask_bin.nii.gz -add 
post/Anatomical/lesion_mask_coreg2preT1C.nii.gz 
post/Anatomical/lesion_mask_GTR.nii.gz 
fslmaths post/Anatomical/lesion_mask_GTR.nii.gz –div 
post/Anatomical/lesion_mask_GTR.nii.gz post/Anatomical/lesion_mask_GTR_bin.nii.gz 
18. Resection p 
Post/Anatomical/lesion_mask_coreg2preT1C.nii.gz intersection with 
pre/DTI/prep_lesion_mask.nii.gz 
Use Matlab  
mask1=load_untouch_nii('pre/DTI/prep_lesion_mask.nii.gz'); 
roi1=logical(mask1.img); 
mask2=load_untouch_nii('post/Anatomical/lesion_mask_GTR.nii.gz'); 
roi2=logical(mask2.img); 
roi3=combineroi(roi2,roi1,'intersection'); 
temp=mask1; 
temp.img=roi3; 
save_untouch_nii(temp,'post/DTI/Resection_p_mask.nii.gz'); 
19. Resection q 
mask1=load_untouch_nii('pre/DTI/preq_lesion_mask.nii.gz'); 
roi1=logical(mask1.img); 
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mask2=load_untouch_nii('post/Anatomical/lesion_mask_GTR.nii.gz'); 
roi2=logical(mask2.img); 
roi3=combineroi(roi2,roi1,'intersection'); 
temp=mask1; 
temp.img=roi3; 
save_untouch_nii(temp,'post/DTI/Resection_q_mask.nii.gz'); 
20. Resection T2F 
 mask1=load_untouch_nii('pre/Anatomical/preT2F_lesion_mask.nii.gz'); 
 roi1=logical(mask1.img); 
mask2=load_untouch_nii('post/Anatomical/lesion_mask_GTR.nii.gz'); 
roi2=logical(mask2.img); 
roi3=combineroi(roi2,roi1,'intersection'); 
temp=mask1; 
temp.img=roi3; 
save_untouch_nii(temp,'post/Anatomical/Resection_T2F_mask.nii.gz'); 
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APPENDIX F – 3D voxel-wise approach MRS data acquisition 
Example of the acquisition of Choline (GPC+PCh/Cr) 
MakeCSInii_voxnum 
% This script creates a template CSI grid that will be needed for 
% Voxel-wise analysis 
%  Need the header.txt and the 'Spec_voxels.xlsx' template 
pats={'P'}; 
for kk=1:length(pats) 
     headerinfo=CSIinfo('header.txt');        
F=[headerinfo.ImageOrientationPatient(4),headerinfo.ImageOrientationPatient
(1);headerinfo.ImageOrientationPatient(5),headerinfo.ImageOrientationPatien
t(2);headerinfo.ImageOrientationPatient(6),headerinfo.ImageOrientationPatie
nt(3)]; 
        n=cross(F(:,1),F(:,2));      
CSIa=[F(1,1)*headerinfo.PixelSpacing(1),F(1,2)*headerinfo.PixelSpacing(2),n
(1)*headerinfo.SliceThickness,headerinfo.ImagePositionPatient(1);F(2,1)*hea
derinfo.PixelSpacing(1),F(2,2)*headerinfo.PixelSpacing(2),n(2)*headerinfo.S
liceThickness,headerinfo.ImagePositionPatient(2);F(3,1)*headerinfo.PixelSpa
cing(1),F(3,2)*headerinfo.PixelSpacing(2),n(3)*headerinfo.SliceThickness,he
aderinfo.ImagePositionPatient(3);0,0,0,1];         
        if exist([pats{kk},'/Coregistered\T2tse_brain.nii']); 
        t2=load_untouch_nii([pats{kk},'/Coregistered/T2tse_brain.nii']); 
    else 
        t2=load_untouch_nii([pats{kk},'/Coregistered/T2tse_brain.nii.gz']); 
    end 
     T2a=[t2.hdr.hist.srow_x;t2.hdr.hist.srow_y;t2.hdr.hist.srow_z;0,0,0,1]; 
        % Convert affine to be same as would get from dicom header using 
formula above 
        T2a=[-T2a(1,:);-T2a(2,:);T2a(3,:);T2a(4,:)]; 
        T2a=[T2a(:,2),T2a(:,1),T2a(:,3),T2a(:,4)]; 
        if headerinfo.HeaderType==2 
        af=-0.5; 
        else 
        af=0; 
        end         
         % Draw spectrosocpy grid for slice used for planning 
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        grid=zeros(headerinfo.Rows+1,headerinfo.Columns+1,3); 
        for ii=0:headerinfo.Rows 
        for jj=0:headerinfo.Columns 
            temp=CSIa*[ii+af;jj+af;0;1]; 
            temp=(T2a\temp)+[1;1;1;0]; 
            grid(ii+1,jj+1,:)=temp(1:3); 
        end 
        end 
        slice=int8(grid(1,1,3)); 
        imshow(t2.img(:,:,slice)',[]) 
        hold on 
        for ii=1:17 
        plot([grid(ii,1,2),grid(ii,end,2)],[grid(ii,1,1),grid(ii,end,1)]); 
        plot([grid(1,ii,2),grid(end,ii,2)],[grid(1,ii,1),grid(end,ii,1)]); 
        end 
        hold off 
         % Determine shift in x,y and z for spectroscopy voxel. 
        temp=CSIa*[af;af;1;1]; 
        temp=(T2a\temp)+[1;1;1;0]; 
        % Conver to a shift per slice of the T2 image         
        deltax=(grid(1,1,1)-temp(1))/(grid(1,1,3)-temp(3)); 
        deltay=(grid(1,1,2)-temp(2))/(grid(1,1,3)-temp(3)); 
        % Number of slices from T2 image to cover in z 
        deltaz=floor(grid(1,1,3)-temp(3)); 
         % Import the spectroscopy data 
        tempXLSholder=('Spec_voxels.xlsx'); 
        spec=xlsread(tempXLSholder); 
        % Mask for saving as Nifti 
        mask=t2; 
        img=mask.img(:,:,slice); 
        mask.img=zeros(size(mask.img)); 
        temp=zeros(size(mask.img)); 
         for col=5:12 
        for row=5:12 
            for snum=0:deltaz-1 
temp(:,:,slicesnum)=roipoly(img,[grid(col,row,1)+(deltax*snum),grid(col+1,r
ow,1)+(deltax*snum);grid(col+1,row+1,1)+(deltax*snum),grid(col,row+1,1)+(de
ltax*snum)];grid(col+1,row+1,2)+(deltay*snum),grid(col,row+1,2)+(deltay*snu
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m)]); 
            end 
            mask.img(temp==1)=spec(row,col); 
        end 
        end 
        % Modify the header so the data is stored as floating point 
        mask.hdr.dime.datatype=16; 
save_untouch_nii(mask,[pats{kk,'CSIvoxel_VoxNum.nii']); 
end 
Calc_ratio_loop_Cho_forColourMAP 
% Calculate the ratio of total creatinine to total choline from 
spectroscopy data  
% This script needs the metabolite 'spreadsheet.csv' to be available for 
each patient 
pats={'P'};  
for ii=1:length(pats) 
        res=zeros(16); 
        % Import the spectroscopy data 
        spec=importdata([pats{ii},'spreadsheet.csv'],','); 
        % Sort the data values based on column and row 
        spec.data=sortrows(spec.data); 
         % Identify which columns of the spec data to use for the overlay 
        ChoCrcol=find(strcmp(' GPC+PCh/Cr+PCr',spec.colheaders)); 
        Crcol=find(strcmp(' Cr+PCr',spec.colheaders)); 
         % Want to extract voxels based on column then row 
        for jj=1:size(spec.data,1) 
            col=spec.data(jj,1); 
            row=spec.data(jj,2); 
        % Calculate Cho/Cr ratio for voxels where both have SD <= 20% 
            if spec.data(jj,ChoCrcol-1)<=20&&spec.data(jj,Crcol+1)<=20 
                res(row,col)=spec.data(jj,ChoCrcol/Crcol); 
            end 
        end 
        % Save the data to an excel sheet 
        xlswrite([pats{ii},'ChoCr_ratio_data_forColourMAP.xls'],res) 
end 
%This .xls output will be used to create the respective .nii 
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MakeCSInii_Metabolite_loop 
 
% FIRST need to create metabolite spreadsheets using Calc_ratio_loop for 
the respective metabolites... 
% Make sure the respective header.txt is in each patient file  
  
pats={'P'}; 
for kk=1:length(pats) 
     headerinfo=CSIinfo([pats{kk},'header.txt']);  
% Create affine matrix from header information patient        
F=[headerinfo.ImageOrientationPatient(4),headerinfo.ImageOrientationPatient
(1);headerinfo.ImageOrientationPatient(5),headerinfo.ImageOrientationPatien
t(2);headerinfo.ImageOrientationPatient(6),headerinfo.ImageOrientationPatie
nt(3)]; 
        n=cross(F(:,1),F(:,2)); 
CSIa=[F(1,1)*headerinfo.PixelSpacing(1),F(1,2)*headerinfo.PixelSpacing(2),n
(1)*headerinfo.SliceThickness,headerinfo.ImagePositionPatient(1);F(2,1)*hea
derinfo.PixelSpacing(1),F(2,2)*headerinfo.PixelSpacing(2),n(2)*headerinfo.S
liceThickness,headerinfo.ImagePositionPatient(2);F(3,1)*headerinfo.PixelSpa
cing(1),F(3,2)*headerinfo.PixelSpacing(2),n(3)*headerinfo.SliceThickness,he
aderinfo.ImagePositionPatient(3); 0,0,0,1]; 
 
% load base line reference, normallt T2 
if exist([pats{kk},'T2tse_brain.nii']); 
  t2=load_untouch_nii([pats{kk},'/Coregistered/T2tse_brain.nii']); 
    else 
        t2=load_untouch_nii([pats{kk},'/Coregistered/T2tse_brain.nii.gz']); 
    end       
T2a=[t2.hdr.hist.srow_x;t2.hdr.hist.srow_y;t2.hdr.hist.srow_z;0,0,0,1]; 
        % Convert affine to be same as would get from dicom header using 
formula above 
        T2a=[-T2a(1,:);-T2a(2,:);T2a(3,:);T2a(4,:)]; 
        T2a=[T2a(:,2),T2a(:,1),T2a(:,3),T2a(:,4)]; 
        % left corner of the first spectroscopy voxel, the other describes 
the middle of the top left spoectroscopy volxel. 
        % Need to add an adjustment factor for the second type. 
        if headerinfo.HeaderType==2 
        af=-0.5; 
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        else 
        af=0; 
        end         
        % Draw spectrosocpy grid for slice used for planning 
        grid=zeros(headerinfo.Rows+1,headerinfo.Columns+1,3); 
        for ii=0:headerinfo.Rows 
        for jj=0:headerinfo.Columns 
            temp=CSIa*[ii+af;jj+af;0;1]; 
            temp=(T2a\temp)+[1;1;1;0]; 
            grid(ii+1,jj+1,:)=temp(1:3); 
        end 
        end 
        slice=int8(grid(1,1,3)); 
        imshow(t2.img(:,:,slice)',[]) 
        hold on 
        for ii=1:17 
        plot([grid(ii,1,2),grid(ii,end,2)],[grid(ii,1,1),grid(ii,end,1)]); 
        plot([grid(1,ii,2),grid(end,ii,2)],[grid(1,ii,1),grid(end,ii,1)]); 
        end 
        hold off 
        % Determine shift in x,y and z for spectroscopy voxel. 
        temp=CSIa*[af;af;1;1]; 
        temp=(T2a\temp)+[1;1;1;0]; 
        % Conver to a shift per slice of the T2 image         
        deltax=(grid(1,1,1)-temp(1))/(grid(1,1,3)-temp(3)); 
        deltay=(grid(1,1,2)-temp(2))/(grid(1,1,3)-temp(3)); 
        % Number of slices from T2 image to cover in z 
        deltaz=floor(grid(1,1,3)-temp(3)); 
        % Import the spectroscopy data 
        spec=xlsread([pats{kk},'ChoCr_ratio_data_forColourMAP.xls']); 
        % Mask for saving as Nifti 
        mask=t2; 
        img=mask.img(:,:,slice); 
        mask.img=zeros(size(mask.img)); 
        temp=zeros(size(mask.img)); 
        for col=5:12 
        for row=5:12 
        for snum=0:deltaz-1 
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temp(:,:,slicesnum)=roipoly(img,[grid(col,row,1)+(deltax*snum),grid(col+1,r
ow,1)+(deltax*snum),grid(col+1,row+1,1)+(deltax*snum),grid(col,row+1,1)+(de
ltax*snum)],[grid(col,row,2)+(deltay*snum),grid(col+1,row,2)+(deltay*snum),                  
grid(col+1,row+1,2)+(deltay*snum),grid(col,row+1,2)+(deltay*snum)]); 
        end 
            mask.img(temp==1)=spec(row,col); 
        end 
        end 
        % Modify the header so the data is stored as floating point 
        mask.hdr.dime.datatype=16;       
        save_untouch_nii(mask,[pats{kk},'CSIvoxel_ChoCr.nii']); 
end 
Data_loop_MRS 
% Template file 
[temp_data,temp_text]=xlsread('Data Extraction Template Jimmy_CSI.xlsx'); 
% I can only use patients for whom I have NAWM, p-, q- and spectroscopy CSI 
grid 
pats={'P'}; 
for ii=1:length(pats) 
    
pdata=load_untouch_nii([pats{ii},'/pre/CSI/coregistered_dti_p.nii.gz']); 
qdata=load_untouch_nii([pats{ii},'/pre/CSI/coregistered_dti_q.nii.gz']); 
rcbv_data=load_untouch_nii([pats{ii},'/pre/CSI/coregistered_rCBV.nii.gz']); 
    % Load ADC data files 
adc_data=load_untouch_nii([pats{ii},'/pre/CSI/coregistered_ADC.nii.gz']); 
     adc_data.img=double(adc_data.img);    
    %TEST 1 
    % Adding ROI data 
    NE=load_untouch_nii([pats{ii},'/T2F_mask.nii']); 
    %TESTING addition of all ROIs 
    %    ROI_1 = recurROI           ;q not T1C 
    %    ROI_2 = non-recur ROI 5    ;NotqNotT1C 
    %    ROI_3 = non Recur ROI 10   ;T1C (lesion)    
    ROI_1=load_untouch_nii([pats{ii},'/qNotT1C_mask.nii.gz']); 
    ROI_2=load_untouch_nii([pats{ii},'/NotqNotT1C_mask.nii.gz']); 
    ROI_3=load_untouch_nii([pats{ii},'/lesion.nii']); 
164 
 
   % Check that T1C and T2F masks exist and if so load them 
    T1C_ok=0;T2F_ok=0; 
        T1C=load_untouch_nii([pats{ii},'/lesion.nii']); 
        T1C_ok=1; 
        T2F=load_untouch_nii([pats{ii},'/T2F_mask.nii']); 
        T2F_ok=1;         
    % Need to combine the T1C, FLAIR to make a master roi for each patient 
    master_roi=combineroi(logical(T1C.img),logical(T2F.img),'union'); 
    NEplusCE=load_untouch_nii([pats{ii},'/T2F_mask.nii']); 
       
    % Check that spec data exists and load 
    csi_ok=0; 
    if exist([pats{ii},'/CSIvoxel_ChoCr.nii'],'file') 
        csi1=load_untouch_nii([pats{ii},'/CSIvoxel_ChoNAACr.nii']); 
        csi2=load_untouch_nii([pats{ii},'/CSIvoxel_InsCr.nii']); 
        csi3=load_untouch_nii([pats{ii},'/CSIvoxel_ChoCr.nii']); 
        csi4=load_untouch_nii([pats{ii},'/CSIvoxel_NAACr.nii']);        
        csi6=load_untouch_nii([pats{ii},'/CSIvoxel_GSHCr.nii']); 
        csi7=load_untouch_nii([pats{ii},'/CSIvoxel_GlxCr.nii']);         
        csi9=load_untouch_nii([pats{ii},'/CSIvoxel_LacCr.nii']); 
        csi_vox=load_untouch_nii([pats{ii},'/CSIvoxel_VoxNum.nii']); 
        csi_ok=1; 
    end 
 
    % Now that data is loaded can start analysis 
    % Get the pixel coords of all pixels in the master roi 
    [p_x,p_y,p_z]=ind2sub(size(master_roi),find(master_roi)); 
    % Need the centoid of the qroi 
    T1C_plusNEC_cent=regionprops(T1C.img,'centroid'); 
    % Round off the value to whole numbers 
    T1C_plusNEC_cent=(T1C_plusNEC_cent.Centroid);    
    % Calculate total area and total perimeter of the CE roi 
    totArea_T1C_plusNEC=nnz(T1C.img); 
    totPerim_T1C_plusNEC=0; 
    for jj=1:size(T1C.img,3) 
        temp=MFfunc2D(T1C.img(:,:,jj)); 
        totPerim_T1C_plusNEC=totPerim_T1C_plusNEC+temp(2); 
    end 
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    % Calculate total area and total perimeter of the Master ROI roi 
    totArea_NEplusCE=nnz(NEplusCE.img); 
    totPerim_NEplusCE_roi=0; 
    for jj=1:size(NEplusCE.img,3) 
        temp=MFfunc2D(NEplusCE.img(:,:,jj)); 
        totPerim_NEplusCE_roi=totPerim_NEplusCE_roi+temp(2); 
    end     
    % Will do an output table for each patient and the p and q rois 
seperately    
outdata=cell(length(p_x)+1,size(temp_text,2));%cell(11,size(temp_text,2)); 
    % Fill in the headings 
    for jj=1:size(temp_text,2) 
        outdata{1,jj}=temp_text{1,jj}; 
    end 
    % Fill in the rows for the q ROI 
    for jj=1:length(p_x) 
        % Patient characteristics 
        % % %outdata{jj+1,1}=pat; 
        outdata{jj+1,1}=temp_data(ii,1); % PatientsID 
        outdata{jj+1,2}=pats{ii}; %outdata{jj+1,2}=temp_text{kk,2}; % 
patient number 
        outdata{jj+1,3}=temp_text{ii+1,3}; % PatientID 
        outdata{jj+1,4}=temp_data(ii,4); % wbic id 
        outdata{jj+1,5}=temp_text{ii+1,5}; % Sex 
        outdata{jj+1,6}=temp_data(ii,6); % SexCat 
        outdata{jj+1,7}=temp_data(ii,7); % Age =temp_data(ii-1,5) 
        outdata{jj+1,8}=temp_data(ii,8); % AgeCat =temp_data(ii-1,5) 
        outdata{jj+1,9}=temp_text{ii+1,9}; % EOR 
        outdata{jj+1,10}=temp_data(ii,10); % EORCat  MIGHT BE DATA 
        outdata{jj+1,11}=temp_data(ii,11); %Gliadel 
        outdata{jj+1,12}=temp_data(ii,12); % Status 
        outdata{jj+1,13}=temp_data(ii,13); % OS 
        outdata{jj+1,14}=temp_data(ii,14); % PFS 
        outdata{jj+1,15}=temp_data(ii,15); % MGMT 
        outdata{jj+1,16}=temp_data(ii,16); % R132H 
        % Total area and perimeter of contrast ROI 
        outdata{jj+1,17}=totArea_T1C_plusNEC; 
        outdata{jj+1,18}=totPerim_T1C_plusNEC; 
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        % Total area and perimeter of FLAIR ROI 
        outdata{jj+1,19}=totArea_NEplusCE; 
        outdata{jj+1,20}=totPerim_NEplusCE_roi;         
        % Relative position of the pixel 
        pos=[T1C_plusNEC_cent(2)-p_x(jj),T1C_plusNEC_cent(1)-
p_y(jj),T1C_plusNEC_cent(3)-p_z(jj)]; 
        outdata{jj+1,21}=pos(1); 
        outdata{jj+1,22}=pos(2); 
        outdata{jj+1,23}=pos(3);                    
            % Spectroscopy data 
            if csi_ok&&csi_vox.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,31}=csi_vox.img(p_x(jj),p_y(jj),p_z(jj));  
                % Vox_num ratio 
            end 
            if csi_ok&&csi1.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,32}=csi1.img(p_x(jj),p_y(jj),p_z(jj));  
                % Cho:NAA ratio 
            end 
            if csi_ok&&csi2.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,33}=csi2.img(p_x(jj),p_y(jj),p_z(jj));  
                % Ins:Cr ratio 
            end 
            if csi_ok&&csi3.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,34}=csi3.img(p_x(jj),p_y(jj),p_z(jj));  
                % Cho:Cr ratio 
            end 
            if csi_ok&&csi4.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,35}=csi4.img(p_x(jj),p_y(jj),p_z(jj));  
                % NAA:Cr ratio 
            end 
            if csi_ok&&csi6.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,36}=csi6.img(p_x(jj),p_y(jj),p_z(jj));  
                % GSH:Cr ratio 
            end 
            if csi_ok&&csi7.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,37}=csi7.img(p_x(jj),p_y(jj),p_z(jj));  
                % Glu+Gln:Cr ratio 
            end 
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            if csi_ok&&csi9.img(p_x(jj),p_y(jj),p_z(jj))~=0; 
                outdata{jj+1,38}=csi9.img(p_x(jj),p_y(jj),p_z(jj));  
                % Lac:Cr ratio 
            end 
       
     % INside/outside all ROIs 
        outdata{jj+1,42}=ROI_1.img(p_x(jj),p_y(jj),p_z(jj)); 
        outdata{jj+1,43}=ROI_2.img(p_x(jj),p_y(jj),p_z(jj)); 
        outdata{jj+1,44}=ROI_3.img(p_x(jj),p_y(jj),p_z(jj));       
    end   
writecsv(outdata,['VoxelWise_CSI_Output/',pats{ii},'_ROIs_voxel_data.csv'])    
end 
  
Load Data (in R) 
#HGG Load Data Algorithm 
memory.limit(size=20000) 
#Load Data 
HGG_001<-read.csv('F:/MRS/VoxelWise_CSI_Output/P001_ROIs_voxel_data.csv', header = 
TRUE) 
(repeat to load all patients’ data) 
#All patients 
ALL_ROI_DATA<-rbind(HGG_001…) 
write.csv(ALL_ROI_DATA,'F:/MRS/VoxelWise_CSI_Output/Merged_DATA.csv') 
rm() 
#End 
 
Algorithm spec_voxel_Jimmy 
#HGG Multimodality Statistical Algorithm 
#Increase Memory limit 
memory.limit(size=20000) 
#Load Packages Required 
library(ggplot2) 
library(lme4) 
options(digits=10,width=85, show.signif.stars = FALSE, 
        lattice.theme = function() canonical.theme("pdf", color = FALSE), 
        str = strOptions(strict.width = "cut")) 
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library(lme4) 
library(mcmc) 
library(languageR) 
library(afex) 
library(lmerTest) 
library(mtcars) 
#Open data 
HGG<-read.csv('F:/MRS/VoxelWise_CSI_Output/Merged_DATA.csv', header = TRUE)     
#Check data 
#edit(HGG) 
#Format variables 
HGG$Patient.1<-as.factor(HGG$Patient.1)     
HGG$voxel_spec<-as.factor(HGG$voxel_spec) 
HGG$Age<-as.numeric(as.character(HGG$Age)) 
HGG$R132H<-as.numeric(as.character(HGG$R132H)) 
HGG$MGMT<-as.numeric(as.character(HGG$MGMT))    
HGG$Status<-as.numeric(as.character(HGG$Status)) 
HGG$ROI1<-as.numeric(as.character(HGG$ROI1)) 
HGG$ROI2<-as.numeric(as.character(HGG$ROI2)) 
HGG$ROI3<-as.numeric(as.character(HGG$ROI3)) 
HGG$Cho.NAA<-as.numeric(as.character(HGG$Cho.NAA)) 
HGG$Ins.Cr<-as.numeric(as.character(HGG$Ins.Cr)) 
HGG$Cho.Cr<-as.numeric(as.character(HGG$Cho.Cr)) 
HGG$NAA.Cr<-as.numeric(as.character(HGG$NAA.Cr)) 
HGG$GSH.Cr<-as.numeric(as.character(HGG$GSH.Cr)) 
HGG$GluGln.Cr<-as.numeric(as.character(HGG$GluGln.Cr))    
HGG$Lac.Cr<-as.numeric(as.character(HGG$Lac.Cr))    
HGG$OS<-as.numeric(as.character(HGG$OS)) 
HGG$PFS<-as.numeric(as.character(HGG$PFS)) 
HGG$rCBV.data[HGG$rCBV.data==0] <- NA 
HGG$NIrCBV.data[HGG$NIrCBV.data==0] <- NA 
HGG$ADC.data[HGG$ADC.data==0] <- NA 
HGG$MD.data[HGG$MD.data==0] <- NA 
HGG$p.data[HGG$p.data==0] <- NA 
HGG$q.data[HGG$q.data==0] <- NA 
#Step 1 - Takes all data and provides single value across each spectroscopy voxel by patient 
HGG_spec<-aggregate(.~ voxel_spec + Patient.1,HGG,function(x) c(mean = 
mean(x)),na.action=na.pass) 
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#Check variables 
str(HGG_spec) 
#Establish hypotheses 
#1. Are there metabolic differences amongst my ROIs? 
#- 
#Step 2 - Takes all spectroscopy voxels that fall into ROI of interest dependent on what 
fraction is present in your ROI 
#HGG_spec.ROI1<-subset(HGG_spec, ROI1>0.5) 
#HGG_spec.ROI2<-subset(HGG_spec, ROI2>0.5) 
HGG_spec.ROI3<-subset(HGG_spec, ROI3>0.5) 
#Step 3 - Calculates average of all spectroscopy voxels by patient in your ROI of interest 
#HGG_spec.ROI1.Final<-aggregate(.~ Patient.1, HGG_spec.ROI1,function(x) c(mean = 
mean(x,na.rm=TRUE)),na.action=na.pass) 
#HGG_spec.ROI2.Final<-aggregate(.~ Patient.1, HGG_spec.ROI2,function(x) c(mean = 
mean(x,na.rm=TRUE)),na.action=na.pass) 
HGG_spec.ROI3.Final<-aggregate(.~ Patient.1, HGG_spec.ROI3,function(x) c(mean = 
mean(x,na.rm=TRUE)),na.action=na.pass) 
#write.csv(HGG_spec.ROI1.Final,'F:/MRS/VoxelWise_CSI_Output/Spec_ROI1.csv') 
#write.csv(HGG_spec.ROI2.Final,'F:MRS/VoxelWise_CSI_Output/Spec_ROI2.csv') 
write.csv(HGG_spec.ROI3.Final,'F:/MRS/VoxelWise_CSI_Output/Spec_ROI3.csv') 
#End 
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